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  This	   thesis	   examined	   how	   and	   why	   TRPV1	   function	   is	   being	   modulated	   in	  sensory	   neuropathy	   and	   explored	   the	   potential	   of	   its	   rescue	   in	   the	   urinary	  bladder	  of	  STZ-­‐induced	  diabetic	  rats.	  	  Diabetes	  induced	  a	  rapid	  decline	  in	  TRPV1	  function	  and	  changes	   in	  neurogenically	  mediated	  electrically-­‐evoked	  responses	  together	   with	   a	   gradual	   decline	   in	  muscarinic	   function.	   	   Diabetic	   bladder	   was	  also	  deficient	  in	  muscarinic	  and	  TRPV1	  organ	  bath	  temperature-­‐induced	  changes	  but	   not	   in	   those	   affecting	   spontaneous	   contractile	   activity.	   Exposure	   to	   a	  potential	   neuropathy	   causative	   agent,	   methylglyoxal	   was	   studied	   and	   its	  mechanism	  of	  action	  explored	  through	  the	  use	  of	  TRPA1	  ligands.	  Methylglyoxal	  exposure	   mimicked	   some	   of	   the	   effects	   of	   diabetes	   on	   TRPV1,	   neurogenic	  electrically	   evoked	   responses	   and	   muscarinic	   function.	   	   Methylglyoxal	   effects	  were	   seen	   to	   be	   partly	   through	   TRPA1	   receptor	   activation	   but	   other	   as	   yet	  undefined	   pathways	   were	   also	   involved.	   	   Use	   of	   TRPA1	   ligands	   revealed	   an	  unexpected	  complexity	  of	  the	  interaction	  of	  the	  TRPA1	  receptor	  with	  TRPV1.	  	  Finally	  the	  potential	  of	  reversing	  the	  diminished	  TRPV1	  response	  was	  examined	  through	  the	  use	  of	  three	  known	  sensitising	  agents,	  bradykinin,	  NGF	  and	  insulin.	  	  Bradykinin	  was	  the	  only	  agent	  seen	  to	  reverse	  the	  TRPV1	  diminished	  response	  back	   up	   to	   to	   control	   equivalent	   levels	   and	   through	   the	   use	   of	   bradykinin	  selective	  ligands,	  it	  was	  seen	  that	  the	  dual	  activation	  of	  BK-­‐1	  and	  BK-­‐2	  receptor	  was	  necessary	  to	  rescue	  the	  TRPV1	  response.	  	  The	  likely	  mechanism	  of	  action	  of	  bradykinin	   was	   through	   prostaglandin	   production	   as	   indomethacin	   blocked	  TRPV1	  rescue.	  	  In	   the	   acute	   stage	   of	   diabetes,	   TRPV1	   function	   is	   downregulated	   and	   may	   be	  caused	  by	  exposure	   to	  a	  neuropathy-­‐causing	  metabolite	   such	  as	  methylglyoxal.	  	  The	  TRPV1	   function	   still	   retains	   plasticity	   at	   this	   acute	   stage	   because	   function	  could	  be	   enhanced	  back	   to	   control	   levels	   by	  bradykinin	   receptor	   activation	   :	   a	  potential	  for	  early	  therapeutic	  intervention.	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Neuropathy	  affects	  three	  main	  types	  of	  neurons:	  autonomic,	  motor	  and	  sensory	  neurons	  and	  the	  term	  sensory	  neuropathy	  refers	  to	  the	  nerve	  damage	  seen	  specifically	  to	  sensory	  neurons.	  	  Sensory	  neuropathy	  is	  a	  painful	  complication	  often	  associated	  with	  diabetes.	  Commonly	  sensory	  neuropathy	  is	  associated	  with	  a	  tingling	  burning	  pain,	  and	  a	  loss	  of	  sensation	  that	  has	  been	  likened	  to	  wearing	  stockings	  or	  gloves.	  The	  prevalence	  of	  neuropathy	  is	  high,	  estimated	  to	  occur	  in	  around	  66%	  of	  people	  with	  diabetes	  (Dyck	  et	  al.,	  1993).	  	  	  	  
Other	  medical	  conditions	  that	  are	  associated	  with	  neuropathy	  include	  chronic	  liver	  disease(Knill-­‐Jones	  et	  al.,	  1972),	  kidney	  disease	  (Maser	  et	  al.,	  1989),	  HIV	  infection	  and	  AIDS	  (Keswani	  et	  al.,	  2002),	  chronic	  alcohol	  consumption	  (Martyn	  and	  Hughes,	  1997),	  nutritional	  deficiencies	  such	  as	  Vitamin	  B	  deficiency	  (Mccombe	  and	  Mcleod,	  1984),	  	  cancer	  (Roelofs	  et	  al.,	  1984),	  Lyme	  disease	  (Halperin	  et	  al.,	  1987),	  Charcot-­‐Marie-­‐Tooth	  (De	  Jonghe	  et	  al.,	  1997),	  	  Guillain-­‐Barre	  (Brown	  and	  Feasby,	  1984)	  and	  Diphtheria	  (Mcleod,	  1995).	  
Why	  is	  sensory	  function	  important?	  
Sensory	  nerve	  function	  is	  critical	  to	  an	  organism’s	  survival.	  	  Primary	  afferent	  sensory	  nerves	  act	  to	  convey	  information	  such	  as	  pain,	  cold	  and	  heat	  from	  their	  local	  environment	  to	  the	  central	  nervous	  system.	  	  These	  neurons	  may	  also	  have	  efferent	  functions	  to	  signal	  to	  their	  local	  environment	  by	  the	  release	  of	  neuropeptides	  such	  as	  Substance	  P,	  neurokinins	  and	  calcitonin	  gene-­‐related	  peptide	  (CGRP)(Szallasi	  et	  al.,	  2007).	  Dysfunction	  in	  the	  afferent	  and	  efferent	  systems	  of	  peripheral	  sensory	  neurons	  could	  be	  detrimental	  to	  organ	  functioning	  and	  may	  be	  causative	  to	  inappropriate	  sensory	  signalling	  and	  neuronal	  injury.	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Sensory	  neuropathy	  in	  diabetes	  
Principally	  diabetic	  neuropathy	  affects	  multiple	  sensory	  neurons.	  This	  neuropathy	  appears	  predominantly	  in	  the	  hands	  and	  feet,	  and	  manifests	  as	  sensory	  alterations	  that	  range	  from	  a	  loss	  of	  sensation,	  an	  increased	  sensitivity	  to	  sensory	  stimuli	  (hyperesthesia)	  to	  allodynia,	  pain	  due	  to	  normally	  innocuous	  tactile	  stimuli.	  	  There	  are	  also	  signs	  of	  functional	  changes	  in	  the	  extremities,	  such	  as	  coldness,	  loss	  of	  hair,	  thinness	  of	  skin,	  and	  sweating	  disorders.	  	  The	  sensory	  loss	  seen	  with	  diabetic	  neuropathy	  is	  thought	  to	  be	  the	  primary	  cause	  of	  foot	  problems	  where	  minor	  foot	  injuries	  go	  unnoticed	  by	  the	  patient	  and	  can	  progress	  to	  the	  development	  of	  foot	  ulcers	  (Boulton	  et	  al.,	  2005).	  The	  consequence	  of	  a	  foot	  ulcer	  that	  is	  non-­‐responsive	  to	  treatment	  can	  be	  amputation,	  and	  this	  is	  10-­‐30	  times	  more	  likely	  to	  occur	  in	  a	  diabetic	  (Trautner	  et	  al.,	  1996).	  	  
A	  common	  characteristic	  of	  diabetic	  sensory	  neuropathy	  is	  hyperalgesia,	  defined	  as	  an	  increased	  responsiveness	  to	  a	  noxious	  stimulus.	  	  	  Hyperalgesia	  can	  be	  caused	  through	  sensitisation	  of	  the	  peripheral	  nerve	  fibres,	  so	  that	  an	  increased	  number	  of	  action	  potentials	  are	  generated	  in	  response	  to	  thermal	  or	  mechanical	  stimuli.	  Neuropathic	  pain	  as	  a	  result	  of	  neuropathy	  often	  also	  has	  an	  element	  of	  allodynia,	  which	  is	  defined	  as	  pain	  resulting	  from	  a	  normally	  innocuous	  stimulus.	  	  Normal	  tactile	  sensations	  are	  perceived	  as	  painful	  due	  to	  changes	  in	  the	  spinal	  cord	  driven	  by	  nociceptors.	  	  
In	  diabetes	  some	  reduction	  of	  the	  neuropathic	  symptoms	  can	  be	  achieved	  with	  long-­‐term	  glucose	  homeostasis	  and	  insulin	  replacement.	  	  However,	  some	  neuropathies	  remain	  resistant	  to	  resolution	  and	  may	  represent	  either	  irreversible	  neuropathy	  or	  a	  neuropathy	  with	  unknown	  causative	  factors.	  	  Even	  with	  good	  glucose	  control	  over	  a	  number	  of	  years,	  only	  around	  60%	  of	  diabetics	  achieve	  a	  partial	  resolution	  of	  their	  symptoms.	  
Existing	  therapies	   fail	   to	  effectively	  treat	  the	  painful	  neuropathic	  symptoms	  for	  the	  majority	   of	   patients,	   for	   example	   the	   gold	   standard	   treatment	   for	   diabetic	  
	   3	  
neuropathy,	   pregabalin,	   treats	   only	   1	   in	   4	   patients	   and	   the	   relief	   gained	   is	  generally	   only	   a	   50%	   reduction	   in	   pain	   (Finnerup	   et	   al.,	   2005,	   Lesser	   et	   al.,	  2004).	   	  Pregabalin	  does	  show	  show	  some	  efficacy	  clinically	  against	  neuropathic	  pain	  and	  although	  its	  mechanism	  of	  action	  is	  still	  not	  clear,	  it	  is	  believed	  to	  act	  via	  a	   selective	   inhibitory	   effect	   on	   voltage-­‐gated	   calcium	   channels	   containing	   the	  α2δ1	  subunit	  (Sills,	  2006).	  	  	  Diabetic	  sensory	  neuropathy	  is	  resistant	  to	  resolution	  with	  glucose	  control	  and	  is	  symptomatically	  hard	  to	  treat.	  So	  there	  is	  a	  need	  for	  the	  better	  understanding	  of	  the	  underlying	  functional	  changes	  seen	  in	  sensory	  neuropathy.	   	  This	  could	  lead	  to	  the	  development	  of	  novel,	  more	  effective	  therapies	  for	  diabetic	  complications.	  	  
	  
Diabetes:	  classification,	  prevalence	  and	  treatment	  	  Diabetes	  mellitus	   is	  a	  disorder	  of	  carbohydrate	  metabolism	  caused	  by	  deficient	  action	   and/or	   production	   of	   insulin,	   an	   endocrine	   hormone	   produced	   by	   the	  pancreas.	   	   As	   insulin	   facilitates	   glucose	   uptake	   and	   utilization,	   the	   disease	   is	  characterized	  by	  a	  chronic	  high	  level	  of	  glucose	  in	  the	  blood,	  hyperglycemia.	  	  The	  disease	   can	   be	   categorized	   to	   two	   main	   types	   depending	   on	   the	   form	   of	   the	  insulin	  deficiency:	  Type	  1	  Diabetes	  (T1D)	  which	  accounts	  for	  5-­‐10%	  of	  the	  total	  diabetic	  population,	  and	  the	  more	  prevalent	   form,	  Type	  2	  Diabetes	  (T2D).	   	  The	  insulin	  deficit	   seen	   in	  T1D	   is	  caused	  by	  a	  profound	  reduction	   in	   the	  number	  of	  functional	   pancreatic	   β-­‐cells,	   commonly	   as	   a	   result	   of	   their	   destruction	   by	  autoimmune	   disease.	   In	   T2D	   the	   deficiency	   is	   in	   insulin	   secretion	   and	   its	  subsequent	  action	  often	  termed	  insulin	  resistance.	  	  Globally,	   the	  diabetic	   population	   is	   already	   large	   and	  numbers	   are	   expected	   to	  increase:	  in	  2000	  the	  worldwide	  estimate	  was	  a	  staggering	  171	  million	  with	  this	  predicted	  to	  more	  than	  double	  to	  366	  million	  by	  2030.	  	  Being	  obese	  is	  the	  main	  risk	  factor	  for	  development	  of	  diabetes	  and	  shockingly	  the	  majority	  of	  sufferers,	  around	   80%,	   could	   have	   avoided	   this	   disease	   simply	   by	  maintaining	   a	   weight	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within	  the	  normal	  range	  (Bruno	  and	  Landi,	  2011)	  .Obesity	  is	  increasingly	  being	  associated	  now	  with	  poverty	  and	  this	  presents	  a	  concerning	  combination	  for	  this	  vulnerable	  population	  due	  to	  the	  minimal	  access	  they	  have	  to	  medical	  assistance.	  	  	  	  The	   initial	   symptoms	   of	   diabetes	   are	   excessive	   thirst	   and	   urination,	   blurred	  vision,	  and	  rapid	  weight	  loss.	  	  	  	  Left	  untreated	  diabetes	  is	  acutely	  life	  threatening	  and	  severely	  disabling.	   	  The	  acute	  metabolic	  complications	  of	  ketoacidosis	  or	  a	  non-­‐ketotic	  hyperosmolar	  state	  can	  develop	  which	  can	   lead	  to	  coma	  and	  prove	  fatal.	   	   Chronically	   uncontrolled	   diabetes	   causes	   progressive	   damage	   to	   and	  dysfunction	  and	  failure	  of	  numerous	  organs.	  	  	  However,	  diabetes	  can	  be	  avoided	  with	  dietary	  control	   to	  reduce	  carbohydrate	   intake	  and	  obesity,	  and	  treated	  by	  restoration	  of	  the	  insulin	  deficit	  to	  facilitate	  glucose	  homeostasis.	  	  T1D	  is	  treated	  by	   insulin	   replacement	   using	   recombinant	   human	   insulin,	   whereas	   T2D	   is	  treated	  by	  drugs	  that	  act	  to	  increase	  insulin	  secretion	  and	  by	  sensitizing	  agents	  that	  enhance	  insulin	  effects.	  Successful	  diabetes	  management	  is	  currently	  seen	  as	  maintaining	  blood	  glucose	  levels	  at	  levels	  below	  10	  mmoles/dl.	  	  The	  better	  blood	  glucose	  control	  has	  transformed	  the	  prognosis	  for	  diabetics	  as	  this	  has	  markedly	  reduced	  the	  incidence	  of	  mortality	  and	  extended	  their	  life	  expectancy.	  	  However,	  with	  disease	  progression	  severe	  diabetic	  complications	  continue	  to	  develop	  such	  as	   retinopathy,	   nephropathy,	   neuropathy	   and	   ulceration.	   Diabetes	   is	   also	  associated	   with	   increased	   risks	   of	   cardiovascular,	   peripheral	   vascular	   and	  cerebrovascular	   disease	   (WHO,	   1999).	   	   These	   numerous	   disease-­‐associated	  complications	  are	  often	  resistant	  to	  treatment	  and	  cause	  considerable	  distress	  to	  the	  patient.	  
Diabetic	  complications	  	  	  Diabetic	  complications	  affect	  multiple	  organs	  including	  the	  kidneys,	  eyes,	  gastro-­‐intestinal	   system	   and	   nervous	   system.	   	   The	   causative	   events	   underlying	   the	  pathogenesis	   of	   diabetic	   complications	   are	   complex	   and	   not	   fully	   understood.	  Chronic	  hyperglycemia	  in	  itself	  certainly	  plays	  a	  major	  precipitating	  and	  directly	  causative	   role	   but	   additional	   factors	   are	   likely	   to	   contribute.	   	   This	   is	   because	  even	   with	   good	   glucose	   homeostasis	   in	   the	   well-­‐controlled	   diabetic,	  complications	  still	  occur	  and	  are	  resistant	  to	  resolution	  (Llorente	  and	  Malphurs,	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What	  causes	  diabetic	  neuropathy?	  	  Exactly	   what	   causes	   diabetic	   neuropathy	   is	   unknown.	   	   However	   a	   number	   of	  pathogenic	   mechanisms	   for	   neuronal	   injury	   and	   altered	   function	   driven	   by	  hyperglycemia	   have	   been	   identified	   (Aronson,	   2008).	   	   These	   include	   the	  saturation	  of	  glucose	  metabolic	  pathways	  that	  ultimately	  lead	  to	  the	  formation	  of	  toxic	   polyols	   through	   the	   polyol	   pathway,	   increased	   advanced	   glycation	   end	  (AGE)	  products	  which	  often	  have	  altered	  properties,	  nerve	  hypoxia	  or	  ischemia,	  deficiency	   of	   linolenic	   acid,	   increased	   protein	   kinase	   C	   especially	   the	   beta	  isoform	  and	   a	  deficiency	   in	   growth	   factors.	   	   All	   of	   these	  pathways	   converge	   in	  producing	  oxidative	  stress	   that	   seems	   to	  be	  more	  severe	  at	   site	  of	   the	  primary	  sensory	  neurons,	  the	  dorsal	  root	  ganglia	  (DRG),	  than	  at	  other	  nerves	  leading	  to	  the	   hypothesis	   that	   a	   primary	   target	   of	   diabetic	   neural	   complications	   is	   the	  sensory	   neuron	   (Nickander	   et	   al.,	   1994).	   	   In	   order	   to	   treat	   this	   serious	  complication	  it	  is	  important	  to	  gain	  an	  increased	  understanding	  of	  the	  molecular	  mechanisms	   that	   drive	   the	   onset	   of	   sensory	   neuropathy,	   and	   prevent	   its	  resolution.	  	  	  	  
	  
Animal	  models	  of	  diabetes	  
Diabetes	  is	  a	  complex	  metabolic	  disorder	  and	  is	  hard	  to	  model	   in	  vitro.	   	  Animal	  models	   of	   diabetes	   are	   therefore	   very	   important	   for	   the	   study	   of	   the	   disease	  pathogenesis	   and	   can	   be	   used	   for	   the	   study	   of	   diabetic	   complications	   that	   are	  seen	  clinically.	  	  Over	  130	  years	  ago,	  the	  surgical	  removal	  of	  the	  pancreas	  in	  a	  dog	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and	   the	   consequent	   polyuria,	   polydipsia	   and	   diabetes,	   highlighted	   the	   role	   the	  pancreas	  plays	  in	  diabetes	  (Von-­‐Mering,	  1889).	  More	  recently	  developed	  rodent	  diabetic	   models	   use	   administration	   of	   chemicals	   such	   as	   streptozotocin	   (STZ)	  and	  alloxan	  (ALX)	  that	  are	  selectively	  toxic	  to	  the	  β-­‐islet	  pancreatic	  cells	  (Lenzen,	  2008).	  	  Transgenic	  or	  highly	  inbred	  animal	  strains	  have	  also	  been	  developed	  that	  spontaneously	  or	   conditionally	  develop	  diabetes,	   although	   the	  use	  of	   these	  can	  be	  restricted	  by	  their	  cost	  (Rees	  and	  Alcolado,	  2005).	  	  The	  most	  commonly	  used	  inbred	  models	  used	  in	  research	  are	  the	  non-­‐obese	  diabetic	  mouse	  (NOD)	  and	  the	  bio	  breeding	  rat	  (Rees	  and	  Alcolado,	  2005).	  	  Both	  of	  these	  models	  spontaneously	  develop	  diabetes	  but	  there	  are	  drawbacks	  in	  that	  the	  NOD	  model	  demonstrates	  a	  large	   gender	   difference	   with	   females	   showing	   an	   increased	   propensity	   of	  developing	  diabetes	  and	  the	  BB	  rat	  requires	  administration	  of	  exogenous	  insulin	  to	  survive	  (Rees	  and	  Alcolado,	  2005).	  Additionally	  the	  TRPV1	  receptor	  has	  been	  shown	  in	  the	  NOD	  model	  to	  be	  functionally	  mutated	  (Razavi	  et	  al.,	  2006)	  which	  would	   of	   no	   doubt	   add	   a	   confounding	   issue	   to	   the	   study	   of	   this	   channel	   in	  diabetes.	   	   There	   are	   numerous	   models	   of	   T2D	   due	   to	   the	   complexity	   and	  heterogeneity	  of	  the	  human	  disease.	  	  They	  include	  ob/ob	  and	  db/db	  mice,	  which	  have	   been	   shown	   to	   be	   leptin	   deficient	   and	   leptin	   resistant	   respectively	   (Rees	  and	   Alcolado,	   2005)	   and	   the	   Zucker	   rat	   (also	   leptin	   resistant).	   	   Transgenic	  models	  have	  been	  developed	  for	  the	  study	  of	  specific	  elements	  of	  the	  disease	  but	  the	   use	   of	   these	   is	   very	   economically	   restrictive	   and	   has	   other	   drawbacks	  especially	  when	  wanting	  to	  look	  at	  a	  disease	  from	  a	  non-­‐biased	  viewpoint.	  	  	  There	  is	  no	  perfect	  animal	  model	  of	  the	  human	  disease	  however,	  and	  all	  of	  the	  models	  have	  their	   limitations	  and	  drawbacks	  as	  well	  as	  their	  advantages.	   	   	  	  For	  many	   researchers,	   STZ	   is	   the	   agent	   of	   choice	   due	   to	   its	   more	   reproducible	  induction	   of	   diabetes	   through	   greater	   stability	   than	   ALX	   at	   physiological	   pH	  (Lenzen,	  2008).	  
	  	  STZ	   is	   an	   antimicrobial	   chemotherapeutic	   agent	   (Schein	   et	   al.,	   1974),	   derived	  from	  the	  earthborn	  microbe	  Streptomyces	  achromogenes,	  and	  was	  identified	  as	  a	  diabetogenic	  agent	   in	  1963.	  When	  delivered	  systemically	   to	  rodents	  as	  a	  single	  large	   dose	   (>50	  mg/kg)	   STZ	   induces	   a	   rapid	   and	   sustained	   diabetic	   state	   as	   a	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result	   of	   direct	   toxicity	   on	   the	   pancreatic	   β-­‐cells.	   	   	   It	   has	   taken	   decades	   of	  research	   to	   uncover	   how	   STZ	   is	   selectively	   toxic	   towards	   pancreatic	   β-­‐cells	  (Weiss,	  1982,	  Szkudelski,	  2001,	  Lenzen,	  2008).	  STZ	  gains	  entry	  with	  reasonable	  specificity	   to	   rodent	   pancreatic	   β-­‐cells	   via	   the	   low	   affinity	   glucose	   transporter	  GLUT2.	  Once	  within	  the	  β-­‐cell,	  STZ	  is	  split	  into	  glucose	  and	  the	  alkylating	  moiety,	  methylnitroso-­‐urea	   which	   is	   cytotoxic	   through	   modification	   of	   biological	  macromolecules	   and	   DNA	   fragmentation.	   STZ	   evokes	   pancreatic-­‐β	   cell	  destruction	  and	  thus	  induces	  the	  diabetic	  state.	   	   	  Following	  STZ	  administration,	  three	  distinct	  phases	  of	  blood	  glucose	  responses	  are	  seen	  (Lenzen,	  2008).	   	  The	  first	   phase	   is	   hyperglycaemia	   occurring	   around	   one	   hour	   post	   STZ	  administration	  and	  lasts	  for	  2-­‐4	  hours	  and	  is	  caused	  by	  the	  inhibition	  of	  insulin	  secretion.	   The	   second	   phase	   is	   a	   transient	   hypoglycaemia,	   typically	   occurring	  between	   4-­‐	   8	   hrs	   following	   STZ,	   and	   can	   be	   so	   severe	   that,	   without	   glucose	  administration,	  it	  is	  fatal.	  The	  rupture	  of	  secretory	  granules	  and	  release	  of	  insulin	  cause	  this	  hypoglycaemia	  during	  necrosis	  of	  the	  pancreatic	  β-­‐cells.	  	  Within	  12-­‐48	  hours	   the	   STZ-­‐treated	   animal	   enters	   the	   third	   permanent	   diabetic	  hyperglycaemic	   phase,	   so	   by	   48	   hours	   a	   long	   lasting	   diabetic	   state	   is	   induced.	  Given	   as	   a	   single	  high	  dose	   to	   adult	   rats,	   the	   STZ	  model	   can	  be	  described	   as	   a	  model	  of	  T1D	  as	  STZ	  administration	  evokes	  pancreatic	  β-­‐cell	  destruction	  and	  a	  subsequent	  deficiency	  in	  insulin	  production.	  	   	  A	  model	  of	  autoimmune	  T1D	  can	  also	  be	  established	  using	  multiple	  small	  doses	   of	   STZ	   (e.g.	   40	   mg/kg	   on	   five	   consecutive	   days)	   which	   has	   been	   used	  extensively	  for	  the	  study	  of	  the	  immunological	  pathways	  that	  lead	  to	  insulitis	  and	  pancreatic	   β-­‐cell	   death	   (Rees	   and	   Alcolado,	   2005).	   	   	   Some	   investigators	   also	  utilize	   STZ	   administered	   neonatally	   or	   in	   combination	   with	   a	   high	   fat	   diet	   to	  adult	  animals	  to	  induce	  a	  T2D	  model	  (Islam	  and	  Loots,	  2009).	  	  The	  in-­‐house	  established	  model	  of	  diabetes	  utilizes	  a	  single	  high	  dose	  of	  STZ	  (65	  mg/kg)	  delivered	  to	  male	  rats	  (300-­‐400g),	  followed	  by	  supply	  of	  2%	  sucrose	  in	  drinking	  water	  for	  48	  hours.	  	  This	  is	  a	  model	  of	  T1D,	  and	  has	  been	  demonstrated	  to	  display	  a	  reasonably	  robust	  diabetic	  state	   together	  with	   the	  appearance	  of	  a	  number	   of	   diabetic	   complications	   including	   neuropathy,	   without	   the	   need	   for	  administration	  of	   insulin	   to	   the	  animals.	   	  Although	   the	  more	  prevalent	   form	  of	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diabetes	   is	   T2D	   and	   complications	   such	   as	   neuropathy	   do	   occur	   in	   T2D,	   the	  animal	  models	  for	  T2D	  are	  economically	  more	  expensive	  and	  the	  appearance	  of	  complications	  takes	  longer	  and	  is	  more	  variable.	  
	  
	  
TRPV1	  is	  a	  candidate	  for	  investigation	  of	  diabetic	  neuropathy	  
A	  candidate	  for	  investigation	  of	  diabetic	  neuropathy	  is	  the	  prototypical	  Transient	  Receptor	  Potential	  (TRP)	  family	  member,	  TRP	  Vanilliod	  1	  (TRPV1)	  due	  to	  its	  expression,	  function	  and	  changes	  to	  its	  function	  in	  diabetes.	  	  
Firstly	  TRPV1	  is	  expressed	  on	  the	  cells	  affected	  by	  sensory	  neuropathy,	  the	  sensory	  neurons.	  	  Secondly	  TRPV1	  is	  known	  to	  play	  an	  important	  role	  in	  pain	  transmission	  (nociception),	  the	  major	  symptom	  of	  neuropathy.	  	  Furthermore	  stimulation	  of	  the	  TRPV1	  receptor	  results	  in	  a	  burning-­‐like	  pain	  similar	  to	  that	  described	  in	  sensory	  neuropathy.	  	  Finally	  there	  is	  a	  correlation	  in	  TRPV1	  function	  and	  expression	  levels	  with	  the	  evolution	  of	  sensory	  neuropathy	  symptoms:	  in	  the	  early	  stages	  of	  diabetes,	  the	  activity	  of	  TRPV1	  is	  both	  attenuated	  and	  augmented	  (pain),	  whereas	  in	  the	  later	  stages	  of	  diabetes,	  a	  loss	  of	  TRPV1	  activity	  and	  expression	  is	  seen	  (sensory	  loss)	  (Pabbidi	  et	  al.,	  2008b).	  	  
	  So	  a	  strong	  association	  between	  sensory	  neuropathy	  symptoms	  and	  TRPV1	  expression,	  function	  and	  disease-­‐related	  changes	  exist	  and	  from	  this,	  the	  notion	  arises	  that	  modulation	  of	  TRPV1	  activity	  may	  actually	  be	  causative	  to	  the	  onset	  and	  maintenance	  of	  sensory	  neuropathy.	  	  	  
TRP	  channels	  	  Transient	  receptor	  potential	  (TRP)	  channels	  are	  a	  large	  family	  of	  functionally	  diverse	  cation-­‐permeant	  ion	  channels.	  	  They	  are	  present	  in	  almost	  all	  mammalian	  cell	  types.	  The	  first	  member	  was	  discovered	  in	  the	  eye	  of	  drosophila	  melanogaster	  and	  was	  called	  the	  TRP	  channel	  due	  to	  a	  mutation	  that	  resulted	  in	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a	  transient	  voltage	  response	  to	  light	  (Minke,	  2010).	  	  Based	  on	  sequence	  homology,	  the	  large	  superfamily	  of	  related	  ion	  	  channels	  is	  divided	  into	  six	  main	  sub-­‐families:	  canonical	  (TRPC),	  vanilloid	  (TRPV)	  ,melastatin-­‐related	  (TRPM),	  polycystin	  (TRPP),	  mucolipin	  (TRPML)	  and	  the	  ankyrin	  (TRPA)	  channels.	  	  Common	  features	  of	  these	  channels	  include	  the	  six	  transmembrane	  spanning	  structure	  that	  embeds	  the	  channel	  within	  the	  lipid	  bilayer	  of	  cells	  and	  for	  the	  channels	  to	  become	  functional,	  the	  requirement	  of	  a	  tetrameric	  assembly	  of	  homomeric	  or	  heteromeric	  TRP	  units.	  Most	  also	  share	  a	  non-­‐selective	  permeability	  to	  cations	  and	  a	  low	  sensitivity	  to	  membrane	  voltage.	  Their	  functional	  roles	  are	  diverse	  and	  range	  from	  thermosensation,	  pheromone	  recognition,	  magnesium	  homeostasis,	  to	  regulation	  of	  vascular	  tone.	  	  	  	  Members	  of	  the	  TRP	  family	  share	  a	  basic	  channel	  structure	  that	  is	  similar	  to	  that	  of	  the	  voltage	  gated	  K+	  channels.	  	  The	  TRP	  channel	  structure	  is	  built	  from	  four	  similar	  or	  identical	  subunits,	  each	  of	  which	  have	  six	  transmembrane	  (TM)	  domains	  (TM1-­‐TM6)	  and	  cytosolic	  N-­‐	  and	  C-­‐terminal	  tails.	  	  There	  is	  a	  central	  cation-­‐conducting	  pore	  that	  consists	  of	  the	  TM5,	  TM6	  domains	  with	  a	  connecting	  loop.	  	  Regulatory	  domains	  which	  control	  how	  the	  channel	  is	  gated	  are	  thought	  to	  lie	  on	  the	  regions	  TM1-­‐TM4	  and	  the	  tail	  C-­‐and	  N-­‐terminals.	  	  	  
TRPV1	  channels	  	  TRPV1	  is	  the	  first	  member	  of	  the	  TRPV	  family	  (TRPV1-­‐TRPV6).	  	  TRPV1	  is	  a	  voltage-­‐dependent	  cation	  channel	  and	  can	  be	  directly	  activated	  by	  numerous	  stimuli	  that	  include	  noxious	  heat	  (>43	  °	  C),	  and	  reduced	  pH	  (<6),	  endogenous	  lipoxygenase	  products	  and	  fatty	  acid	  amides	  such	  as	  anandamide	  as	  well	  as	  a	  number	  of	  plant	  derived	  products	  such	  as	  capsaicin,	  gingerols,	  eugenol,	  resiniferatoxin,	  piperine	  and	  camphor	  (Pingle	  et	  al.,	  2007).	  	  TRPV1	  function	  can	  also	  be	  potentiated	  by	  a	  range	  of	  mediators	  that	  include	  endogenous	  pro-­‐nociceptive	  mediators	  such	  as	  prostaglandins,	  bradykinin	  and	  ATP	  (Moriyama	  et	  al.,	  2005),	  as	  well	  as	  substances	  such	  as	  ethanol	  and	  DMSO	  (Vetter	  et	  al.,	  2008)	  .	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The	  properties	  of	  the	  TRPV1	  channel	  make	  it	  the	  principal	  integrator	  of	  noxious	  information	  in	  a	  large	  number	  of	  primary	  afferent	  neurons	  and	  therefore	  an	  interesting	  target	  for	  novel	  analgesic	  development	  (Premkumar	  and	  Sikand,	  2008).	  
	  
TRPV1	  expression	  	  TRPV1	  is	  expressed	  in	  the	  cell	  bodies	  of	  small	  to	  medium	  sized	  primary	  afferents	  which	  are	  located	  in	  dorsal	  root,	  trigeminal	  and	  nodose	  ganglia,	  with	  an	  intense	  expression	  in	  the	  dorsal	  root	  ganglia,	  the	  nociceptive	  primary	  afferent	  sensory	  neurons.	  	  Brain	  expression	  of	  TRPV1	  extends	  to	  regions	  of	  the	  limbic	  system	  such	  as	  the	  hippocampus	  and	  the	  amygdala,	  striatum,	  locus	  ceruleus,	  cerebellum	  and	  the	  hypothalamus	  (Menigoz	  and	  Boudes,	  2011).	  	  TRPV1	  has	  been	  shown	  to	  regulate	  synaptic	  transmission	  (glutaminergic	  and	  or	  GABAergic)	  (Anwar	  and	  Derbenev,	  2013)	  and	  additionally	  may	  function	  to	  regulate	  body	  temperature	  in	  the	  hypothalamus	  as	  well	  as	  playing	  a	  role	  in	  reward	  and	  appetite.	  	  TRPV1	  is	  also	  found	  in	  the	  peripheral	  terminals	  of	  afferents	  in	  many	  body	  structures	  including	  skin,	  muscle	  and	  viscera.	  	  Epithelial	  cells	  have	  also	  been	  shown	  to	  express	  TRPV1	  receptors	  and	  these	  cells	  include	  keratinocytes	  and	  urothelial	  cells,	  the	  umbrella-­‐like	  lining	  to	  the	  bladder	  (Yamada	  et	  al.,	  2009).	  	  In	  the	  bladder,	  TRPV1	  appears	  to	  be	  involved	  in	  normal	  bladder	  function	  and	  has	  been	  shown	  to	  play	  a	  role	  in	  mechanically	  (stretch)	  evoked	  purinergic	  signaling	  in	  the	  urothelium	  (Gevaert	  et	  al.,	  2007).	  	  In	  keratinocytes,	  TRPV1	  and	  other	  temperature	  sensitive	  TRPV	  channels	  such	  as	  TRPV3	  and	  TRPV4,	  are	  thought	  to	  contribute	  to	  thermosensation.	  	  Mast	  cells	  also	  express	  TRPV1,	  here	  TRPV1	  plays	  a	  role	  in	  regulating	  the	  immune	  response	  (Ständer	  et	  al.,	  2004).	  	  
	  
TRPV1	  association	  with	  disease	  
	  Homozygous	  and	  conditional	  TRPV1	  knockout	  mutant	  mice	  demonstrate	  abnormal	  nociception,	  a	  deficient	  response	  to	  capsaicin	  and	  development	  of	  thermal	  hyperalgesia,	  reduced	  DRG	  electrophysiological	  responses	  to	  capsaicin,	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heat	  and	  acid	  and	  a	  reduced	  hypersensitivity	  response	  during	  inflammation	  (Davis	  et	  al.,	  2000,	  Caterina	  et	  al.,	  2000).	  	  Additionally	  they	  display	  abnormal	  anxiety-­‐	  and	  conditioning-­‐related	  behaviors,	  increased	  sensitivity	  to	  deoxycorticosterone	  acetate	  -­‐salt-­‐induced	  renal	  damage,	  resistance	  to	  diet-­‐induced	  obesity,	  altered	  taste	  sensitivity,	  and	  an	  impaired	  febrile	  response	  (Blake	  Ja,	  2014)	  .	  Other	  evidence	  gained	  from	  the	  use	  of	  TRPV1	  transgenic	  mice	  models	  have	  suggested	  that	  the	  TRPV1	  receptor	  is	  associated	  with	  thermal	  hyperalgesia,	  allodynia,	  functional	  bowel	  disease,	  inflammatory	  bowel	  disease,	  vulvodynia,	  osteoarthritis,	  pancreatitis,	  gastroesophageal	  reflux	  disease,	  bladder	  disease,	  cystitis,	  asthma,	  migraine,	  schizophrenia	  and	  pain	  in	  general	  (Nilius	  et	  al.,	  2007).	  	  Genetics	  and	  genetic	  mapping	  evidence	  (OMIM)	  have	  identified	  a	  potential	  association	  of	  the	  TRPV1	  receptor	  with	  breast	  cancer,	  myasthenic	  syndrome	  and	  non-­‐insulin	  dependent	  diabetes	  mellitus	  (Nilius	  et	  al.,	  2007).	  	  
TRPV1	  on	  sensory	  neurons	  is	  a	  noxious	  molecular	  integrator	  that	  may	  play	  
a	  role	  in	  neuropathy	  	  The	  TRPV1	  ion	  channel	  has	  particular	  importance	  in	  noiciception	  and	  is	  of	  interest	  as	  a	  pain	  therapy	  target	  (Roberts	  and	  Connor,	  2006).	  	  The	  discovery	  of	  TRPV1	  antagonists	  (Bevan	  et	  al.,	  1992)	  and	  the	  subsequent	  proof	  of	  their	  efficacy	  in	  models	  of	  pain	  (Culshaw	  et	  al.,	  2006)	  has	  fuelled	  a	  great	  deal	  of	  interest	  in	  this	  channel	  both	  in	  academia	  and	  in	  industry.	  	  TRPV1	  is	  a	  non-­‐selective	  cation	  channel,	  expressed	  in	  around	  40%	  of	  DRG	  (Zacharova	  and	  Palecek,	  2009).	  	  	  The	  TRPV1	  receptor	  rapidly	  and	  directly	  detects	  potentially	  damaging	  thermal	  and	  chemical	  stimuli,	  which	  are	  then	  perceived	  as	  painful.	  Additionally	  TRPV1	  activation	  plays	  a	  role	  in	  the	  establishment	  of	  persistent	  peripheral	  inflammation	  and	  central	  sensitisation.	  
TRPV1	  activation	  causes	  the	  release	  of	  pro-­‐inflammatory	  peptides	  from	  peripherally	  located	  nerve	  terminals	  and	  evokes	  action	  potential	  driven	  vesicular	  release	  of	  glutamate	  and	  neuropeptides	  from	  the	  central	  nerve	  terminals.	  	  The	  glutamate	  release	  from	  primary	  afferent	  terminals	  in	  the	  spinal	  cord	  is	  the	  basic	  event	  in	  pain	  transmission,	  while	  the	  central	  release	  of	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neuropeptides	  acts	  to	  two	  ways:	  firstly	  to	  amplify	  the	  glutamate	  signal	  and	  secondly	  to	  increase	  dorsal	  horn	  neuronal	  sensitivity	  to	  other	  incoming	  signals.	  	  Peripheral	  CGRP	  and	  substance	  P	  (sP)	  release	  contribute	  to	  a	  state	  of	  neurogenic	  inflammation	  through	  blood	  vessel	  and	  immune	  cell	  effects	  (Roberts	  and	  Connor,	  2006)	  	  
Genetic	   deletion	   of	   the	   TRPV1	   gene	   renders	  mice	   non-­‐responsive	   to	   vanilloids	  and	   less	   sensitive	   to	   noxious	   heat	   and	   low	   pH,	   confirming	   the	   important	   role	  TRPV1	   contributes	   to	   vanilloid,	   heat	   and	  proton	   sensitivity	   in	  vivo	  (Caterina	   et	  al.,	   2000).	   	   	   Functional	   TRPV1	   is	   thought	   to	   exist	   as	   tetramers	   in	   the	   plasma	  membrane	  (Hong	  and	  Wiley,	  2005).	   	  Following	  activation	  of	  TRPV1,	  the	  TRPV1	  ion	  channel	  undergoes	  a	  conformational	  change	  and	  opens	  allowing	  cations	  such	  as	  calcium	  (Ca2+)	  to	  enter	  the	  cell.	   	  This	  causes	  an	  increase	   in	   intracellular	  Ca2+	  and	  leads	  to	  activation	  of	  Ca2+-­‐mediated	  signal	  transduction	  pathways.	  	  This	  can	  induce	  exocytosis	  of	  neuropeptides	  such	  as	  CGRP,	  sP,	  or	  neurokinin	  (NK)A	  from	  sensory	  neurons.	  	  Following	  this	  neuronal	  exocytosis,	  the	  neuropeptides	  bind	  to	  their	   respective	   receptors	   such	   as	   CGRP	   receptor,	   sP	   receptor,	   NK1	   or	   NK2	  receptors	   and	   thereby	   elicit	   tissue	   specific	   effects.	   	   In	   the	   urinary	   bladder	   for	  example,	   TRPV1	   activation	   by	   capsaicin	   leads	   to	   detrusor	   muscle	   contraction	  (Saitoh	   et	   al.,	   2007)	   and	   because	   of	   this	   provides	   an	   amenable	   model	   for	   the	  study	  of	  TRPV1	  function	  in	  vitro.	  	  TRPV1	  activation	  of	  perivascular	  nerves	  causes	  CGRP	  and	  sP	  release	  and	  vasodilation	  which	  can	  result	  in	  neurogenic	  inflammation	  (Manzini	  et	  al.,	  1991).	  TRPV1	   induced	   spinal	   cord	   CGRP	   release	   is	   associated	   with	   nociceptive	  transmission	   (Donnerer	   and	   Amann,	   1992)	   and	   elevated	   blood	   levels	   of	   CGRP	  have	  been	  found	  during	  migraines	  and	  cluster	  headaches	  (Dux	  et	  al.)	  as	  well	  as	  in	  mycocardial	   infarction.	   	   The	   role	   of	   TRPV1	   in	   pain	   transmission	   was	   clearly	  demonstrated	  by	  Caterina	  et	  al,	  who	  showed	  a	  thermal	  hypoalgesic	  response	  of	  TRPV1	   knockout	  mice	   (Caterina	   et	   al.,	   2000).	   	   Other	   lines	   of	   evidence	   include	  numerous	  expression	  and	  pharmacological	  manipulation	  studies.	  	  	  	  Upregulation	  of	  TRPV1	  function	  is	  associated	  with	  somatic	  allodynia	  and	  hyperalgesia	   and	   this	   may	   be	   due	   to	   changes	   in	   TRPV1	   trafficking	   and	  phosphoryation	   status	   (Hong	   and	   Wiley,	   2005).	   	   However,	   in-­‐house	   data	   has	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shown	  a	  dramatic	  decrease	  in	  TRPV1	  function	  in	  the	  urinary	  bladder	  from	  a	  rat	  streptozotocin	   (STZ-­‐diabetic)	  model.	   	   	   This	   suggests	   that	  TRPV1	  modulation	   is	  complex	  and	  may	  be	  site	  specific.	  	  
Changes	   in	   TRPV1	   functionality	   are	   dynamically	   regulated	   by	   receptor	  
phosphorylation	  and	  dephosphorylation	  	  	  TRPV1	  activity	  is	  modulated	  by	  two	  distinct	  processes:	  firstly	  through	  alteration	  of	   the	   functional	   activity	   of	   TRPV1	   channels	   already	   present	   in	   the	   plasma	  membrane	  and	  secondly	  through	  translocation	  of	  additional	  TRPV1	  channels	  to	  the	   cell	   membrane	   (Figure	   1.1).	   	   Both	   these	   processes	   may	   be	   controlled	   by	  phosphorylation	  of	  the	  channel	  at	  different	  structural	  sites	  (Zhang	  et	  al.,	  2005b).	  	  
	  
	  
Figure	  1.1	  	  Examples	  of	  signaling	  pathways	  associated	  with	  TRPV1	  function	  and	  modulation	  (TRPV1	  in	  cell	  signalling)	  Black	  arrows	  denote	  positive	  modulation,	  while	   an	   orthogonal	   line	   at	   the	   end	   denotes	   inhibition.	   Blue	   arrows	   denote	  biosynthesis.	   TRPV1	   is	   schematically	   depicted	   in	   red,	   with	   both	   its	  transmembrane	   and	   cytoplasmic	   domains.	   PKA,	   PKC,	   CaMKII	   sensitize	   TRPV1	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(Figure	   1.1	   legend	   continued)	   through	   phosphorylation,	   denoted	   as	   a	   pink-­‐encircled	  “P”	  in	  the	  channel.	  Calcineurin	  (PP2B)	  desensitizes	  the	  channel	  through	  dephosphorylation.	   Both	   Gq-­‐	   and	   Gs-­‐protein	   coupled	   receptors	   (GPCRs)	   are	  depicted	  with	  some	  of	   its	  agonists.	  AC	  denotes	  Gs-­‐stimulated	  adenylate	  cyclase.	  Phospholipase	   Cβ	   and	   Cγ	   catalize	   the	   formation	   of	   1,4,5	   inositoltriphosphate	  (IP3)	  and	  diacylglycerol	  (DAG)	   from	  PIP2,	  depicted	  as	  a	  yellow	  oval,	  after	   their	  activation	   by	   a	   Gq	   protein	   or	   a	   receptor	   tyrosine	   kinase	   (TRK).	   Calcium-­‐stimulated	  phospholipase	  A2	  (PLA2)	  catalyzes	  arachidonic	  acid	  (AA)	  formation,	  which	   is	   further	   converted	   into	  TRPV1-­‐activating	  eicosanoids	   and	   leukotrienes	  such	  as	  HPETEs	  by	  the	  lipoxygenase	  enzymes	  (LOX).	  TRPV1	  agonist	  anandamide	  (AEA)	  is	  shuttled	  into	  the	  cell	  by	  the	  anandamide	  membrane	  transporter	  (AMT),	  and	   is	   also	   synthesized	   from	   phospholipids	   by	   phospholipase	   D	   (PLD).	   AEA	   is	  transformed	   to	   AA	   by	   the	   fatty	   acid	   amide	   hydrolase	   (FAAH).	   TRK-­‐stimulated	  phosphoinositide	   3-­‐kinase	   (PI3	   K)	   stimulates	   TRPV1	   trafficking	   to	   the	  membrane	   and	   Src-­‐mediated	   channel	   phosphorylation,	   which	   also	   stimulates	  channel	   trafficking.	  Membrane	  cholesterol	   can	  directly	   inhibit	   channel	   function	  and	  lysophosphatidic	  acid	  (LPA),	  which	  is	  synthesized	  by	  the	  integrin-­‐associated	  enzyme	   autotaxin,	   activates	   the	   channel	   after	   its	   translocation	   into	   the	   cell.	  	  Taken	  from	  (Kamkin	  et	  al.,	  2012)	  
	  
	  
Alteration	  of	  the	  functional	  activity	  of	  TRPV1	  channels	  	  The	  TRPV1	  channel	  has	  numerous	  phosphorylation	  sites	  within	  its	  structure	  that	  affect	   the	   functionality.	   	   Exposure	   to	   TRPV1	   agonists,	   interaction	  with	   cellular	  components	  such	  as	  phospholipids	  and	  activation	  of	  G-­‐protein	  coupled	  receptors	  or	  other	  ion	  channels	  all	  can	  act	  to	  affect	  the	  functional	  and	  state	  of	  TRPV1.	  	  
TRPV1	  agonist	  exposure	  causes	  TRPV1	  desensitisation	  	  Repeated	   application	   of	   vanilloid	  TRPV1	   agonists,	   even	   briefly,	   results	   in	   Ca2+-­‐	  dependent	  desensitization	  of	  TRPV1.	  The	  Ca2+	  dependence	  has	  been	  evidenced	  by	   the	   observation	   that	   in	   the	   absence	   of	   extracellular	   Ca2+,	   application	   of	  capsaicin	   to	   urinary	   bladder	   does	   not	   result	   in	   contraction	   or	   desensitisation,	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whereas	   application	   in	   the	   presence	   of	   Ca2+	   produces	   urinary	   bladder	  contraction	  and	  desensitisation	  (Santicioli	  et	  al.,	  1987b)	  This	  desensitization	  to	  agonist	   exposure	   is	  used	   therapeutically	   for	   example	   to	   treat	  neuropathic	  pain	  by	   application	   of	   topical	   capsaicin	   cream	   (Mason	   et	   al.,	   2004)	   or	   to	   treat	  neurogenic	   overactive	   bladder	   by	   intravesicular	   application	   of	   resiniferatoxin	  (Lazzeri	   et	   al.,	   1997).	   This	   agonist	   driven	   desensitisation	   is	   dependent	   on	  calcium	   and	   occurs	   through	   activation	   of	   calmodulin	   causing	   promotion	   of	  calcineurin-­‐mediated	   dephosphorylation	   of	   TRPV1.	   	   Conversely	   however,	  activation	   of	   calmodulin-­‐	   dependent	   kinase	   II	   (CaMKII)	   phosphorylates	   TRPV1	  and	  acts	  to	  enhance	  TRPV1	  function	  so	  inhibition	  of	  CaMK11	  has	  been	  shown	  to	  reduce	  TRPV1	  responses	  (Price	  et	  al.,	  2005).	  	  	  
Cross-­‐desensitisation	  of	  TRPV1	  
	  TRPV1	   is	   co-­‐expressed	  with	   a	   number	   of	   other	   ion	   channels	   and	   receptors	   in	  sensory	  neurons	  (Streng	  et	  al.,	  2008).	  This	  close	  association	  can	  also	  impact	  on	  TRPV1	   receptor	   function	   as	   it	   has	   been	   seen	   that	   activation	   of	   the	   TRPA1	   ion	  channel	   can	   act	   to	   either	   positively	   or	   negatively	   affect	   TRPV1	   function	   (N	  Akopian,	   2011).	   Cross-­‐talk	   between	   TRPV1	  with	   the	   purinergic	   receptor	   P2X3	  has	   also	   been	   demonstrated	   resulting	   in	   inhibition	   (Stanchev	   et	   al.,	   2009)	  whereas	   sensitisation	   of	   TRPV1	   by	   ATP	   ,a	   purinergic	   agonist	   has	   been	   well	  described	  in	  the	  literature	  	  (Tominaga	  and	  Moriyama,	  2007).	  
	  	  
TRPV1	   function	   can	   be	   altered	   through	   interaction	   with	   cell	   membrane	  
lipids	  	  TRPV1	  function	  may	  also	  rely	  on	  the	  presence	  of	  intact	  membrane	  lipid	  rafts	  and	  has	   been	   found	   to	   be	   altered	   by	   the	   manipulation	   of	   the	   raft	   constituent	  components	   such	   as	   cholesterol,	   the	   phospholipid	   phosphatidylinositol-­‐4,5-­‐bisphosphate	   (PIP2)	   and	   ceramide	   (Liu	   et	   al.,	   2006,	   Zhang	   and	   Nicol,	   2004,	  Prescott	   and	   Julius,	   2003).	   	   	   Phosphorylation	   of	   TRPV1	   by	   PIP2	   is	   believed	   by	  some	  to	  hold	  TRPV1	  under	  an	  inhibited	  state	  and	  sensitisation	  of	  TRPV1	  can	  be	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gained	  by	  PIP2	  hydrolysis	  through	  receptor	  mediated	  activation	  of	  protein	  kinase	  C,	   A,	   or	   phospholipase	   A	   (Prescott	   and	   Julius,	   2003).	   The	   receptors	   that	   can	  mediate	   this	  activation	  are	  numerous	  but	   include	  bradykinin,	  prostaglandin	  E2	  (PGE2),	   5HT	   and	   nerve	   growth	   factor	   (NGF).	   	   Furthermore,	   reinstatement	   of	  active	   TRPV1	   following	   desensitisation	   requires	   PIP2	   phosphorylation	   and	  maintenance	  of	  active	  TRPV1	  may	  depend	  on	  a	  continual	  basal	  phosphorylation	  by	   the	  PKC	   isoform,	  PKC-­‐epsilon	   (Srinivasan	  et	   al.,	   2008).	   So	  evidence	   for	  PIP2	  effect	  on	  TRPV1	  function	  in	  the	  literature	  is	  somewhat	  conflicting,	  with	  evidence	  for	  upregulation	  and	  downregulation	  of	  TRPV1	  activity.	  	  	  	  	  
Translocation	  of	  TRPV1	  to	  the	  cell	  membrane	  	  Factors	   that	   induce	   translocation	  of	  TRPV1	  receptors	   to	   the	  plasma	  membrane	  include	  insulin,	  insulin	  growth	  factor	  and	  NGF.	  Deficiencies	  in	  or	  overexpression	  of	  these	  factors	  could	  either	  impair	  or	  sensitise	  TRPV1	  function	  (Van	  Buren	  et	  al.,	  2005).	   	   Furthermore,	   phosphorylation	   of	   TRPV1	   channel	   can	   impact	   on	   the	  translocation	  of	  the	  channel	  to	  the	  cell	  membrane	  and	  this	  may	  be	  dependent	  on	  the	   presence	   of	   certain	   scaffolding	   proteins	   such	   as	   the	   A-­‐kinase	   Anchoring	  Protein	   150	   which	   has	   been	   shown	   to	   mediate	   PKA	   and	   PKC-­‐directed	  sensitisation	   of	   TRPV1	   in	   various	   nociceptive	   models	   (Jeske	   et	   al.,	   2009b).	  	  Cyclin-­‐dependent	   kinase	   5	   has	   been	   shown	   to	   increase	   surface	   expression	   of	  TRPV1	  providing	  a	  fundamental	  mechanistic	  explanation	  for	  the	  heat	  sensitivity	  of	  nociceptors	  (Xing	  et	  al.,	  2012).	  	  Many	   of	   these	   co-­‐expressed	   receptors,	   enzymes,	   lipids,	   growth	   factors	   and	  mediators	  are	  altered	  during	  diabetes.	  	  
Basis	  for	  this	  thesis	  	  The	  basis	  for	  this	  PhD	  therefore	  was	  to	  examine	  how	  and	  why	  the	  TRPV1	  receptor	  is	  modulated	  during	  diabetes.	  	  This	  could	  gain	  an	  understanding	  of	  the	  potential	  of	  this	  receptor	  in	  causing	  and	  maintaining	  sensory	  neuropathy	  and	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perhaps	  provide	  a	  basis	  for	  a	  therapeutic	  aimed	  at	  prevention	  or	  resolution	  of	  sensory	  neuropathy.	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Chapter	  2	  Validation	  of	  model	  systems	  to	  explore	  modulation	  of	  





	  To	  enable	  the	  reliable	  examination	  of	  TRPV1	  modulation	  in	  sensory	  neuropathy,	  the	  first	  studies	  were	  based	  on	  identifying	  and	  validating	  an	  appropriate	  model	  system.	  An	  appropriate	  model	  system	  would:	  
• express	  TRPV1	  receptors	  which	  when	  activated	  would	  result	  in	  a	  functional	  response	  that	  could	  be	  easily	  measured.	  
• express	  additional	  receptors	  of	  interest	  that	  could	  be	  manipulated	  pharmacologically	  to	  investigate	  modulation	  of	  the	  TRPV1	  receptor.	  
• require	  minimal	  dissection/	  preparation	  to	  avoid	  phenotypical	  alteration	  of	  the	  TRPV1	  receptor	  and	  to	  aid	  throughput.	  
• be	  able	  to	  be	  studied	  under	  diabetic	  conditions.	  
• be	  relevant	  to	  sensory	  neuropathy.	  
• be	  able	  to	  be	  normalized	  to	  reduce	  experimental	  variability	  and	  compensate	  for	  factors	  that	  could	  change	  during	  diabetes.	  	  In	  terms	  of	  choice	  for	  the	  model	  system,	  it	  was	  considered	  that	  a	  native	  cellular	  system	  or	  organ	  would	  provide	  various	  advantages	  over	  a	  recombinant	  system	  in	  that	  they	  possess	  receptors	  in	  the	  native	  state	  i.e.	  expressed	  at	  endogenous	  not	  amplified	  levels	  and	  may	  also	  express	  other	  important	  interacting	  receptors	  such	  as	  bradykinin,	  TRPA1	  and	  TrkA1.	  	  Another	  desirable	  feature	  of	  this	  model	  system	  is	  that	  the	  tissue	  or	  cells	  would	  require	  minimal	  dissection	  and	  preparation	  to	  aid	  not	  only	  assay	  throughput	  but	  more	  importantly	  also	  to	  reduce	  or	  avoid	  a	  potential	  phenotypical	  alteration	  of	  the	  receptor	  state	  from	  that	  seen	  in	  vivo.	  	  	  Diabetes	  is	  a	  too	  complex	  disease	  to	  model	  fully	  in	  vitro	  as	  the	  metabolic	  changes	  that	  occur	  go	  beyond	  a	  simple	  increase	  in	  blood	  glucose	  levels.	  	  Diabetes	  induces	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changes	  in	  lipid	  metabolism,	  membrane	  composition,	  toxic	  glucose	  metabolite	  buildup	  and	  oxidative	  stress.	  	  In	  vivo	  models	  of	  Type	  1	  and	  Type	  2	  diabetes	  are	  numerous	  but	  the	  Type	  1	  STZ-­‐induced	  diabetic	  model	  is	  a	  very	  widely	  used	  model	  for	  study	  of	  the	  complications	  associated	  with	  diabetes.	  	  This	  STZ-­‐induced	  diabetic	  model	  provides	  a	  reasonably	  robust	  animal	  model	  and	  was	  the	  model	  of	  choice	  for	  the	  study	  of	  diabetes.	  	  	  
The	  rat	  urinary	  bladder	  as	  a	  model	  system	  for	  the	  study	  of	  TRPV1	  function	  
in	  sensory	  neurons	  	  The	  first	  step	  was	  to	  identify	  a	  suitable	  organ	  model	  system.	  Sensory	  neurons	  innervate	  a	  multitude	  of	  easily	  accessible	  muscular	  organs	  that	  can	  be	  studied	  in	  organ	  bath	  systems	  using	  muscle	  contraction	  or	  relaxation	  as	  the	  ‘readout’	  for	  activation	  of	  the	  TRPV1	  receptor	  including	  the	  bladder,	  ileum,	  colon	  and	  the	  fundus.	  	  In	  the	  bladder	  TRPV1	  function	  has	  been	  quite	  well	  defined	  and	  the	  bladder	  is	  known	  to	  undergo	  sensory	  neuropathy	  during	  diabetes.	  	  TRPV1	  provides	  sensory	  information	  for	  normal	  bladder	  function	  (Birder	  et	  al.,	  2002,	  Daly	  et	  al.,	  2007)	  and	  sensory	  loss	  through	  TRPV1	  knockout	  results	  in	  changes	  in	  bladder	  function	  somewhat	  similar	  to	  that	  seen	  in	  diabetes.	  Sensory	  neuropathy	  of	  the	  bladder	  is	  known	  to	  exist	  in	  diabetes	  and	  is	  thought	  to	  underlie	  the	  very	  common	  complication	  of	  diabetic	  cystopathy.	  	  	  The	  rat	  urinary	  bladder	  is	  similar	  to	  the	  human	  bladder	  in	  its	  innervation,	  basic	  structure	  and	  receptor	  expression.	  	  Functional	  differences	  do	  occur	  however;	  the	  most	  notable	  difference	  is	  in	  the	  voiding	  frequency	  as	  the	  rat	  urinates	  as	  part	  of	  a	  territorial	  marking	  behavior	  whereas	  humans	  urinate	  much	  more	  infrequently.	  	  In	  the	  daytime,	  rats	  have	  been	  recorded	  as	  urinating	  every	  8	  minutes,	  at	  night	  when	  they	  are	  more	  active,	  the	  voiding	  frequency	  rises	  to	  every	  4	  minutes	  highlighting	  a	  clear	  difference	  between	  rats	  and	  humans	  in	  this	  respect	  (Herrera	  and	  Meredith,	  2010).	  	  Despite	  this	  difference	  between	  humans	  and	  rats,	  the	  primary	  model	  of	  choice	  was	  the	  urinary	  bladder	  smooth	  muscle	  of	  STZ-­‐induced	  diabetic	  rats.	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Human	  Embryonic	  Kidney	  293	  cells	  stably	  expressing	  rat	  TRPV1	  receptor	  
(HEK293-­‐rTRPV1	  cells)	  as	  a	  secondary	  model	  system	  	  An	  assessment	  of	  a	  recombinant	  cellular	  system	  was	  also	  included,	  HEK293	  cells	  stably	  transfected	  with	  rat	  TRPV1	  receptor.	  	  Here	  the	  assay	  methodology	  consisted	  of	  measurement	  of	  intracellular	  calcium	  levels	  through	  the	  use	  of	  FURA-­‐2AM.	  	  	  	  
Validation	  of	  the	  suitability	  of	  model	  systems	  	  In	  terms	  of	  the	  validation	  process	  the	  first	  step	  was	  to	  examine	  responses	  to	  concentration	  ranges	  of	  standard	  tool	  agonists	  of	  TRPV1	  to	  ensure	  that	  the	  model	  system	  responded	  robustly	  to	  TRPV1	  agonist	  activation.	  	  A	  range	  of	  three	  tool	  TRPV1	  agonist	  compounds	  were	  studied	  and	  included	  capsaicin,	  the	  pungent	  component	  of	  capsicum,	  chilli	  pepper,	  resiniferatoxin,	  an	  analogue	  of	  capsaicin	  that	  is	  derived	  from	  the	  latex	  resin	  of	  a	  cactus	  Euphorbia	  resinifera	  and	  anandamide,	  an	  endogenously	  produced	  cannabinoid	  active	  compound	  (Figure	  2.1)	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  Figure	  2.1	  Chemical	  structures	  of	  TRPV1	  agonists:	  two	  vanilloid	  exogenous	  agonists,	  capsaicin	  and	  resiniferatoxin	  (RTX),	  endogenous	  agonists	  anandamide,	  12-­‐S-­‐hydroperoxyeicosatetraenoic	  acid	  (12-­‐S-­‐HPETE),	  N-­‐oleoyldopamine,	  and	  9-­‐hydroxyoctadecadienoic	  acid	  (9-­‐HODE),	  and	  endogenous	  inhibitory	  modulators	  resolvin	  D2	  (RvD2)	  and	  resolvin	  E1	  (RvE1).	  Taken	  from	  Szolcsanyi	  et	  al	  2012	  
	  Next	  the	  effects	  of	  a	  concentration	  range	  of	  a	  TRPV1	  antagonist,	  SB-­‐366791	  versus	  capsaicin	  were	  studied.	  	  SB-­‐377791	  is	  a	  high	  potency	  compound	  with	  good	  selectivity	  (Gunthorpe	  et	  al.,	  2004)	  (Figure	  2.2).	  	  SB-­‐366791	  has	  shown	  activity	  versus	  capsaicin	  induced	  calcium	  influx	  in	  recombinant	  systems	  (Gunthorpe	  et	  al.,	  2004)	  and	  in	  native	  sensory	  neuron	  assays	  (Varga	  et	  al.,	  2005).	  	  Additionally	  this	  compound	  has	  shown	  activity	  in	  isolated	  organ	  assays	  and	  in	  
vivo	  (Varga	  et	  al.,	  2005).	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  Figure	  2.2	  	  	  Chemical	  structure	  of	  the	  TRPV1	  antagonist	  SB-­‐366791	  	  	  Finally	  as	  a	  goal	  of	  this	  thesis	  was	  to	  examine	  the	  effects	  of	  modulating	  agents	  on	  TRPV1	  function	  and	  for	  this	  it	  is	  essential	  that	  the	  system	  contain	  appropriate	  additional	  receptor	  expression,	  the	  effects	  of	  bradykinin	  agonists	  were	  studied.	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Methods	  
	  
Urinary	  bladder	  smooth	  muscle	  strip	  studies	  
	  
Animals	  	  The	   animal	   use	   and	   welfare	   were	   in	   accordance	   with	   the	   Animals	   (Scientific	  Procedures)	  Act,	   1986.	   	   Procedures	   for	   the	   STZ	  model	  were	   carried	   out	   under	  Project	  Licence	  PPL	  70/6788.	  	  Male	  Wistar	  rats	  (Charles	  River	  UK)	  with	  a	  bodyweight	  ranging	  from	  300-­‐500	  g	  were	   used,	   where	   possible	   coordinating	   their	   use	   with	   other	   research	   and	  teaching	  projects.	   	  Animals	  were	  housed	   in	  groups	  of	  between	  two	  to	   four	  rats	  per	   cage	   (Techniplast	   standard	   rat	   housing)	  with	   access	   to	   a	   standard	   rat	   diet	  (LabDiet)	   and	  water	  ad	   libitum.	   	   The	   animal	   facilities	   (Biological	   Services	  Unit,	  Hatfield)	  were	  maintained	  at	  22±	  2°C,	  on	  a	  12	  hour	  light	  /dark	  cycle.	  	  
Urinary	  Bladder	  strip	  preparation	  
 Rats	  were	   euthanized	   by	   an	   approved	   Schedule	   1	  methodology,	   exposure	   to	   a	  rising	   concentration	   of	   CO2	   followed	   by	   cervical	   dislocation.	   	   Animal	   body	  weights	   and	   blood	   glucose	   levels	   from	   tail	   vein	   blood	   were	   measured	   post	  mortem.	   	   Immediately	  post	  mortem,	   the	  abdominal	   cavity	  was	  opened	  and	   the	  whole	   bladder	   removed	   by	   an	   incision	   behind	   the	   bladder	   below	   the	   bladder	  base.	  Care	  was	  taken	  not	  to	  directly	  handle	  the	  bladder	  but	  manipulate	  it	  using	  the	   attached	   glandular	   tissue.	   	   Bladders	   were	   immediately	   placed	   into	   fridge	  temperature	   (4°C)	   Krebs-­‐Henseleit	   solution	   of	   the	   composition	   (in	  mM):	   NaCl	  118.3,	   KCl	   4.4,	   MgSO4	   1.2,	   KH2PO4	   1.2,	   NaHCO3	   25,	   D-­‐glucose	   11.1,	   CaCl2	   2.5,	  gassed	   with	   95%	   O2,	   5%	   CO2.	   	   Placing	   the	   bladder	   on	   a	   Krebs-­‐soaked	   tissue	  covered	  cork-­‐	  board,	  glandular	  and	  fatty	  tissue	  was	  carefully	  dissected	  away	  and	  discarded.	  	  	  A	  single	  incision	  along	  the	  ventral	  longitudinal	  axis	  was	  made	  using	  scissors	   following	   insertion	   of	   the	   scissor	   tip	   into	   the	   bladder	   neck	   midway	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between	   the	   ureters.	   	   The	   bladder	   tissue	  was	   subdivided	   into	   4	   strips	   using	   a	  scalpel.	  	  Coloured	  pins	  were	  placed	  through	  the	  tissue	  at	  the	  top	  of	  each	  strip	  to	  allow	   identification	  of	  ventral	  and	  dorsal	   strips.	   	   Strips	  were	  placed	   into	   fridge	  temperature	   Krebs	   solution	   gassed	   with	   95%	   O2	   5%	   CO2	   during	   thread	  placement	   and	   individual	   tissue	   suspension.	   	   A	   cotton	   thread	   loop	   was	   tied	  around	  the	  base	  of	  each	  strip	  and	  a	  longer	  length	  of	  thread	  tied	  around	  the	  top	  of	  each	   strip.	   	   Strips	  were	   then	   suspended	   between	   tissue	   holders	   and	   isometric	  force	   transducers	   (AD	   instruments)	   in	   15	  mL	   jacketed	   organ	   baths	   (Harvard),	  maintained	  at	  37°C	  with	  a	  steady	  bubble	  stream	  of	  95%	  O2	  ,5%	  CO2.	  
Measurement	  of	  contractile	  force	  of	  bladder	  strips	  	  Isometric	   force	   transducers	   were	   used	   to	   determine	   the	   change	   in	   tension	  generated	   (contraction/relaxation)	   by	   bladder	   strips.	   	   Transducers	   were	  connected	   to	   Labchart	   v5	   Software	   via	   a	   bridge	   amplifier	   (Powerlab	   AD	  instruments).	   	  Prior	  to	  bladder	  strip	  collection	  and	  setup,	  each	  Bridge	  amplifier	  was	  set	   to	  a	  range	  of	  50	  mV	  with	  a	   low	  pass	  of	  20	  Hz	  and	  calibrated	  using	  a	  1	  gram	  weight	  to	  allow	  transformation	  of	  measured	  mV	  values	  to	  grams	  of	  tension.	  	  	  Sampling	   speed	   was	   set	   at	   2	   per	   second	   and	   recording	   started	   before	   tissue	  suspension.	  	  The	  initial	  tension	  for	  bladder	  strips	  was	  set	  to	  1	  gram.	  	  The	  bladder	  strips	  were	   allowed	   to	   equilibrate	   for	  30-­‐45	  minutes	  before	   any	   application	  of	  drug.	  	  Markers	  were	  set	  immediately	  before	  drug	  application.	  	  At	  the	  end	  of	  each	  experiment,	  cotton	  ties	  were	  removed	  from	  the	  bladder	  strips,	  the	  bladder	  strips	  blotted	   and	   mg	   wet	   weights	   measured	   on	   a	   micro-­‐balance.	   	   After	   each	  experiment,	   the	   organ	   baths	   were	   washed	   with	   0.1	   M	   HCl	   and	   rinsed	   with	  distilled	  water	  to	  prevent	  salt	  and	  drug	  build-­‐up.	  
	  
Experimental	  design	  	  After	   the	   initial	   equilibration	   period,	   all	   strips	   were	   exposed	   to	   a	   single	  concentration	  of	  carbachol	  (10-­‐5M)	  allowed	  to	  contract,	  washed	  with	  three	  organ	  bath	   changes	   of	   Krebs	   and	   left	   to	   equilibrate	   for	   30	  minutes.	   	   A	   concentration	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range	  of	  carbachol	  was	  then	  applied	  cumulatively	  (final	  bath	  concentration	  10-­‐8-­‐	  3x	  10-­‐5	  M),	  washed	  x	  3	  and	  left	  to	  equilibrate	  for	  a	  minimum	  of	  30	  minutes.	  	  	  In	  general,	   cumulative	   applications	   of	   drugs	   were	   used,	   diluting	   serially	   diluted	  solutions	   1	   in	   1000	   into	   the	   organ	   bath	   to	   minimize	   solvent	   exposure	   to	   the	  tissue.	  Pilot	  studies	  had	  revealed	  a	  moderate	  level	  of	  strip	  to	  strip	  variability,	  so	  studies	  were	  performed	  on	  duplicate	   tissue	  sets	   (one	  dorsal,	  one	  ventral	   strip)	  which	  would	  allow	  one	  treatment	  group,	  one	  control	  from	  each	  animal.	  	  	  
	  
Data	  measurement	  and	  analysis	  
	  Baseline	   tension	   values	   before	   drug	   response	   and	   tensions	   generated	   in	  response	   to	   drug	   application	  were	  measured	   by	   the	  manual	   positioning	   of	   the	  cursor	   at	   an	   appropriate	   position	   on	   the	   LabChart	   software	   generated	   traces	  which	   reported	   values	   in	   grams	   tension.	   	   In	   general,	   the	   appropriate	  measurement	  position	  for	  response	  to	  drug	  application	  was	  deemed	  to	  be	  at	  the	  point	   of	   maximal	   contraction	   or	   relaxation,	   at	   the	   base	   of	   any	   spontaneous	  activity	  seen.	  	  Manual	  rather	  than	  automatic	  measurement	  of	  responses	  was	  the	  preferred	  method	  as	  it	  allowed	  for	  discrimination	  between	  spontaneous	  activity	  and	   drug-­‐induced	   responses.	   	   Values	   in	   mgs	   were	   recorded	   in	   Excel	   and	  transformed	   to	   net	  mgs	   tension	   by	   subtracting	   resting	   tension	   values.	   	   Values	  were	  further	  transformed	  to	  mg	  tension	  per	  mg	  tissue	  weight	  by	  division	  of	  the	  net	  contraction	  value	  by	  the	  wet	  weight	  of	  the	  tissue	  in	  mgs.	  	  Data	  were	  further	  analysed	   using	   Graphpad	   Prism	   version	   4	  with	   non-­‐linear	   regression	   analysis,	  sigmoidal	   response	   curves	   with	   variable	   slope	   to	   determine	   an	   estimate	   of	  potency	  pEC50	  and	  efficacy	  Emax.	  	  	  	  Statistical	  analysis	  was	  performed	   in	  Graphpad	  Prism	  using	  Student’s	   t-­‐test	   for	  comparison	   of	   two	   data	   groups,	   one-­‐way	   ANOVA	   with	   post-­‐hoc	   Dunnetts	   for	  comparison	   of	  more	   than	   two	   groups	   of	   data	   for	   e.g.	   for	   potency	   and	   efficacy	  estimates,	   and	   two	   way	   ANOVA	   with	   post-­‐hoc	   Bonferroni	   for	   comparison	   of	  concentration	   response	   raw	   data,	   p-­‐values	   of	   <0.05	   were	   taken	   as	   being	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significant.	  As	  the	  data	  was	  analysed	  in	  two	  ways	  :	  by	  scrutiny	  of	  the	  estimated	  potency/efficacy	   values	   (in	   tables)	   and	   by	   scrutiny	   of	   the	   actual	   raw	   data	   (in	  graphs),	   on	   occasion	   statistical	   significance	  was	   only	   observed	   in	   one.	   	   It	   was	  decided	   for	   the	   sake	  of	   transparency	   to	   keep	  both	   analyses	   visible	   as	  both	   are	  valid.	  
	  
	  
Drug	  preparation	  	  All	   drugs	   were	   obtained	   from	   Sigma-­‐Aldrich	   unless	   otherwise	   stated.	   	   	   	   Stock	  solutions	  of	  drugs	  were	  made	  as	  identified	  in	  Table	  2.1,	  aliquoted	  and	  kept	  at	  -­‐20°C	  or	  4	  °C	  before	  use.	  	  Final	  bath	  concentrations	  of	  solvents	  were	  kept	  to	  a	  minimum	  to	  avoid	  potential	  solvent	  induced	  effects.	  Capsaicin	  application	  resulted	  in	  <0.2%	  ETOH	   final	   bath	   concentration,	   when	   applied	   as	   a	   full	   concentration	   range	  with	  cumulative	  additions.	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Table	  2.1	  :Urinary	  bladder	  studies	  drug	  information	  	  Drug	   Mode	   of	  action	   Stock	  	  (mM)	   Solvent	   Dilution	  in	   Used	  to	  Carbachol	  	   muscarinic	  agonist	   10	  	   d.	  H20	   d.	  H20	   monitor	   muscarinic	  response.	  capsaicin	   TRPV1	  agonist	   10	  	   ETOH	  	   20%	  ETOH	   examine	   TRPV1	  function	  Resiniferatoxin	  (RTX)(Tocris)	   TRPV1	  agonist	   1	  mM	   100%	  ETOH	   20%	  ETOH	   examine	   TRPV1	  function	  SB-­‐366791	   TRPV1	  antagonist	   10	  mM	  	   100%	  DMSO	   100%	  DMSO	   examine	   antagonism	  of	  TRPV1	  responses	  Allyl	  isothiocyanate	  (AITC)	   TRPA1	  agonist	   1	  M	   100%	  ETOH	   100%	  ETOH	   explore	   TRPA1	  ligand	  bradykinin	   bradykinin	  receptor	  agonist	   1	   d.	  H20	   d.	  H20	   modulate	   TRPV1	  function	  [Lys-­‐des-­‐Arg9]-­‐BK	   bradykinin-­‐1	  selective	  agonist	   1	  	   d.	  H20	   d.	  H20	   modulate	   TRPV1	  function	  [Phe8-­‐y(CH-­‐NH)-­‐Arg9]-­‐BK	   bradykinin-­‐2	  selective	  agonist	   1	  	   d.	  H20	   d.	  H20	   modulate	   TRPV1	  function	  indomethacin	   cyclo-­‐oxygenase	  inhibitor	   1	  	   ETOH	   -­‐	   cyclooxgenase	  inhibition	  nerve	   growth	  factor	   growth	  factor	   1	  mg/ml	   1%	  BSA/	   d.	  H20	   1%	  BSA/	  d.	  H20	   modulate	   TRPV1	  function	  anandamide	  (Tocris)	   TRPV1	  agonist	   1	  	   ETOH	   20%	  ETOH	   	  	  d.H20	   distilled	   water,	   ETOH	   ethanol,	   BSA	   bovine	   serum	   albumin,	   HBSS	   Hanks	  Balanced	  Salt	  Solution	  	  	  	  
Effects	  of	  TRPV1	  agonists	  	  
	  To	  provide	  a	  validation	  of	  the	  suitability	  of	  the	  urinary	  bladder	  to	  study	  TRPV1	  responses	  a	  study	  of	  the	  responses	  to	  three	  TRPV1	  agonists,	  capsaicin,	  resiniferatoxin	  and	  anandamide	  was	  performed.	  	  A	  concentration	  range	  of	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capsaicin	  (10-­‐9M-­‐	  3x	  10-­‐6M),	  resiniferatoxin	  (10-­‐12-­‐3x10-­‐8M)	  or	  anandamide	  (10-­‐8-­‐	  3	  x10-­‐5M)	  was	  applied	  cumulatively	  to	  the	  isolated	  urinary	  bladder	  strip	  preparation.	  	  In	  a	  subset	  of	  studies	  the	  extent	  of	  desensitization/	  tachyphylaxis	  to	  capsaicin	  following	  washout	  and	  equilibration	  was	  examined	  by	  applying	  a	  second	  concentration	  range	  of	  capsaicin.	  	  To	  examine	  how	  the	  data	  could	  be	  normalised,	  to	  allow	  a	  standardization	  of	  responses	  between	  tissue	  preparations	  obtained	  from	  the	  same	  animal	  or	  from	  different	  animals	  on	  different	  days,	  normalisation	  of	  responses	  to	  tissue	  weight	  were	  performed.	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Recombinant	  HEK293	  rat-­‐TRPV1	  studies	  
	  
Ratiometric	   intracellular	   calcium	   ([Ca]i)	   measurements	   in	   Human	  
embryonic	  kidney	  293	  cells	  stably	  expressing	  rat	  TRPV1	  using	  FURA-­‐2AM	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FURA-­‐2AM	  assay	  of	  intracellular	  calcium	  	  
Cell	  loading	  with	  fluorescent	  calcium	  indicator	  FURA-­‐2AM	  
	  HEK293	   rat	   TRPV1	   cells	   were	   centrifuged	   (400g	   for	   5	   minutes,	   room	  temperature),	   washed	   in	   Hanks	   Balanced	   Salt	   Solution	   +	   calcium	   and	  magnesium,	  supplemented	  with	  2.5	  mM	  probenecid	  and	  HEPES	  (HBSS	  +	  buffer),	  gently	  resuspended	  in	  12	  ml	  HBSS	  +	  buffer	  containing	  2	  mM	  Fura-­‐2AM	  and	  25	  μL	  pluronic	  F-­‐127	  (20%	  solution	  in	  DMSO),	  wrapped	  in	  foil	  and	  incubated	  at	  37°C	  for	   45	   minutes.	   	   After	   this	   time,	   cells	   were	   pelleted	   by	   centrifugation	   (400g,	  5min,	   room	   temperature)	   and	   washed	   twice	   with	   HBSS	   +	   buffer	   before	  resuspension	   in	   20	  mL	   of	   HBSS	   +	   buffer	   /	   T75	   flask.	   	   180	  ml	   (or	   160	  ml	   for	  antagonist	  studies)	  per	  well	  of	  cells	  was	  pipetted	  into	  96-­‐well	  clear	  flat-­‐bottom	  Greiner	  plates,	  wrapped	   in	   foil	  and	   incubated	   in	  a	  shaker-­‐incubator	  at	  37°C	   for	  20	  minutes	  	  prior	  to	  ratiometric	  fluorescence	  measurements	  and	  drug	  additions.	  
	  
	  
Preparation	  of	  drug	  solutions	  	  For	   agonist	   and	   antagonist	   studies	   10	   or	   11-­‐point	   concentration	   ranges	   were	  prepared	  in	  a	  96-­‐well	  clear	  flat	  bottom	  Greiner	  plate	  at	  10	  x	  final	  concentration	  required,	   using	   the	   lowest	   amount	   of	   solvent	  possible	   and	  keeping	   the	   solvent	  levels	  constant	  throughout	  the	  dilution	  series.(Table	  2.2)	  	  
Application	  of	  agonist	  and	  antagonist	  solutions	  to	  cells	  	  20	  μls	  of	   agonist	  or	  antagonist	   solutions	  were	  pipetted	   into	   the	   cell-­‐containing	  plate	  immediately	  before	  ratiometric	  fluorescent	  measurements	  were	  made.	  For	  antagonist	   experiments,	   agonists	   were	   applied	   10	   minutes	   after	   antagonist	  application.	  Duplicate	  or	   triplicate	  wells	  were	  used	   for	  each	  agonist/antagonist	  concentration.	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Ratiometric	  fluorescent	  measurement	  using	  Flexstation.	  	  Fluorescent	   measurements	   (excitation	   340,	   380	   nM,	   emission	   510	   nM)	   were	  made	   immediately	   before	   and	   after	   compound	   addition.	   	   Repeated	  measurements	   were	   made	   in	   a	   subset	   of	   agonist	   studies.	   	   The	   Flexstation	  internal	  incubator	  temperature	  was	  set	  to	  37°C.	  	  	  	  
Data	  analysis	  	  Ratios	  of	  340/380,	  representing	  ratio	  of	  free	  to	  bound	  intracellular	  calcium	  were	  calculated	  using	  Softmax	  Pro	  version	  4	  software	  and	  data	  was	  exported	  as	  a	  text	  file,	   into	   excel	   transformed	   to	   delta-­‐ratios	   and	   inputted	   into	   Graphpad	   Prism	  version	  4	  for	  visualisation	  and	  further	  analysis.	  Data	  is	  presented	  as	  normalised	  values	   to	   capsaicin’s	   maximum	   response,	   or	   percent	   inhibition	   of	   capsaicin’s	  response.	  Non-­‐linear	   regression	   analysis	  was	   performed	   in	  Graphpad	  Prism	   to	  determine	  pEC50	  and	  Emax	  values	   for	   agonist	   responses	   and	  pIC50	  values	   for	  antagonist	  effects.	   	  Statistical	  analysis	  was	  performed	   in	  Graphpad	  Prism	  using	  student’s	  t-­‐test	  for	  comparison	  of	  two	  groups	  or	  one-­‐way	  ANOVA	  with	  post-­‐hoc	  Dunnetts	   for	   comparison	   of	   more	   than	   two	   groups	   of	   data,	   p-­‐values	   of	   <0.05	  were	  taken	  as	  being	  significant.	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Table	  2.2	  :	  HEK293	  rat	  TRPV1	  intracellular	  calcium	  assay	  drug	  information	  	  Drug	   Mode	   of	  action	   Stock	  	   Solvent	   Dilution	  in	   Used	  to	  FURA-­‐2AM	  (invitrogen)	   fluorescent	  calcium	  indicator	   	   100%	  DMSO	   	   measure	   i[Ca]	  responses	  pluronic	  F127	   dispersal	  agent	   	   -­‐	   	   aid	   loading	  of	   FURA-­‐2AM	  probenecid	   	   71	  mg/ml	   50%	   1M	  NaOH,	  50%	  HBSS	  buffer	  
HBSS	  	   prevent	   FURA	  leakage	  from	  cells	  
capsaicin	   TRPV1	  agonist	   10	  mM	   ETOH	  	   20%	   ETOH	  then	   1:10	  in	  HBSS	   examine	   TRPV1	  function	  resiniferatoxin	  (RTX)(Tocris)	   TRPV1	  agonist	   1	  mM	   ETOH	   20%	   ETOH	  then	   1:10	  in	  HBSS	   examine	   TRPV1	  function	  anandamide	  (Tocris)	   TRPV1	  agonist	   	   	   	   	  SB-­‐366791	   TRPV1	  antagonist	   10	  mM	  	   DMSO	   HBSS	   examine	   antagonism	  of	  TRPV1	  responses	  ruthenium	   red	  (Tocris)	   Non-­‐selective	  antagonist	   10	  mM	   ETOH	   d.	  H20	   examine	   antagonism	  of	  TRPV1	  responses	  [Lys-­‐des-­‐Arg9]-­‐BK	   BK-­‐1	  agonist	   10	  mM	   d.	  H20	   d.	  H20	   	  [Phe8-­‐Y-­‐(CH-­‐NH)-­‐des-­‐Arg9]-­‐BK	   BK-­‐2	  agonist	   10	  mM	   d.	  H20	   d.	  H20	   	  DMSO	  dimethyl	  suphoxide,	  HBSS	  Hanks	  Balanced	  Salt	  Solution,	  ETOH	  ethanol	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HEK293	  rat	  TRPV1	  intracellular	  calcium	  study	  details	  	  
	  
TRPV1	  agonist	  and	  antagonist	  validation	  studies	  	  Responses	   to	   the	   TRPV1	   agonists	   capsaicin,	   RTX,	   anandamide	   and	   met-­‐anandamide	  were	   studied.	   	   	  Responses	   to	   capsaicin	  and	  RTX	  were	  additionally	  studied	   over	   a	   period	   of	   time	   (up	   to	   15	   minutes).	   	   The	   effects	   of	   a	   selective	  TRPV1	  antagonist	  SB-­‐366791	  versus	  1	  μM	  capsaicin	  were	  examined.	  	  In	  addition,	  the	   effects	   of	   a	   non-­‐selective	   antagonist,	   ruthenium	   red	  were	   studied	   versus	   a	  full	  concentration	  range	  of	  capsaicin,	  to	  examine	  the	  nature	  of	  this	  antagonist	  in	  this	  system.	  	  	  
Bradykinin	  receptor	  agonist	  studies	  	  Responses	  to	  the	  bradykinin	  selective	  agonists	  were	  studied	  to	  accertain	  whether	  this	  recombinant	  cell	  line	  expressed	  bradykinin	  receptors.	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Results	  	  
Model	  system	  1:	  The	  urinary	  bladder	  strip	  	  
Effects	  of	  the	  muscarinic	  agonist	  carbachol	  	  The	  initial	  study	  of	  a	  muscarinic	  agonist	  carbachol	  revealed	  that	  this	  agonist	  caused	  a	  consistent	  concentration-­‐related	  contraction	  of	  urinary	  bladder	  strips	  from	  naïve	  rats.	  	  The	  normalization	  to	  response	  in	  mgs	  tension	  per	  mg	  tissue	  weight	  did	  not	  detrimentally	  affect	  the	  data	  (Figure	  2.3).	  	  Non-­‐linear	  regression	  analysis	  obtained	  pEC50	  and	  Emax	  values	  for	  carbachol	  (Table	  2.3).	  
	  Figure	  2.3	  Graphs	  showing	  raw	  data	  (A)	  and	  normalized	  to	  tissue	  weight	  (B)	  contractile	  responses	  to	  a	  concentration	  range	  of	  the	  muscarinic	  agonist	  carbachol	  in	  urinary	  bladder	  from	  naïve	  rats.	  	  Data	  represents	  mean	  +	  s.e.m.	  for	  n>6	  urinary	  bladder	  strips.	  	  
Effects	  of	  the	  TRPV1	  agonists,	  capsaicin,	  resiniferatoxin	  and	  anandamide	  
	  Next	  responses	  to	  three	  TRPV1	  agonists	  were	  examined	  in	  urinary	  bladder.	  	  All	  three	  agonists	  caused	  contractile	  responses	  in	  urinary	  bladder	  tissue,	  with	  a	  range	  of	  potency	  and	  efficacies	  observed.	  	  The	  responses	  to	  resiniferatoxin	  (RTX)	  and	  anandamide	  (AEA)	  had	  a	  lower	  maximal	  efficacy	  response	  than	  to	  capsaicin.	  	  Again	  normalization	  of	  tension	  responses	  to	  tissue	  weight	  did	  not	  appear	  to	  have	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a	  detrimental	  effect	  on	  the	  dataset	  (Figure	  2.4).	  	  Non-­‐linear	  regression	  analysis	  provided	  estimates	  of	  potency	  and	  efficacy	  for	  all	  three	  TRPV1	  agonists	  (Table	  2.3).	  	  Resiniferatoxin	  was	  found	  to	  be	  the	  most	  potent	  TRPV1	  agonist	  with	  a	  pEC50	  of	  11.18,	  followed	  by	  capsaicin	  at	  7.82,	  with	  the	  lowest	  potency	  TRPV1	  agonist	  being	  anandamide	  with	  a	  potency	  of	  5.37.	  	  Capsaicin	  gave	  the	  highest	  maximal	  efficacy,	  with	  resiniferatoxin	  and	  anandamide	  having	  considerably	  lower	  maximal	  efficacies.	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Following	  the	  application	  of	  a	  concentration	  range	  of	  capsaicin,	  washout	  and	  equilibration,	  a	  second	  application	  of	  capsaicin	  was	  performed.	  	  Here	  no	  response	  to	  this	  second	  application	  of	  capsaicin	  was	  observed,	  indicating	  that	  a	  complete	  desensitisation	  or	  tachyphylaxis	  had	  occurred.	  	  
Effects	  of	  a	  selective	  TRPV1	  antagonist	  SB-­‐366791	  	  The	  next	  part	  of	  the	  validation	  studies	  of	  urinary	  bladder	  were	  to	  examine	  the	  effects	  of	  a	  selective	  TRPV1	  antagonist	  on	  capsaicin	  responses.	  	  Here	  a	  concentration	  range	  of	  SB-­‐366791	  or	  vehicle	  control	  were	  applied	  to	  the	  urinary	  bladder,	  incubated	  for	  10	  minutes	  with	  no	  washout	  and	  a	  cumulative	  concentration	  range	  of	  capsaicin	  applied.	  	  SB-­‐366791	  caused	  a	  parallel	  rightward	  shift	  in	  capsaicin	  potency	  with	  no	  depression	  of	  efficacy	  (Figure	  2.5).	  	  Schild	  analysis	  was	  performed	  and	  a	  pA2	  estimate	  of	  6.32	  with	  a	  slope	  of	  1.05,	  close	  to	  unity,	  was	  obtained.	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Bradykinin	  receptor	  agonist	  effects	  
	  The	  final	  validation	  step	  for	  the	  urinary	  bladder	  model	  system	  was	  to	  examine	  bradykinin	  responses.	  	  Previous	  in-­‐house	  data	  had	  shown	  contractile	  responses	  to	  a	  bradykinin	  concentration	  range	  (Katisart,	  2011)and	  these	  studies	  were	  to	  repeat	  this	  and	  extend	  by	  the	  use	  of	  bradykinin	  selective	  agonists:	  	  BK-­‐1	  selective	  agonist,	  [Lys-­‐des-­‐Arg9]-­‐BK,	  and	  the	  BK-­‐2	  selective	  agonist,	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK.	  	  Application	  of	  a	  concentration	  range	  of	  bradykinin	  elicited	  a	  concentration	  dependent	  contraction	  (Figure	  2.6).	  	  BK-­‐1	  and	  BK-­‐2	  agonists	  also	  caused	  a	  concentration-­‐dependent	  contraction	  (Figure	  2.6).	  The	  BK-­‐2	  agonist	  was	  seen	  to	  be	  the	  most	  potent	  and	  efficacious,	  followed	  by	  bradykinin	  and	  lastly	  the	  BK-­‐1	  agonist.	  From	  these	  data,	  pEC50	  and	  Emax	  estimates	  were	  calculated	  where	  the	  rank	  order	  of	  potency	  was	  seen	  to	  be	  BK-­‐2	  agonist>	  bradykinin>	  BK-­‐1	  agonist	  (Table	  2.4)	  
	  Figure	  2.6	  Graph	  showing	  contractile	  responses	  of	  control	  urinary	  bladder	  strips	  to	  bradykinin	  and	  bradykinin	  selective	  agonists	  for	  BK-­‐1	  and	  BK-­‐2.	  	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***p<0.001,	  compared	  to	  bradykinin	  response.	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Table	  2.4	  Direct	  contractile	  effects	  of	  bradykinin	  and	  bradykinin	  selective	  agonists:	  potency	  and	  efficacy	  in	  urinary	  bladder	  strips	  from	  control	  rats.	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	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Model	  system	  2	  :	  Recombinant	  HEK293	  rat-­‐TRPV1	  cells	  	  
TRPV1	  agonist	  effects	  
	  First	  the	  responses	  to	  three	  TRPV1	  agonists	  capsaicin,	  resiniferatoxin	  and	  anandamide	  were	  examined	  in	  the	  HEK293-­‐rTRPV1	  cellular	  assay	  of	  intracellular	  calcium.	  	  Here	  resiniferatoxin	  and	  capsaicin	  elicited	  clear	  increases	  in	  intracellular	  calcium,	  whereas	  anandamide	  did	  not	  produce	  a	  notable	  response.	  	  Resiniferatoxin	  gave	  equivalent	  maximal	  efficacy	  responses	  to	  capsaicin	  and	  was	  seen	  to	  be	  more	  potent	  than	  capsaicin.	  (Figure	  2.7)	  (Table	  2.5)	  	  
	  	  	  Figure	  2.7	  Graph	  showing	  intracellular	  calcium	  responses	  measured	  by	  FURA-­‐2AM	  ratiometric	  fluorescence	  to	  TRPV1	  agonists	  capsaicin,	  resiniferatoxin	  (RTX)	  and	  anandamide.	  	  Data	  represents	  mean	  +	  s.e.m	  n	  of	  3	  separate	  experiments	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Table	  2.5	  Potency	  and	  efficacy	  estimates	  for	  the	  TRPV1	  agonists	  in	  the	  HEK293-­‐rTRPV1	  intracellular	  calcium	  model	  system.	  	  Data	  represent	  mean	  +	  s.e.m.	  n	  of	  3	  experiments.	  
	  	  
TRPV1	  antagonist	  effects	  
	  Next	  the	  effects	  of	  a	  concentration	  range	  of	  the	  selective	  TRPV1	  antagonist	  SB-­‐366791	  and	  the	  non-­‐selective	  Ruthenium	  Red	  were	  studied	  against	  1	  μM	  capsaicin	  response.	  	  Both	  antagonists	  inhibited	  capsaicin	  response	  in	  a	  concentration–related	  manner	  (Figure	  2.8).	  	  pIC50	  estimates	  were	  calculated	  using	  this	  data	  ,	  SB-­‐366791	  yielded	  a	  pIC50	  estimate	  of	  5.60	  +	  0.68,	  Ruthenium	  Red	  pIC50	  6.51	  +	  0.07.	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An	  additional	  study	  of	  Ruthenium	  Red	  activity	  versus	  a	  full	  concentration	  range	  of	  capsaicin	  was	  examined.	  	  Here	  increasing	  Ruthenium	  Red	  concentration	  was	  seen	  to	  cause	  a	  depression	  in	  efficacy	  of	  capsaicin	  responses	  (Figure	  2.9)	  	  
Figure	  2.9	  Graph	  showing	  the	  effect	  of	  a	  range	  of	  Ruthenium	  Red	  concentrations	  on	  intracellular	  calcium	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  in	  HEK293-­‐rTRPV1	  cells.	  	  Data	  represents	  mean	  +	  s.e.m.	  n	  of	  3	  separate	  experiments.	  	  
Effects	  of	  bradykinin	  agonists	  	  Finally	  to	  examine	  the	  utility	  of	  this	  model	  system	  on	  exploration	  of	  a	  modulating	  agent	  of	  TRPV1	  function,	  the	  effects	  of	  bradykinin	  selective	  agonists	  were	  examined:	  BK-­‐1	  selective	  agonist,	  [Lys-­‐des-­‐Arg9]-­‐BK,	  and	  the	  BK-­‐2	  selective	  agonist,	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK.	  	  Firstly	  intracellular	  calcium	  responses	  to	  the	  bradykinin	  selective	  agonists	  were	  monitored.	  	  No	  intracellular	  calcium	  response	  to	  bradykinin	  agonists	  was	  observed.	  	  Secondly,	  capsaicin	  responses	  were	  monitored	  following	  bradykinin	  agonist	  application.	  	  No	  potentiation	  of	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capsaicin	  responses	  were	  seen	  following	  bradykinin	  agonist	  application	  either	  separately	  or	  in	  combination	  (Figure	  2.10).	  
	  Figure	  2.10	  Graphs	  showing	  intracellular	  calcium	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  following	  application	  of	  control	  or	  1	  μM	  bradykinin-­‐1	  selective	  agonist	  (A),	  1	  μM	  bradykinin-­‐2	  selective	  agonist	  (B)	  or	  a	  combination	  of	  1	  μM	  bradykinin-­‐1	  and	  1	  μM	  bradykinin-­‐2	  selective	  agonists	  (C).	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  of	  3	  separate	  experiments.	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Discussion	  
	  
The	  urinary	  bladder	  model	  responded	  robustly	  to	  the	  muscarinic	  agonist	  
carbachol	  Carbachol	  elicited	  a	  very	  robust	  contractile	  response	  in	  urinary	  bladder	  strips	  from	  naïve	  rats.	  	  This	  response	  could	  be	  used	  to	  monitor	  myogenic	  responses	  throughout	  the	  diabetic	  model	  and	  following	  exposure	  to	  modulating	  agents	  in	  
vitro.	  
	  
The	  urinary	  bladder	  model	  responded	  robustly	  to	  all	  three	  TRPV1	  agonists	  
	  The	  urinary	  bladder	  model	  system	  responded	  to	  all	  three	  TRPV1	  agonists	  tested.	  Robust	  pEC50	  and	  Emax	  values	  could	  be	  obtained	  which	  was	  seen	  to	  be	  important	  for	  the	  future	  study	  of	  modulation	  of	  the	  TRPV1	  response	  in	  sensory	  neuropathy.	  	  However	  no	  response	  to	  a	  second	  application	  of	  capsaicin	  was	  seen	  indicative	  of	  a	  complete	  desensitisation	  to	  capsaicin.	  	  This	  posed	  a	  limitation	  on	  the	  study	  design.	  	  	  Normalisation	  to	  mgs	  tension	  per	  mg	  tissue	  weight	  did	  not	  appear	  to	  cause	  a	  detriment	  to	  the	  dataset.	  This	  normalization	  was	  thought	  to	  be	  necessary	  because	  diabetes	  is	  known	  to	  cause	  increases	  in	  bladder	  weight	  through	  smooth	  muscle	  hypertrophy.	  	  Without	  a	  normalization	  to	  weight	  or	  muscle	  mass,	  an	  overestimation	  of	  responses	  would	  be	  seen	  in	  the	  STZ-­‐induced	  diabetic	  group	  and	  a	  direct	  comparison	  to	  control	  tissue	  could	  not	  be	  made.	  	  
The	  TRPV1	  selective	  antagonist	  SB-­‐366791	  inhibited	  capsaicin	  responses	  
in	  urinary	  bladder	  	  Increasing	  concentrations	  of	  SB-­‐366791,	  a	  selective	  TRPV1	  antagonist,	  caused	  parallel	  rightward	  shifts	  in	  capsaicin	  responses	  with	  no	  depression	  of	  efficacy.	  	  A	  pA2	  estimate	  was	  obtained	  which	  was	  similar	  to	  that	  reported	  in	  the	  literature,	  although	  no	  pA2	  value	  could	  be	  found	  in	  the	  literature	  for	  a	  native	  tissue	  assay	  such	  as	  the	  urinary	  bladder	  system	  used	  here.	  	  The	  competitive	  inhibitory	  profile	  for	  SB-­‐366791	  added	  confidence	  that	  this	  native	  tissue	  assay	  was	  a	  suitable	  model	  system	  for	  examining	  TRPV1	  modulation	  on	  two	  counts.	  	  Firstly	  it	  was	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seen	  that	  the	  capsaicin	  response	  could	  be	  shifted	  within	  the	  confines	  of	  the	  concentration	  range	  that	  could	  be	  applied	  and	  responses	  obtained.	  	  Secondly	  the	  use	  of	  a	  selective	  TRPV1	  antagonist	  further	  verified	  the	  validity	  of	  this	  model	  system	  as	  having	  TRPV1	  receptors	  present	  that	  on	  activation	  cause	  a	  recordable	  response.	  	  Previous	  in-­‐house	  data	  had	  demonstrated	  that	  bradykinin	  application	  caused	  a	  contractile	  response	  in	  urinary	  bladder	  tissue	  and	  caused	  a	  potentiated	  response	  to	  the	  subsequent	  application	  of	  capsaicin	  in	  tissue	  from	  STZ-­‐induced	  diabetic	  rats	  (Katisart,	  2011)	  	  As	  a	  primary	  model	  system,	  initial	  validation	  studies	  on	  urinary	  bladder	  tissue	  proved	  to	  be	  successful.	  Additionally	  the	  potential	  utility	  of	  a	  recombinant	  cellular	  system,	  HEK293	  rTRPV1	  cells	  was	  examined.	  	  
Two	  out	  of	  three	  TRPV1	  agonists	  cause	  a	  response	  in	  HEK293-­‐rTRPV1	  cell	  
intracellular	  calcium	  assay	  	  Capsaicin	  and	  resiniferatoxin	  but	  not	  anandamide	  caused	  increases	  in	  intracellular	  calcium	  in	  HEK293	  cells	  stably	  transfected	  with	  rat	  TRPV1.	  	  The	  responses	  to	  resiniferatoxin	  and	  capsaicin	  appeared	  to	  be	  of	  the	  same	  magnitude	  (efficacy)	  but	  resiniferatoxin	  was	  found	  to	  be	  more	  potent	  than	  capsaicin.	  This	  efficacy	  /potency	  profile	  differed	  from	  that	  seen	  in	  the	  native	  tissue	  system	  of	  urinary	  bladder	  where	  Emax	  values	  for	  resiiferatoxin	  were	  clearly	  lower	  than	  that	  seen	  for	  capsaicin.	  	  Additionally,	  although	  a	  low	  response	  to	  anandamide	  in	  urinary	  bladder	  was	  seen,	  it	  was	  identifiable	  as	  a	  response	  and	  able	  to	  be	  measured	  within	  the	  confines	  of	  the	  concentration	  range	  that	  could	  be	  applied.	  	  This	  was	  not	  the	  case	  for	  the	  HEK293	  rTRPV1	  system,	  where	  potencies	  were	  lower	  indicating	  	  lower	  receptor	  expression	  than	  that	  seen	  in	  the	  native	  tissue	  urinary	  bladder.	  	  This	  may	  appear	  counter	  intuitive	  given	  that	  the	  HEK293	  rTRPV1	  system	  is	  a	  recombinant	  system	  transfected	  with	  exogenous	  receptor	  and	  might	  be	  expected	  to	  contain	  very	  high	  levels	  of	  TRPV1	  receptor.	  	  Ion	  channel	  recombinant	  expression	  systems	  tend	  to	  have	  a	  self-­‐limiting	  expression	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level	  of	  receptor	  as	  over	  expression	  of	  receptor	  will	  lead	  to	  cellular	  toxicity	  and	  cell	  death	  as	  will	  low	  expression	  as	  in	  this	  system	  it	  is	  under	  G418	  selection.	  	  Therefore	  the	  expression	  levels	  could	  well	  be	  lower	  than	  that	  seen	  in	  a	  native	  tissue	  system.	  	  	  	  
Resiniferatoxin	  displayed	  partial	  agonism	  in	  the	  urinary	  bladder	  system	  	  Low	  receptor	  reserve	  could	  explain	  the	  appearance	  of	  partial	  agonism.	  	  In	  these	  studies	  resiniferatoxin	  (and	  anandamide)	  appeared	  to	  be	  partial	  agonists	  in	  the	  urinary	  bladder	  system.	  	  However	  comparing	  potencies	  between	  the	  two	  model	  systems,	  it	  could	  be	  seen	  that	  the	  urinary	  bladder	  system	  reported	  higher	  potency	  values	  than	  the	  HEK293	  rTRPV1	  system.	  	  This	  indicates	  a	  higher	  receptor	  expression	  in	  urinary	  bladder	  than	  the	  HEK293	  cells	  and	  precluded	  the	  low	  receptor	  reserve	  explanation	  for	  the	  partial	  agonism	  exhibited	  by	  resiniferatoxin	  and	  anandamide.	  	  An	  alternate	  explanation	  for	  these	  data	  could	  be	  that	  the	  association	  rate	  for	  resiniferatoxin	  was	  slow	  and	  may	  elicit	  a	  lower	  calcium	  influx	  in	  a	  native	  system.	  	  Indeed	  this	  has	  been	  identified	  in	  the	  literature	  as	  a	  high	  potency	  low	  pungency	  agonist	  (Raisinghani	  et	  al.,	  2005).	  	  This	  initial	  validation	  work	  was	  to	  identify	  the	  most	  suitable	  model	  assay	  system	  to	  allow	  modulation	  of	  TRPV1	  receptor	  in	  sensory	  neuropathy.	  	  Here	  it	  was	  seen	  that	  the	  urinary	  bladder	  model	  proved	  to	  be	  the	  most	  suitable	  assay	  system	  as	  it:	  	  
• expressed	  TRPV1	  receptors	  which	  when	  activated	  by	  tool	  agonists	  resulted	  in	  a	  contractile	  response	  that	  could	  be	  easily	  measured,	  and	  was	  blocked	  by	  the	  use	  of	  a	  selective	  TRPV1	  antagonist	  SB-­‐366791.	  
• expressed	  bradykinin	  receptors	  that	  could	  be	  manipulated	  pharmacologically	  	  by	  bradykinin	  and	  selective	  agonists	  ,	  causing	  an	  initial	  contractile	  response	  which	  would	  allow	  investigation	  of	  the	  modulation	  of	  the	  TRPV1	  receptor	  and	  quantification	  of	  changes	  to	  bradykinin	  receptor	  by	  diabetes.	  
• required	  minimal	  dissection	  and	  preparation	  thus	  hopefully	  avoiding	  phenotypical	  alteration	  of	  the	  TRPV1	  receptor.	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• able	  to	  be	  studied	  under	  diabetic	  conditions	  through	  the	  use	  of	  an	  animal	  model	  of	  diabetes.	  
• 	  relevant	  to	  sensory	  neuropathy.	  
• be	  able	  to	  be	  normalized	  through	  the	  use	  of	  tissue	  weight	  to	  reduce	  experimental	  variability	  and	  monitored	  through	  the	  use	  of	  a	  muscarinic	  agonist	  carbachol	  to	  compensate	  for	  factors	  that	  could	  change	  during	  diabetes.	  	  	  The	  HEK-­‐rTRPV1	  recombinant	  system	  was	  considered	  to	  be	  less	  suitable	  than	  the	  urinary	  bladder	  system	  for	  a	  number	  of	  reasons:	  	  Firstly	  although	  this	  system	  responded	  to	  TRPV1	  agonists	  and	  antagonists,	  the	  potencies	  seen	  here	  were	  some	  10	  fold	  lower	  than	  the	  native	  tissue	  system.	  	  Secondly	  the	  system	  required	  a	  reasonable	  level	  of	  in	  vitro	  manipulation	  which	  potentially	  could	  impact	  on	  the	  phenotypic	  expression	  of	  TRPV1-­‐	  mainly	  during	  passage	  cells	  were	  removed	  from	  the	  plasticware	  by	  accutase,	  although	  this	  product	  is	  believed	  to	  be	  less	  harsh	  than	  tryptase	  treatment,	  it	  was	  unknown	  whether	  this	  would	  activate	  any	  protease	  activated	  receptors	  which	  are	  known	  to	  interact	  with	  and	  sensitise	  the	  TRPV1	  receptor	  (Amadesi	  et	  al.,	  2006).	  Mechanical	  dissociation,	  e.g.	  scraping,	  is	  also	  known	  to	  cause	  ATP	  release	  which	  again	  could	  potentially	  affect	  TRPV1	  function.	  	  Using	  a	  plated	  format	  rather	  than	  a	  suspension	  method	  could	  be	  utilized	  however	  these	  cells	  were	  very	  easily	  removed	  from	  the	  96-­‐well	  plates	  and	  the	  wash	  steps	  used	  in	  this	  format	  caused	  a	  high	  degree	  of	  variability	  in	  the	  assay.	  Looking	  at	  the	  way	  in	  which	  these	  cells	  were	  grown,	  it	  was	  recognized	  that	  the	  use	  of	  G418	  as	  a	  selection	  media,	  could	  also	  impact	  on	  the	  phenotype	  of	  the	  TRPV1	  receptor.	  G418	  is	  an	  analogue	  of	  neomycin	  and	  neomycin	  is	  known	  to	  sequester	  cholesterol	  and	  is	  used	  in	  dispersal	  studies	  of	  PIP2,	  which	  could	  release	  TRPV1	  from	  an	  inhibited	  state	  and	  cause	  TRPV1	  sensitisation	  (Thompson	  et	  al.,	  1970).	  Thirdly	  it	  was	  seen	  that	  bradykinin	  selective	  agonists	  had	  no	  effects	  on	  intracellular	  calcium	  or	  on	  subsequent	  capsaicin	  responses.	  	  This	  would	  preclude	  the	  use	  of	  this	  system	  to	  study	  the	  effects	  of	  potential	  interacting	  receptors	  without	  the	  additional	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transfection	  of	  individual	  receptors	  into	  the	  cells.	  	  Finally	  diabetes	  is	  a	  complex	  disease	  and	  is	  hard	  to	  model	  in	  vitro.	  	  Taking	  everything	  into	  consideration	  it	  was	  decided	  to	  focus	  efforts	  on	  the	  urinary	  bladder	  system	  to	  study	  the	  modulation	  of	  TRPV1	  receptor	  in	  sensory	  neuropathy.	  	  The	  next	  studies	  were	  undertaken	  to	  map	  the	  onset	  of	  dysfunction	  of	  TRPV1	  in	  a	  diabetic	  rat	  model:	  STZ-­‐induced	  diabetes.	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  To	  initially	  gain	  an	  understanding	  of	  when	  and	  how	  TRPV1	  is	  being	  modulated	  during	  the	  onset	  of	  sensory	  neuropathy,	  these	  studies	  were	  undertaken	  specifically	  to	  map	  the	  onset	  of	  TRPV1	  dysfunction	  following	  diabetic	  induction	  by	  STZ	  administration.	  	  Previous	  in-­‐house	  data	  had	  shown	  a	  reasonably	  rapid	  onset	  of	  TRPV1	  dysfunction	  (Katisart,	  2011),	  where	  a	  diminished	  response	  had	  been	  seen	  by	  8	  weeks	  post	  STZ	  treatment.	  	  The	  model	  used	  here	  was	  the	  bladder	  muscle	  in	  control	  or	  STZ-­‐treated	  rats	  at	  2	  day,	  2	  week,	  5-­‐6	  week	  and	  7-­‐10	  weeks	  post	  treatment.	  	  The	  bladder	  is	  thought	  to	  be	  a	  good	  model	  for	  mapping	  sensory	  neuropathy	  as	  the	  dysfunction	  in	  this	  organ	  that	  develops	  in	  diabetes	  is	  thought	  to	  be	  directly	  caused	  by	  neuropathy	  (Burakgazi	  et	  al.,	  2012).	  	  In	  diabetes,	  cystopathy	  is	  a	  very	  common	  complication.	  Between	  43%	  and	  87%	  of	  Type	  1	  diabetics	  have	  cystopathy	  whereas	  in	  Type	  2	  diabetics	  the	  incidence	  is	  lower	  at	  around	  25%	  (Frimodt-­‐Møller,	  1980)	  .	  	  Cystopathy	  can	  be	  defined	  as	  bladder	  dysfunction	  and	  this	  mainly	  refers	  to	  a	  diminished	  voiding	  capacity	  i.e.	  incomplete	  emptying	  of	  the	  bladder.	  	  Cystopathy	  manifests	  as	  decreased	  bladder	  sensation,	  increased	  post-­‐void	  residual	  volume,	  reduced	  bladder	  muscle	  contractility	  and	  a	  diminished	  urinary	  flow	  (Kaplan	  and	  Blaivas,	  1988).	  	  	  Cystopathy	  has	  been	  seen	  clinically	  in	  patients	  who	  have	  been	  diagnosed	  with	  diabetes	  for	  less	  than	  12	  months	  (Ueda	  et	  al.,	  1997)	  which	  clearly	  demonstrates	  that	  the	  onset	  of	  bladder	  dysfunction	  in	  diabetes	  can	  be	  rapid.	  	  However,	  even	  with	  quite	  abnormal	  bladder	  function,	  diabetics	  are	  often	  unaware	  that	  they	  have	  cystopathy	  until	  they	  develop	  a	  urinary	  tract	  infection,	  which	  can	  result	  from	  incomplete	  bladder	  emptying	  (Burakgazi	  et	  al.,	  2012).	  	  During	  a	  urinary	  tract	  infection,	  the	  symptoms	  of	  cystopathy	  become	  much	  more	  apparent.	  	  In	  animal	  models	  of	  diabetes,	  cystopathy	  has	  been	  observed	  at	  8	  weeks	  post	  diabetic	  induction	  using	  cytometry	  (Yenilmez	  et	  al.,	  2006),	  indicating	  a	  rapid	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onset	  of	  bladder	  dysfunction.	  	  	  The	  association	  of	  peripheral	  neuropathy	  with	  cystopathy	  is	  very	  high	  between	  75-­‐100%	  (Frimodt-­‐Møller,	  1980),	  indicating	  that	  neuropathy	  plays	  a	  major	  role	  in	  cystopathy.	  Clinical	  and	  animal	  studies	  have	  revealed	  that	  cystopathy	  is	  a	  direct	  result	  of	  sensory	  and	  autonomic	  neuropathies	  (Burakgazi	  et	  al.,	  2012).	  The	  symptoms	  and	  occurrence	  of	  cystopathy	  have	  been	  observed	  in	  various	  animal	  models	  of	  diabetes	  (Dahlstrand	  et	  al.,	  1992).	  Here	  capsaicin	  responses	  have	  been	  seen	  to	  be	  diminished	  which	  is	  suggestive	  of	  a	  role	  of	  TRPV1	  for	  the	  sensory	  loss	  and	  development	  of	  cystopathy	  (Dahlstrand	  et	  al.,	  1992).	  	  In	  house	  data	  has	  also	  highlighted	  that	  TRPV1	  function	  is	  diminished	  in	  detrusor	  preparations	  from	  STZ-­‐induced	  diabetes	  in	  rats	  by	  8	  weeks	  post	  diabetic	  induction(Katisart,	  2011).	  	  Whether	  the	  reduced	  functionality	  of	  TRPV1	  is	  due	  to	  reduced	  neuropeptide	  content	  of	  the	  sensory	  nerves	  or	  to	  reduced	  receptor	  expression	  is	  as	  yet	  unclear.	  	  	  There	  is	  also	  evidence	  that	  diabetic	  cystopathy	  has	  a	  myogenic	  component	  (Longhurst	  and	  Belis,	  1986)	  and	  one	  of	  the	  symptoms	  of	  cystopathy	  is	  reduced	  muscle	  contractility.	  	  In	  early	  stage	  diabetes,	  the	  bladder	  rapidly	  increases	  in	  size	  to	  a)	  accommodate	  for	  the	  increased	  volumes	  of	  urine	  that	  are	  eliminated,	  and	  b)	  due	  to	  bladder	  stretching	  which	  arises	  from	  decreased	  bladder	  sensation.	  	  In	  TRPV1	  knockout	  mice,	  an	  increased	  bladder	  size	  is	  seen	  alongside	  altered	  micturition	  thresholds	  and	  is	  indicative	  of	  the	  role	  TRPV1	  plays	  in	  bladder	  sensation	  (Daly	  et	  al.,	  2007).	  The	  expansion	  of	  bladder	  volume	  is	  associated	  with	  increased	  bladder	  mass	  mainly	  through	  detrusor	  muscle	  hyperplasia	  and	  hypertrophy	  (Suzuki	  et	  al.,	  2006).	  	  This	  increased	  muscle	  mass	  has	  a	  reduced	  contractility	  in	  response	  to	  some	  agonists	  when	  corrected	  to	  force	  generated	  per	  unit	  of	  mass	  (Du	  et	  al.,	  2000,	  Longhurst	  and	  Belis,	  1986),	  although	  some	  investigators	  report	  no	  change	  in	  sensitivity(Lincoin	  et	  al.,	  1984)	  and	  even	  increased	  muscarinic	  receptor	  expression	  (Tong	  et	  al.,	  1999).	  However,	  the	  general	  consensus	  is	  that	  despite	  an	  increased	  muscular	  component,	  the	  ability	  of	  the	  bladder	  to	  contract	  to	  elicit	  effective	  urinary	  discharge	  is	  impaired.	  	  	  An	  altered	  cholinergic	  enzyme	  activity	  has	  been	  seen	  in	  the	  bladder	  of	  the	  STZ-­‐
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induced	  diabetic	  model	  (Tong	  et	  al.,	  2006,	  Lincoin	  et	  al.,	  1984)	  so	  for	  this	  reason	  carbachol	  is	  the	  muscarinic	  agonist	  of	  choice	  to	  examine	  myogenic	  function.	  	  Carbachol	  is	  resistant	  to	  degradation	  by	  acetylcholine	  esterase	  activity	  and	  therefore	  should	  provide	  an	  unbiased	  measure	  of	  muscle	  contractility.	  	  As	  well	  as	  contractile	  strength,	  contractile	  speed	  has	  a	  bearing	  on	  the	  ability	  of	  a	  muscle	  to	  contract	  and	  has	  been	  reported	  to	  be	  impaired	  in	  aged	  rats	  and	  humans	  (Saito	  et	  al.,	  1991,	  Coolsaet	  and	  Blok,	  1986).	  	  To	  examine	  the	  speed	  of	  muscular	  force	  generation,	  an	  examination	  of	  the	  carbachol	  response	  was	  undertaken,	  where	  a	  single	  high	  concentration	  of	  carbachol	  was	  applied	  and	  the	  time	  taken	  to	  reach	  50%	  of	  maximum	  response	  measured.	  	  To	  evaluate	  the	  total	  neurogenic	  component	  of	  detrusor	  muscle	  contraction,	  as	  TRPV1	  is	  not	  the	  only	  receptor	  present	  in	  bladder	  sensory	  neurons,	  an	  examination	  of	  electric	  field	  stimulation	  evoked	  contraction	  was	  undertaken.	  	  In	  TRPV1	  knockout	  mice,	  an	  increased	  spontaneous	  activity	  i.e.	  non-­‐voiding	  contractions	  of	  bladder	  muscle	  is	  present	  (Birder	  et	  al.,	  2002),	  therefore	  an	  examination	  of	  spontaneous	  activity	  of	  the	  detrusor	  muscle	  was	  undertaken.	  	  Therefore	  this	  series	  of	  studies	  were	  undertaken	  to	  map	  the	  changes	  primarily	  in	  TRPV1	  function	  that	  may	  occur	  following	  induction	  of	  diabetes	  by	  STZ	  administration.	  	  Secondly	  carbachol	  responses	  were	  monitored	  to	  provide	  information	  on	  changes	  in	  muscular	  contractility.	  Thirdly,	  where	  robust	  changes	  in	  TRPV1	  function	  had	  been	  seen,	  some	  bladder	  tissue	  was	  examined	  for	  changes	  in	  electrical	  field	  stimulation	  evoked	  contractility	  as	  a	  measure	  of	  total	  neuronal	  function.	  Finally,	  an	  examination	  of	  spontaneous	  activity	  of	  the	  detrusor	  muscle	  was	  undertaken.	  	  In	  this	  series	  of	  studies,	  age-­‐matched,	  control	  animals	  received	  the	  same	  volumetric	  dose	  of	  citrate	  buffer.	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Methods	  
Induction	  and	  monitoring	  of	  streptozotocin	  (STZ)	  model	  	  




	  Rats	  were	  terminated	  by	  a	  schedule	  1	  approved	  methodology	  (exposure	  to	  rising	  CO2	  followed	  by	  cervical	  dislocation)	  at	  various	  timepoints	  following	  STZ	  or	  control	  solution	  administration:	  2	  days,	  2	  weeks,	  5-­‐6	  weeks,	  7-­‐10	  weeks,	  over	  a	  series	  of	  studies.	  Body	  weights	  and	  blood	  glucose	  levels	  from	  tail	  vein	  blood	  were	  measured.	  	  Bladders	  were	  dissected	  out,	  weighed	  and	  set	  up	  in	  organ	  baths	  as	  described	  previously.	  	  	  
	   52	  
	  
Effects	  of	  STZ	  on	  TRPV1-­‐mediated	  contraction	  of	  the	  urinary	  bladder	  The	  responses	  to	  a	  concentration	  range	  of	  the	  TRPV1	  agonist	  capsaicin	  (1x	  10-­‐9-­‐	  1	  x	  10-­‐5M)	  made	  in	  20%	  ETOH,	  applied	  in	  a	  cumulative	  fashion,	  were	  examined.	  	  Following	  the	  top	  concentration	  of	  capsaicin,	  tissues	  were	  washed	  x	  3	  and	  allowed	  to	  equilibrate	  for	  30	  minutes.	  	  	  	  
Recovery	  after	  capsaicin	  contraction	  	  In	  a	  subset	  of	  studies,	  following	  the	  final	  top	  concentration	  of	  capsaicin,	  tissues	  were	  not	  washed	  but	  measurements	  taken	  every	  minute	  until	  tension	  had	  returned	  to	  baseline,	  at	  which	  point	  tissues	  were	  washed	  x	  3	  and	  allowed	  to	  equilibrate	  for	  30	  minutes.	  	  
Monitoring	  of	  carbachol	  responses	  following	  control	  or	  STZ	  administration	  	  The	  responses	  to	  a	  concentration	  range	  of	  the	  muscarinic	  agonist	  carbachol	  (1x	  10-­‐8-­‐	  3x10-­‐5M)	  made	  in	  distilled	  water,	  applied	  cumulatively	  were	  measured.	  	  Following	  the	  top	  concentration	  of	  carbachol,	  tissues	  were	  washed	  x	  3	  and	  allowed	  to	  equilibrate	  for	  30	  minutes.	  	  
Kinetics	  of	  carbachol	  contraction	  	  To	  monitor	  the	  speed	  of	  contraction	  of	  the	  bladder	  muscle	  strips	  to	  carbachol,	  a	  subset	  of	  tissues	  were	  exposed	  to	  1	  x	  10-­‐5M	  carbachol	  and	  raw	  data	  covering	  the	  complete	  timescale	  of	  contraction,	  sampled	  every	  0.5	  sec,	  were	  extracted.	  	  Data	  was	  normalised	  to	  %	  values	  of	  maximum	  contraction	  to	  account	  for	  the	  differences	  between	  control	  and	  STZ-­‐treated	  animals,	  and	  plotted	  using	  Graphpad	  Prism.	  	  The	  time	  taken	  to	  reach	  50%	  of	  maximum	  was	  measured	  and	  data	  was	  further	  divided	  to	  enable	  a	  comparison	  of	  the	  anatomically	  different	  bladder	  strips	  (dorsal	  and	  ventral)	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Comparison	  of	  changes	  in	  capsaicin	  and	  carbachol	  responses	  
	  To	  allow	  a	  direct	  comparison	  of	  the	  changes	  seen	  in	  Emax	  values	  for	  capsaicin	  and	  carbachol,	  Emax	  values	  for	  each	  timepoint	  were	  normalised	  to	  their	  respective	  control	  animal	  values	  and	  these	  ratios	  plotted	  together.	  	  	  
Measurement	  of	  spontaneous	  activity	  	  Using	  cycle	  variable	  analysis	  in	  Labchart,	  with	  the	  noise	  threshold	  set	  to	  zero	  and	  trigger	  point	  at	  maximum	  ,frequency	  and	  average	  maximum	  and	  minimum	  values	  of	  spontaneous	  activity	  were	  obtained	  over	  5-­‐10	  minutes.	  	  An	  example	  of	  the	  triggering	  pattern	  is	  shown	  in	  Figure	  3.1.	  	  Amplitudes	  were	  calculated	  from	  maximum	  and	  minimum	  values	  and	  normalized	  to	  mgs	  response	  per	  mg	  tissue	  weight	  to	  compensate	  for	  tissue	  weight	  difference	  between	  control	  and	  STZ-­‐treated	  tissue.	  	  
	  	  	  Figure	  3.1	  Example	  of	  triggering	  pattern	  used	  for	  spontaneous	  activity	  analysis	  of	  raw	  data	  from	  urinary	  bladder.	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Electrical	  Field	  stimulation	  	  Where	  robust	  changes	  in	  TRPV1	  function	  had	  been	  seen	  a	  subset	  of	  studies	  in	  2-­‐week	  post	  control	  or	  STZ	  administration	  was	  undertaken	  to	  monitor	  electrical	  field	  stimulated	  contraction.	  	  Urinary	  bladder	  strips	  were	  mounted	  between	  platinum	  electrodes	  within	  the	  organ	  bath	  setup.	  	  The	  electrodes	  were	  attached	  to	  a	  Harvard	  electrical	  stimulator	  and	  a	  Harvard	  cycle	  Timer.	  	  A	  train	  of	  electrical	  pulses	  was	  applied	  (0.1	  ms	  pulse	  width,	  rate	  of	  50	  Hz,	  10	  sec	  duration)	  firstly	  to	  a	  range	  of	  voltages	  (20-­‐100	  Volt)	  to	  identify	  the	  submaximal	  voltage.	  Then	  using	  this	  submaximal	  voltage,	  to	  a	  range	  of	  frequencies	  (0.25	  Hz-­‐40	  Hz).	  	  The	  frequency	  range	  study	  was	  then	  repeated	  following	  application	  of	  1	  μM	  tetradotoxin	  (TTX)	  to	  determine	  whether	  the	  electrical	  field	  stimulation	  was	  evoking	  contractions	  neurogenically.	  	  
Analysis	  of	  data	  	  Data	  was	  extracted	  from	  Labchart	  and	  exported	  into	  excel	  where	  raw	  data	  was	  transformed	  into	  mgs	  tension	  per	  mg	  tissue	  weight.	  	  Raw	  data	  and	  transformed	  data	  were	  plotted	  using	  Graphpad	  Prism,	  and	  non-­‐linear	  regression	  analysis	  performed	  to	  obtain	  pEC50	  and	  Emax	  values	  for	  capsaicin	  and	  carbachol.	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Results	  
	  
Monitoring	  of	  body	  weights	  and	  blood	  glucose	  	  Control	  rats	  gained	  weight	  at	  a	  rate	  of	  around	  10	  g	  per	  day	  throughout	  the	  study	  up	  until	  the	  5-­‐6	  week	  timepoint	  where	  weight	  gain	  reduced.	  	  STZ-­‐treated	  rats	  failed	  to	  gain	  weight	  as	  quickly	  as	  control	  animals	  but	  in	  general	  maintained	  their	  starting	  weight.	  	  Control	  rats	  maintained	  a	  blood	  glucose	  level	  within	  the	  normal	  expected	  range,	  at	  all	  timepoints	  examined.	  	  In	  the	  STZ-­‐treated	  rats,	  blood	  glucose	  increased	  to	  three	  to	  four	  fold	  above	  control	  levels	  by	  day	  2	  following	  STZ	  administration	  and	  remained	  consistently	  high	  upto	  the	  last	  timepoints,	  7-­‐10	  weeks	  (Table	  3.1).	  	  	  Table	  3.1	  Body	  weight	  and	  blood	  glucose	  measurements	  from	  rats	  at	  various	  timepoints	  following	  administration	  of	  either	  control	  buffer	  or	  STZ.	  	  Data	  are	  mean	  +	  s.e.m	  for	  n>3	  animals	  per	  group	  	  
	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Dunnetts	  comparing	  to	  start	  control	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001;	  comparing	  to	  time-­‐matched	  control	  $$$	  p<0.001	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Bladder	  weights	  	  Bladder	  weights	  were	  monitored	  post	  mortem.	  Bladders	  from	  control	  and	  STZ-­‐	  treated	  rats	  both	  increased	  with	  increasing	  time.	  	  The	  increases	  seen	  in	  the	  control	  animals	  appeared	  to	  increase	  gradually,	  with	  an	  apparent	  linear	  relationship	  of	  bladder	  weight	  over	  time.	  	  	  At	  the	  day	  2	  timepoint,	  no	  difference	  was	  seen	  in	  bladder	  weight	  between	  the	  control	  and	  STZ-­‐treated	  rat	  bladders.	  	  By	  2	  weeks	  and	  throughout	  the	  remaining	  time-­‐points	  to	  7-­‐10	  weeks,	  STZ-­‐treated	  animals	  had	  significantly	  higher	  weight	  bladders	  than	  control	  animals.	  (Figure	  3.2).	  	  
	  Figure	  3.2	  Barchart	  showing	  bladder	  weights	  from	  control	  and	  STZ-­‐treated	  rats	  at	  2	  days,	  2	  weeks,	  5-­‐6	  weeks	  and	  7-­‐10	  weeks	  post	  control	  or	  STZ	  treatment.	  	  Data	  represents	  mean	  +	  s.e.m.	  n>3	  bladders.	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	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Effects	  of	  STZ	  on	  TRPV1-­‐mediated	  contraction	  of	  the	  urinary	  	  bladder	  
	  Capsaicin	  produced	  a	  concentration-­‐related	  contractile	  response	  in	  urinary	  bladder	  tissue	  from	  control	  and	  from	  STZ-­‐treated	  animals,	  representative	  traces	  from	  2	  week	  post-­‐control	  or	  STZ-­‐administration	  are	  shown	  (Figure	  3.3).	  
	  	  Figure	  3.3	  Representative	  raw	  data	  traces	  of	  responses	  to	  a	  cumulative	  concentration	  range	  of	  capsaicin	  in	  urinary	  bladder	  tissue	  from	  2-­‐week	  post	  control	  (A)	  and	  STZ-­‐treated	  (B)	  rats.	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  Data	  indicated	  that	  TRPV1	  responses	  in	  STZ-­‐treated	  rats	  was	  not	  significantly	  different	  from	  control	  at	  the	  2	  day	  time-­‐point	  (Figure	  3.4A),	  but	  was	  depressed	  from	  2	  weeks	  (Figure	  3.4B)	  up	  to	  7-­‐10	  weeks	  (Figures	  3.4	  C,D)	  post	  administration	  of	  STZ.	  The	  difference	  in	  response	  to	  capsaicin	  was	  one	  of	  depressed	  eMax	  responses	  as	  opposed	  to	  a	  difference	  in	  pEC50	  (Table	  3.2).	  	  
	  	  Figure	  3.4.	  Graphs	  showing	  responses	  of	  urinary	  bladder	  from	  age-­‐matched	  controls	  or	  STZ-­‐treated	  rats	  to	  a	  concentration	  range	  of	  capsaicin	  at	  2	  days	  (A),	  2	  weeks	  (B),	  5-­‐6	  weeks	  (C)	  and	  7-­‐10	  weeks	  (D)	  post	  administration	  of	  STZ	  or	  vehicle	  control.	  Values	  represent	  mean	  +	  s.e.m	  n	  of	  6-­‐20	  urinary	  bladder	  strips.	  	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	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  Table	  3.2	  :	  Potency	  and	  efficacy	  values	  for	  capsaicin	  responses	  in	  urinary	  bladder	  strips	  from	  control	  or	  STZ-­‐treated	  rats	  at	  various	  times	  following	  control	  or	  STZ	  administration.	  Data	  represent	  mean	  +	  s.e.m	  n>6	  urinary	  bladder	  strips	  
	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Dunnetts	  comparing	  to	  time-­‐matched	  control	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001	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  Figure	  3.5	  Graphs	  showing	  responses	  of	  urinary	  bladder	  from	  age-­‐matched	  controls	  or	  STZ-­‐treated	  rats	  to	  a	  concentration	  range	  of	  capsaicin	  at	  2	  days	  (A),	  2	  weeks	  (B),	  5-­‐6	  weeks	  (C)	  and	  7-­‐10	  weeks	  (D)	  post	  administration	  of	  control	  or	  STZ.	  Values	  represent	  mean	  +	  s.e.m.	  n	  of	  6-­‐20	  urinary	  bladder	  strips.	  	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	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  Figure	  3.6	  Graphs	  showing	  calculated	  maximal	  responses,	  eMax(A)	  and	  potency	  estimates,	  pEC50	  (B)	  of	  capsaicin	  in	  urinary	  bladder	  strips	  over	  time	  following	  	  control	  	  or	  STZ-­‐administration.	  	  Values	  represent	  mean+	  s.e.m.	  n	  of	  6-­‐20	  urinary	  bladder	  strips.	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	  	  	  
Recovery	  after	  capsaicin	  contraction	  	  To	  monitor	  the	  rate	  of	  tissue	  recovery	  back	  to	  baseline	  tension	  following	  capsaicin	  induced	  contraction,	  a	  subset	  of	  tissues	  from	  2	  week	  post	  control	  or	  STZ-­‐treated	  rats	  were	  examined.	  	  A	  concentration	  range	  of	  capsaicin	  was	  applied	  and	  following	  the	  application	  of	  maximal	  concentration,	  measurements	  of	  contractile	  state	  were	  taken	  every	  minute	  with	  no	  wash	  out	  until	  tissues	  had	  relaxed	  to	  baseline.	  	  When	  normalised	  to	  percent	  of	  maximum	  capsaicin	  response	  to	  accommodate	  for	  the	  differences	  seen	  between	  control	  and	  STZ	  treated	  tissue,	  no	  differences	  were	  seen	  in	  the	  rate	  of	  relaxation	  of	  urinary	  bladder	  tissue	  back	  to	  baseline	  levels	  between	  control	  and	  STZ	  treated	  rats	  (Figure	  3.7).	  	  The	  tissue	  returned	  to	  baseline	  levels	  by	  15	  minutes	  following	  maximal	  capsaicin	  concentration	  application,	  in	  control	  and	  STZ-­‐treated	  rats.	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  Figure	  3.7	  Graph	  showing	  decline	  of	  capsaicin-­‐induced	  contraction	  with	  no	  washout	  in	  bladder	  tissue	  from	  control	  and	  STZ-­‐treated	  rats.	  	  Data	  represents	  mean	  +	  s.e.m	  n	  >6	  urinary	  bladder	  strips.	  	  No	  significant	  differences	  were	  seen	  using	  two-­‐way	  ANOVA	  .	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Monitoring	  of	  Carbachol	  responses	  following	  control	  or	  STZ	  administration	  	  Carbachol	  responses	  of	  urinary	  bladder	  strips	  were	  monitored	  following	  control	  or	  STZ	  administration,	  representative	  traces	  are	  shown	  from	  	  2-­‐week	  post	  control	  or	  STZ-­‐treated	  rats	  (Figure	  3.8)	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Carbachol	  produced	  a	  concentration-­‐related	  increase	  in	  contraction	  in	  urinary	  bladder	  tissue	  from	  control	  and	  STZ-­‐treated	  rats.	  	  	  Responses	  to	  a	  concentration	  range	  of	  carbachol	  in	  control	  tissue	  were	  consistent	  at	  all	  timepoints	  studied.	  	  	  Carbachol	  responses	  of	  bladder	  tissue	  from	  STZ-­‐treated	  rats	  were	  increased	  significantly	  in	  terms	  of	  magnitude	  at	  2	  days,	  2	  weeks	  and	  5-­‐6	  weeks	  post	  STZ	  administration	  compared	  to	  controls.	  (Figure	  3.9)	  	  
	  	  	  Figure	  3.9	  Graphs	  showing	  responses	  of	  urinary	  bladder	  from	  age-­‐matched	  	  buffer	  treated	  controls	  or	  STZ-­‐treated	  rats	  to	  a	  concentration	  range	  of	  carbachol	  at	  2	  days	  (A),	  2	  weeks	  (B),	  5-­‐6	  weeks	  (C)	  and	  7-­‐10	  weeks	  (D)	  post	  administration	  of	  STZ	  or	  vehicle	  control.	  	  Values	  represent	  mean	  +	  s.e.m.	  n	  >12	  urinary	  bladder	  strips.	  	  .	  	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	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  Table	  3.3	  Potency	  and	  efficacy	  values	  for	  carbachol	  responses	  in	  urinary	  bladder	  strips	  from	  control	  or	  STZ-­‐treated	  rats	  at	  various	  times	  following	  control	  or	  STZ	  administration.	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  	  
	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Dunnetts	  comparing	  to	  time-­‐matched	  control	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001	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  Figure	  3.10	  Graphs	  showing	  responses	  of	  urinary	  bladder	  to	  a	  concentration	  range	  of	  carbachol	  at	  2	  days	  (A),	  2	  weeks	  (B),	  5-­‐6	  weeks	  (C)	  and	  7-­‐10	  weeks	  (D)	  post	  administration	  of	  control	  or	  STZ.	  	  Values	  represent	  mean	  +	  s.e.m.	  n	  >12	  urinary	  bladder	  strips.	  	  .	  	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	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  Figure	  3.11	  Graphs	  showing	  calculated	  maximal	  responses	  to	  carbachol	  ,Emax	  (A)	  and	  potency	  estimates	  ,pEC50	  (B)	  over	  time	  following	  control	  or	  STZ	  administration.	  	  Values	  represent	  mean	  +	  s.e.m.	  n	  >	  12	  urinary	  bladder	  strips.	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  control.	  	  
	  
Comparison	  of	  changes	  in	  capsaicin	  and	  carbachol	  responses	  
	  
	  
Maximal	  potency	  values	  normalised	  to	  respective	  time-­‐matched	  controls	  
	  To	  provide	  a	  direct	  comparison	  between	  the	  decline	  in	  Emax	  for	  capsaicin	  and	  carbachol,	  	  Emax	  values	  for	  each	  timepoint	  studied	  were	  normalised	  to	  their	  respective	  time-­‐matched	  control	  animal	  Emax	  value	  and	  presented	  as	  an	  Emax	  ratio	  for	  capsaicin	  and	  carbachol	  (Figure	  3.12).	  	  Emax	  ratio	  values	  for	  capsaicin	  declined	  rapidly	  by	  2	  weeks	  and	  remained	  low	  throughout	  the	  remaining	  time	  period	  studied.	  	  Carbachol	  Emax	  ratio	  declined	  at	  a	  more	  consistent	  rate	  throughout	  the	  time-­‐period	  studied.	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  Figure	  3.12	  Graph	  showing	  eMax	  values	  normalised	  to	  respective	  time-­‐matched	  control	  values	  for	  capsaicin	  and	  carbachol	  in	  STZ-­‐treated	  rats.	  	  Data	  represent	  mean	  +	  s.e.m.	  for	  n>6	  urinary	  bladder	  strips.	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  compared	  to	  carbachol.	  	  
	  	  
Kinetics	  of	  carbachol	  contraction	  	  A	  comparison	  between	  2-­‐	  week	  	  post	  control	  and	  STZ	  responses	  to	  a	  single	  application	  of	  a	  submaximal	  concentration	  of	  carbachol	  (1	  x	  10-­‐5	  M)	  was	  	  made.	  	  First	  raw	  data	  was	  extracted	  to	  represent	  the	  entire	  muscle	  contraction	  following	  carbachol	  application	  dataset,	  normalised	  to	  maximum	  response	  seen	  and	  finally	  measurement	  of	  the	  time	  taken	  to	  reach	  50%	  of	  this	  response.	  	  Mean	  data	  was	  plotted	  (Figure	  3.13).	  	  No	  difference	  was	  seen	  in	  the	  kinetics	  of	  response	  between	  control	  and	  STZ	  animals.	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  Figure	  3.13:	  Graph	  showing	  normalised	  contraction	  over	  time	  following	  application	  of	  1	  x	  10-­‐5	  M	  carbachol.	  	  Data	  represent	  mean	  +	  s.e.m.	  n	  of	  20	  urinary	  bladder	  strips.	  No	  statistical	  significant	  difference	  was	  seen	  using	  two-­‐way	  ANOVA.	  	  	  Data	  for	  time	  taken	  to	  reach	  50	  %	  contraction	  was	  plotted	  on	  a	  scatter	  plot,	  and	  separated	  into	  dorsal	  and	  ventral	  bladder	  muscle	  tissue,	  to	  additionally	  examine	  the	  potential	  of	  differences	  in	  muscle	  contractile	  kinetics	  between	  anatomically	  distinct	  muscle	  sections	  (Figure	  3.14).	  	  No	  differences	  were	  seen	  between	  control	  and	  STZ	  tissue,	  or	  between	  dorsal	  and	  ventral	  located	  urinary	  bladder	  tissue	  responses	  to	  carbachol.	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  Figure	  3.14	  Scatter	  plot	  showing	  time	  taken	  following	  application	  of	  carbachol	  to	  reach	  50%	  contraction.	  	  Data	  represents	  individual	  tissue	  responses	  and	  is	  further	  divided	  into	  the	  dorsal	  or	  ventral	  anatomical	  bladder	  location.	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Spontaneous	  Activity	  	  The	  frequency	  and	  amplitude	  of	  spontaneous	  activity	  were	  measured	  in	  the	  urinary	  bladder	  from	  2	  week	  	  post	  control	  and	  STZ	  –treated	  rats	  (Figure	  3.15).	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There	  was	  no	  difference	  in	  frequency	  of	  spontaneous	  contractions	  between	  control	  and	  STZ.	  	  There	  was	  however	  a	  significant	  reduction	  in	  the	  amplitude	  of	  spontaneous	  contractions	  in	  the	  STZ-­‐treated	  group	  (Figure	  3.16)	  
	  Figure	  3.16	  Barcharts	  of	  frequency	  (A)	  and	  of	  amplitude	  (B)	  of	  spontaneous	  contractions	  seen	  in	  2-­‐week	  post	  control	  or	  STZ-­‐treated	  animals.	  Data	  represents	  mean	  +	  s.e.m	  n	  of	  20	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  by	  Student’s	  t-­‐test,	  *	  p<0.05	  	  	  
Electrical	  Field	  Stimulation	  	  Electrical	  field	  stimulation	  was	  applied	  to	  urinary	  bladder	  strips	  from	  2	  week	  post	  control	  or	  STZ-­‐treated	  rats.	  	  First	  a	  voltage	  response	  curve	  was	  performed	  and	  responses	  to	  this	  range	  of	  voltages	  were	  measured	  and	  normalised	  to	  mg	  responses	  per	  mg	  tissue	  weight	  (Figures	  3.17,	  3.19A).	  	  Next	  using	  a	  submaximal	  voltage,	  a	  frequency	  response	  curve	  was	  constructed	  and	  normalised	  once	  again	  to	  mgs	  response	  per	  mg	  tissue	  weight	  (Figures	  3.18,	  3.19B).	  	  Electrical	  field	  stimulation	  evoked	  voltage	  related	  contraction	  of	  urinary	  bladder	  tissue	  from	  control	  and	  STZ-­‐treated	  rats.	  	  Urinary	  bladder	  tissue	  responded	  at	  lower	  voltages	  in	  the	  STZ-­‐treated	  group	  as	  seen	  by	  a	  leftward	  shift	  in	  voltage	  response	  curve,	  with	  a	  	  statistically	  significant	  lower	  maximal	  efficacy.	  	  	  	  Electrical	  field	  stimulation	  evoked	  frequency	  related	  contraction	  of	  urinary	  bladder	  tissue	  from	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control	  and	  STZ-­‐treated	  rats.	  	  No	  differences	  	  in	  frequency	  responses	  were	  observed	  between	  control	  and	  STZ-­‐treated	  rats.	  Following	  application	  of	  1	  μM	  TTX,	  no	  response	  to	  the	  frequency	  range	  of	  electrical	  field	  stimulation	  was	  observed	  (data	  not	  shown).	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Figure	  3.18:	  Representative	  traces	  of	  raw	  data	  from	  EFS-­‐evoked	  contractions	  to	  a	  frequency	  range	  in	  control	  rat	  (A)	  or	  STZ-­‐treated	  rat	  (B)	  urinary	  bladder	  tissue	  	  	  
	  Figure	  3.19.	  Graphs	  of	  electrically	  stimulated	  responses	  of	  urinary	  bladder	  strips	  from	  2	  week	  post	  control	  or	  STZ-­‐treated	  rats	  to	  a	  range	  of	  voltages	  (A)	  or	  to	  a	  range	  of	  frequencies	  (B)	  using	  the	  submaximal	  voltage	  obtained	  from	  the	  voltage	  response	  curve.	  Data	  represent	  mean	  +	  s.e.m.	  n	  of	  12	  urinary	  bladder	  strips.	  	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferroni:	  *	  p<0.05,**	  p<0.01,	  ***p<0.001	  comparing	  to	  control.	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Discussion	  	  	  
Induction	  of	  diabetes	  	  	  STZ-­‐administration	  was	  seen	  to	  induce	  a	  diabetic	  state	  by	  2	  days	  post	  treatment	  where	  a	  three-­‐fold	  increase	  in	  blood	  glucose	  was	  seen.	  	  This	  high	  blood	  glucose	  was	  maintained	  throughout	  the	  studies	  until	  the	  last	  time	  points	  at	  7-­‐10	  weeks.	  	  Animal	  health	  was	  closely	  monitored	  and	  it	  was	  noted	  that	  although	  the	  STZ-­‐treated	  animals	  failed	  to	  increase	  body	  weight	  they	  did	  manage	  to	  maintain	  their	  starting	  weights.	  Many	  investigators	  record	  a	  loss	  of	  body	  weight	  (Tammela	  et	  al.,	  1994,	  Thule	  and	  Liu,	  2000),	  however	  the	  acute	  time	  points	  together	  with	  the	  administration	  protocol	  used	  in	  this	  study	  appears	  to	  be	  less	  detrimental	  to	  animal	  health.	  	  The	  STZ-­‐treated	  rats	  pattern	  of	  activity	  changed	  noticeably	  with	  increased	  lethargy	  coupled	  with	  more	  time	  taken	  eating.	  The	  insulinopenia	  evoked	  by	  STZ	  is	  known	  to	  induce	  hyperphagia	  through	  increased	  neuropeptide	  Y	  levels	  in	  the	  hypothalamus	  (Kalra	  et	  al.,	  1999).	  	  A	  nutrient	  study	  with	  STZ-­‐rats	  has	  shown	  that	  in	  the	  3	  weeks	  post	  STZ-­‐administration	  a	  rat	  will	  choose	  to	  increase	  carbohydrate	  and	  protein	  and	  reduce	  fat	  intake,	  after	  this	  time	  period	  however,	  the	  rat	  will	  choose	  to	  increase	  fat	  and	  reduce	  carbohydrate	  intake	  (Kanarek	  and	  Ho,	  1984).	  	  At	  the	  later	  time	  points	  of	  this	  study	  (7-­‐10	  weeks),	  animals	  had	  noticeably	  less	  body	  fat	  compared	  to	  control	  treated	  animals	  although	  body	  composition	  analysis	  was	  not	  performed.	  	  The	  STZ-­‐mediated	  destruction	  of	  the	  pancreatic	  β-­‐cells	  results	  in	  an	  insulinopaenic	  state	  so	  that	  carbohydrates	  can	  no	  longer	  be	  utilized	  as	  an	  energy	  source	  efficiently.	  	  This	  lack	  of	  insulin	  leads	  to	  a	  greater	  reliance	  on	  energy	  from	  fat	  and	  protein	  to	  meet	  the	  energy	  demands	  of	  the	  animal.	  	  It	  is	  likely	  that	  a	  residual	  pancreatic	  function	  remains	  following	  STZ	  administration	  although	  this	  is	  not	  enough	  to	  prevent	  the	  onset	  and	  progression	  of	  the	  diabetic	  state	  (Cam	  et	  al.,	  1993).	  	  Bladder	  weights	  increased	  gradually	  in	  the	  control	  treated	  animal	  groups,	  due	  to	  these	  animals	  still	  being	  in	  the	  adolescent	  growth	  phase.	  	  The	  bladder	  weights	  in	  the	  STZ-­‐treated	  group	  increased	  markedly	  by	  the	  2	  week	  time	  point	  and	  continued	  to	  increase	  throughout	  the	  remaining	  time	  points.	  	  This	  STZ-­‐related	  enhanced	  increase	  in	  bladder	  weight	  and	  size	  is	  likely	  due	  to	  the	  increased	  demands	  on	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this	  organ	  i.e.	  increased	  output	  of	  urine,	  and	  this	  was	  clearly	  observable	  in	  the	  animal	  husbandry	  with	  an	  increased	  need	  to	  change	  animal	  bedding	  due	  to	  dampness	  from	  urine.	  	  
	  
	  
Acute	  onset	  of	  TRPV1	  dysfunction	  during	  diabetes	  	  The	  responses	  of	  control	  treated	  animal	  tissue	  to	  capsaicin	  throughout	  all	  the	  time	  points	  studied	  was	  reasonably	  consistent,	  albeit	  less	  consistent	  than	  carbachol	  responses.	  This	  reduced	  consistency	  highlights	  the	  requirement	  for	  inclusion	  of	  age-­‐matched	  controls	  for	  future	  STZ	  studies,	  as	  it	  indicates	  an	  increased	  variability	  of	  this	  neuronally	  mediated	  response	  and	  may	  be	  affected	  by	  animal	  age	  as	  well	  as	  logistical	  factors	  such	  as	  room	  temperature,	  time	  taken	  to	  dissect	  tissue	  etc.	  With	  increasing	  age,	  a	  minor	  depression	  in	  capsaicin	  efficacy	  in	  controls	  was	  seen	  again	  highlighting	  the	  need	  for	  age-­‐matched	  controls.	  There	  did	  appear	  to	  be	  a	  small	  leftward	  shift	  in	  capsaicin	  potency	  at	  the	  2-­‐day	  post	  treatment	  time	  point,	  but	  this	  was	  seen	  to	  be	  non-­‐significant	  on	  statistical	  analysis.	  Capsaicin	  concentration	  response	  curves	  clearly	  indicated	  a	  reduced	  responsiveness	  to	  capsaicin	  in	  the	  STZ-­‐treated	  groups	  from	  the	  2-­‐week	  post	  treatment	  time	  points.	  The	  nature	  of	  diminished	  response	  was	  in	  the	  efficacy	  of	  capsaicin	  to	  elicit	  a	  response,	  Emax,	  rather	  than	  in	  the	  potency	  of	  capsaicin.	  	  The	  patterns	  of	  diminished	  responses	  to	  capsaicin	  were	  retained	  when	  transforming	  the	  data	  to	  mgs	  response	  per	  mg	  tissue	  weight.	  	  This	  is	  an	  important	  finding	  as	  the	  increase	  in	  bladder	  weight	  alone	  could	  account	  for	  an	  apparent	  diminished	  responsiveness.	  	  When	  visualizing	  the	  data	  of	  Emax	  and	  EC50	  over	  time,	  it	  is	  clear	  that	  by	  2	  weeks	  an	  almost	  maximal	  reduced	  responsiveness	  in	  Emax	  to	  capsaicin	  is	  seen.	  	  Additional	  data	  on	  1-­‐week	  post	  treatment	  was	  undertaken	  where	  a	  more	  variable	  diminished	  response	  was	  seen	  (data	  not	  shown).	  	  So	  robust	  changes	  in	  TRPV1	  function	  are	  seen	  by	  2	  weeks	  post	  STZ	  administration	  providing	  an	  early	  time	  point	  at	  which	  modulation	  of	  TRPV1	  function	  in	  sensory	  neuropathy	  can	  be	  examined.	  	  This	  early	  onset	  of	  a	  depression	  in	  function	  has	  been	  observed	  in	  central	  neurons	  of	  the	  dorsal	  motor	  nucleus	  of	  the	  vagus	  3-­‐7	  days	  post	  STZ	  in	  mice	  (Zsombok	  et	  al.,	  2011)	  and	  was	  not	  due	  to	  an	  alteration	  in	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expression.	  	  In	  the	  DRG	  however,	  early	  increases	  in	  TRPV1	  mRNA	  expression	  are	  correlated	  to	  thermal	  hyperalgesia	  (Pabbidi	  et	  al.,	  2008a)and	  suggests	  that	  there	  is	  a	  location-­‐dependent	  modulation	  of	  TRPV1	  during	  diabetes.	  When	  examining	  the	  recovery	  from	  capsaicin	  induced	  contraction	  between	  control	  and	  STZ	  treated	  animals	  at	  this	  2-­‐week	  time	  point,	  no	  differences	  in	  the	  rate	  of	  recovery	  were	  seen.	  	  This	  measurement	  was	  included	  to	  compare	  the	  longevity	  of	  response	  as	  a	  less	  sustained	  response	  might	  translate	  into	  reduced	  efficacy.	  	  Recovery	  from	  capsaicin-­‐induced	  contraction	  could	  be	  governed	  by	  neuropeptide	  breakdown	  by	  protease	  enzymes	  as	  it	  is	  conceivable	  that	  alterations	  in	  the	  neuropeptide	  breakdown	  mechanisms	  i.e.	  peptidase	  levels	  may	  occur	  in	  diabetes.	  	  However	  no	  such	  differences	  were	  observed	  at	  this	  2-­‐week	  time	  point,	  which	  excludes	  this	  possible	  explanation	  for	  the	  difference	  in	  capsaicin	  efficacy.	  	  Additionally	  no	  reduction	  in	  bladder	  levels	  of	  neuropeptides	  for	  e.g.	  substance	  P	  have	  been	  reported	  in	  the	  early	  stages	  of	  STZ-­‐induced	  diabetic	  model	  (Steers	  et	  al.,	  1994).	  	  Conversely	  some	  investigators	  have	  reported	  increases	  in	  the	  neuropeptides	  associated	  with	  TRPV1	  (substance	  P,	  CGRP,	  neurokinin-­‐A)	  although	  no	  diminishment	  of	  capsaicin	  responses	  were	  seen	  in	  this	  study	  (Santicioli	  et	  al.,	  1987a).	  	  However	  alterations	  of	  neuropeptide	  levels	  have	  been	  reported	  in	  the	  skin	  (Karanth	  et	  al.,	  1990)	  which	  may	  suggest	  that	  the	  effector	  mechanisms	  for	  TRPV1	  activation	  are	  differentially	  altered	  in	  diabetes	  dependent	  on	  their	  anatomical	  location.	  An	  alternate	  process	  governing	  this	  recovery	  from	  contraction	  is	  that	  the	  receptors	  causing	  the	  contractile	  response	  desensitise,	  and	  because	  the	  rates	  are	  similar	  between	  control	  and	  STZ,	  this	  desensitisation	  process	  is	  not	  responsible	  for	  the	  functional	  differences	  seen	  in	  this	  model	  of	  diabetes.	  	  
Monitoring	  of	  carbachol	  responses	  revealed	  a	  gradual	  progressive	  decline	  
	  An	  examination	  of	  carbachol	  responses	  was	  also	  included	  to	  monitor	  myogenic	  changes	  following	  diabetic	  induction.	  	  Throughout	  all	  the	  time	  points	  studied,	  responses	  to	  controls	  were	  very	  consistent.	  	  2-­‐days	  post	  STZ	  administration,	  a	  small	  increased	  response	  to	  carbachol	  was	  seen,	  this	  increased	  markedly	  at	  the	  2-­‐week	  and	  5-­‐6	  week	  time	  points	  returning	  back	  to	  control	  levels	  by	  7-­‐10	  weeks.	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However	  when	  data	  was	  transformed	  to	  accommodate	  for	  the	  increased	  bladder	  mass,	  an	  increase	  was	  still	  seen	  at	  the	  2-­‐day	  time	  point,	  but	  this	  changed	  to	  a	  decreased	  efficacy	  that	  appeared	  to	  progress	  throughout	  the	  remaining	  time	  points	  studied.	  	  This	  decline	  in	  muscarinic	  function	  is	  indicative	  of	  a	  progressive	  myogenic	  dysfunction	  caused	  by	  the	  diabetic	  state.	  	  Examining	  the	  kinetics	  of	  muscular	  contraction	  to	  a	  single	  concentration	  of	  carbachol	  revealed	  no	  differences	  in	  the	  rate	  of	  contraction.	  	  This	  means	  that	  in	  this	  early	  stage	  of	  diabetes	  the	  muscular	  cell	  shortening	  rate	  is	  unaffected,	  at	  a	  time	  where	  force	  generation	  capacity	  has	  been	  diminished.	  	  	  	  The	  further	  examination	  of	  dorsal	  versus	  ventrally	  located	  bladder	  strips	  was	  undertaken	  as	  on	  physical	  examination	  of	  the	  tissue,	  morphological	  changes	  did	  appear	  to	  be	  occurring	  at	  the	  2-­‐week	  time	  point.	  These	  changes	  included	  an	  expansion	  of	  the	  circular	  banding	  clearly	  identifiable	  on	  the	  ventral	  strips,	  round	  to	  the	  dorsal	  sections.	  	  However	  no	  differences	  in	  contractile	  speed	  between	  dorsal	  and	  ventral	  sections	  were	  seen.	  	  When	  directly	  comparing	  the	  changes	  seen	  in	  capsaicin	  with	  carbachol,	  it	  was	  apparent	  that	  the	  carbachol	  changes	  were	  more	  gradually	  progressive	  whereas	  the	  changes	  to	  capsaicin	  function	  presented	  more	  acutely	  and	  were	  sustained	  throughout.	  	  	  	  
Changes	  in	  spontaneous	  activity	  likely	  to	  be	  due	  to	  myogenic	  changes	  	  Spontaneous	  contractile	  activity	  of	  bladder	  smooth	  muscle	  is	  known	  to	  occur	  during	  the	  filling	  stage	  (Araki,	  2011).	  As	  it	  has	  been	  reported	  that	  a)	  TRPV1	  knockout	  mice	  have	  an	  higher	  frequency	  lower	  amplitude	  non-­‐voiding	  bladder	  contractions	  and	  b)	  the	  diabetic	  state	  causes	  increased	  amplitude	  and	  frequency	  of	  spontaneous	  activity	  due	  in	  part	  to	  increased	  prostaglandin	  production	  (Tammela	  et	  al.,	  1994),	  an	  examination	  of	  spontaneous	  activity	  	  was	  made.	  It	  is	  still	  unclear	  what	  drives	  spontaneous	  activity	  but	  numerous	  mechanisms	  have	  been	  identified	  including	  the	  Interstitial	  Cells	  of	  Cajal,	  prostanoids,	  gap	  junctions,	  and	  intermural	  ganglia	  (Araki,	  2011).	  	  At	  the	  2	  –week	  post	  treatment	  time	  point,	  no	  differences	  were	  seen	  in	  the	  frequency	  of	  spontaneous	  activity,	  whereas	  a	  significant	  reduction	  in	  amplitude	  to	  transformed	  data	  (mgs	  response	  to	  mgs	  tissue	  weight).	  	  The	  alteration	  seen	  here,	  a	  decrease	  of	  amplitude	  of	  spontaneous	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activity,	  is	  suggestive	  of	  no	  change	  to	  the	  driving	  pathways	  to	  spontaneous	  activity,	  such	  as	  prostaglandin	  production,	  rather	  an	  influence	  of	  decreased	  myogenic	  activity	  as	  seen	  in	  the	  carbachol	  responses.	  	  An	  explanation	  for	  reduced	  spontaneous	  activity	  seen	  at	  this	  early	  stage	  could	  be	  that	  the	  architecture	  of	  the	  bladder	  wall	  has	  changed	  which	  in	  turn	  has	  altered	  the	  communicative	  ability	  of	  the	  driver	  behind	  spontaneous	  activity	  for	  e.g.	  the	  interaction	  of	  the	  interstitial	  cells	  with	  the	  smooth	  muscle	  cells.	  	  This	  is	  unlikely,	  as	  any	  such	  change	  would	  likely	  alter	  not	  only	  amplitude	  of	  spontaneous	  activity	  but	  frequency	  as	  well.	  	  These	  specialised	  interstitial	  cells	  are	  believed	  to	  be	  important	  communicator	  type	  cells	  that	  form	  associations	  with	  neuronal	  and	  muscular	  cells	  and	  whose	  role	  is	  thought	  to	  be	  one	  of	  coordinating	  bladder	  activity	  (McCloskey,	  2010).	  Later	  stage	  changes	  in	  spontaneous	  activity,	  where	  a	  disorganized	  spontaneous	  activity	  is	  seen	  may	  contribute	  to	  a	  loss	  of	  coordinated	  contraction	  and	  could	  underlie	  in	  part	  the	  dysfunctional	  voiding	  of	  a	  diabetics	  bladder.	  	  	  	  
Electrical	  field	  stimulation	  revealed	  that	  other	  neurogenic	  alterations	  
occur	  acutely	  	  Electrical	  field	  stimulation	  was	  included	  at	  the	  2-­‐week	  time	  point	  to	  ascertain	  whether	  at	  this	  time	  point	  where	  TRPV1	  function	  is	  clearly	  diminished	  whether	  total	  neurogenically	  mediated	  responses	  had	  been	  affected.	  	  A	  clear	  leftward	  shift	  in	  voltage	  responses	  was	  observed	  in	  the	  STZ-­‐group.	  	  This	  increased	  voltage	  sensitivity	  has	  been	  reported	  by	  numerous	  laboratories	  at	  later	  time	  points	  post	  STZ	  treatment	  than	  used	  here	  (Tammela	  et	  al.,	  1994,	  Longhurst	  et	  al.,	  1991).	  	  The	  reasons	  for	  this	  increased	  sensitivity	  have	  been	  postulated	  as	  an	  alteration	  in	  the	  membrane	  lipid	  composition	  or	  other	  membrane	  changes	  or	  the	  presence	  of	  a	  partial	  depolarized	  state	  perhaps	  due	  to	  diabetic	  neuropathy	  (Tammela	  et	  al.,	  1994)	  or	  could	  additionally	  be	  due	  to	  changes	  in	  inhibitory	  factor	  release.	  	  	  However	  using	  a	  submaximal	  voltage,	  no	  differences	  in	  frequency	  responses	  were	  seen	  in	  these	  early	  time	  point	  studies.	  	  	  Some	  investigators	  have	  reported	  increased	  sensitivity	  to	  frequency	  responses	  in	  later	  stage	  diabetic	  animals,	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initially	  described	  as	  due	  to	  increased	  cholinergic	  transmitter	  release	  in	  response	  to	  the	  electrical	  field	  stimulation	  (Luheshi	  and	  Zar,	  1991).	  	  The	  reasons	  for	  this	  enhanced	  transmitter	  release	  were	  postulated	  as	  either	  being	  an	  early	  sign	  of	  degenerative	  change	  in	  the	  cholinergic	  nerve	  population	  whereby	  they	  lose	  the	  normal	  control	  over	  the	  amount	  of	  transmitter	  release	  in	  response	  to	  electrical	  field	  stimulation	  or	  a	  compensatory	  mechanism	  where	  the	  cholinergic	  system	  attempts	  to	  compensate	  for	  a	  progressive	  failure	  of	  the	  non-­‐cholinergic	  systems.	  	  However	  other	  investigators	  have	  dissected	  out	  pharmacologically	  the	  different	  components	  of	  the	  neurogenic	  responses	  into	  cholinergic,	  purinergic	  and	  residual	  NANC	  components	  albeit	  in	  later	  stage	  diabetic	  animals.	  	  Here	  they	  saw	  increased	  sensitivity	  to	  electrical	  field	  stimulation	  with	  a	  decreased	  cholinergic	  proportion	  and	  an	  increased	  residual	  component	  (Liu	  and	  Daneshgari,	  2005).	  In	  the	  early	  stage	  post	  diabetic	  studies	  a	  clear	  alteration	  was	  only	  seen	  in	  voltage	  sensitivity	  to	  electrical	  field	  stimulation.	  	  These	  data	  suggest	  that	  even	  at	  this	  acute	  stage	  post	  diabetic	  induction,	  changes	  in	  neuronal	  responses	  are	  occurring	  which	  are	  different	  to	  those	  seen	  at	  a	  later	  stage	  of	  diabetes.	  	  	  Clearly	  TRPV1	  dysfunction	  has	  a	  very	  rapid	  onset	  following	  induction	  of	  diabetes.	  	  The	  dysfunction	  in	  TRPV1	  is	  one	  of	  reduced	  efficacy	  rather	  than	  altered	  potency.	  This	  reduced	  efficacy	  may	  transpire	  to	  reduced	  sensitivity	  in	  the	  bladder,	  which	  could	  contribute	  to	  bladder	  volume	  changes	  and	  cystopathy.	  Changes	  are	  also	  occurring	  in	  the	  myogenic	  responses.	  	  These	  muscular	  changes	  appear	  more	  gradual	  and	  progressive	  and	  could	  result	  in	  the	  overt	  reduced	  contractility	  seen	  in	  later	  stage	  cystopathy.	  	  	  The	  neurogenic	  TRPV1	  changes	  have	  a	  different	  onset	  time	  to	  the	  myogenic	  changes,	  appearing	  more	  acutely,	  and	  because	  of	  this	  it	  is	  probable	  that	  the	  myogenic	  changes	  do	  not	  underlie	  the	  TRPV1	  neurogenic	  changes.	  	  It	  is	  conceivable	  however	  that	  the	  neurogenic	  changes	  could	  underlie	  and	  be	  causative,	  at	  least	  in	  part	  to	  the	  myogenic	  changes.	  	  At	  these	  acute	  time	  points,	  no	  changes	  in	  contractile	  speed	  of	  the	  muscle	  was	  seen,	  and	  changes	  in	  spontaneous	  activity	  were	  only	  of	  amplitude,	  which	  could	  be	  accounted	  for	  by	  the	  myogenic	  alterations	  seen.	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  The	  next	  phase	  of	  work	  was	  to	  investigate	  whether	  the	  diminished	  response	  profile	  of	  TRPV1	  was	  altered	  by	  organ	  bath	  temperature.	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Chapter	  4	  :	  TRPV1	  responses	  at	  reduced	  organ	  bath	  
temperatures	  	  	  
Introduction	  	  All	  the	  studies	  on	  urinary	  bladder	  for	  this	  thesis	  have	  been	  run	  at	  an	  organ	  bath	  temperature	  of	  37	  °C,	  normal	  body	  temperature.	  	  However	  the	  TRPV1	  receptor	  is	  well	  recognized	  to	  be	  a	  temperature	  sensitive	  receptor,	  responding	  directly	  to	  noxious	  heat	  >43	  °C.	  	  It	  is	  thought	  that	  the	  heat	  sensor	  on	  the	  TRPV1	  receptor	  is	  a	  structural	  component	  of	  the	  receptor	  (Yao	  et	  al.,	  2011)	  although	  there	  is	  still	  controversy	  over	  the	  exact	  mechanism	  of	  temperature	  sensing.	  	  Importantly	  the	  temperature	  threshold	  for	  TRPV1	  is	  not	  fixed	  at	  43	  °C	  and	  can	  be	  altered	  through	  potentiation	  by	  chemical	  mediators	  and	  the	  phosphorylation	  state	  of	  TRPV1	  (Benham	  et	  al.,	  2003).	  	  A	  number	  of	  inflammatory	  mediators	  such	  as	  prostaglandin	  E2	  and	  prostaglandin	  I2	  can	  potentiate	  TRPV1	  function	  and	  reduce	  the	  heat	  threshold	  to	  35	  °C,	  which	  means	  that	  the	  TRPV1	  receptors	  can	  become	  activated	  at	  normal	  body	  temperature	  (Moriyama	  et	  al.,	  2005).	  Phosphorylation	  of	  TRPV1	  through	  activation	  of	  protein	  kinase	  C	  also	  induces	  a	  reduced	  temperature	  threshold	  of	  TRPV1	  (Vellani	  et	  al.,	  2001).	  Thinking	  about	  temperature	  prompted	  the	  notion	  that	  the	  profile	  of	  a	  diminished	  capsaicin	  response	  could	  be	  altered	  at	  lower	  organ	  bath	  temperature.	  	  If	  the	  thermal	  threshold	  for	  TRPV1	  had	  been	  reduced	  in	  the	  STZ-­‐diabetic	  model	  then	  this	  may	  have	  driven	  the	  subsequent	  reduction	  in	  TRPV1	  response.	  	  
Core	  body	  temperature	  is	  reduced	  and	  thermoregulatory	  mechanisms	  are	  
impaired	  in	  diabetes	  	  In	  animal	  models	  of	  diabetes	  there	  is	  a	  rapid	  onset	  of	  hypothermia	  within	  3	  days	  of	  induction	  of	  diabetes,	  although	  the	  extent	  of	  the	  reduced	  body	  temperature	  is	  only	  around	  0.5	  °C	  (Howarth	  et	  al.,	  2005).	  People	  with	  diabetes	  find	  it	  difficult	  to	  cope	  with	  environmental	  temperature	  extremes	  and	  also	  have	  a	  reduced	  body	  core	  temperature.	  Furthermore	  diabetics	  with	  peripheral	  neuropathy	  are	  at	  a	  greater	  risk	  of	  developing	  hypothermia	  on	  induction	  of	  general	  anaesthesia	  and	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this	  is	  thought	  to	  be	  caused	  by	  a	  delayed	  thermoregulatory	  vasoconstriction	  response	  (Kitamura	  et	  al.,	  2000).	  	  	  	  	  
Smooth	  muscle	  contractility	  is	  enhanced	  at	  reduced	  organ	  bath	  
temperature	  	  A	  few	  studies	  in	  the	  literature	  have	  observed	  that	  smooth	  muscle	  from	  airways,	  vas	  deferens	  and	  bladder	  has	  increased	  contractility	  at	  lower	  temperatures	  (Ishii	  and	  Shimo,	  1985,	  Souilem	  et	  al.,	  1995,	  Kurihara	  et	  al.,	  1974).	  	  The	  reasons	  behind	  this	  enhancement	  are	  thought	  to	  be	  due	  to	  altered	  calcium	  handling,	  	  inhibition	  of	  Na+/K+	  pump,	  depolarization	  of	  the	  membrane	  or	  increased	  myosin	  light	  chain	  phosphorylation	  (Sugaya	  and	  De	  Groat,	  2000).	  Additionally	  changes	  in	  frequency	  and	  amplitude	  of	  bladder	  smooth	  muscle	  spontaneous	  activity	  have	  been	  reported	  with	  reduced	  temperature	  (Sugaya	  and	  De	  Groat,	  2000).	  	  	  	  To	  examine	  the	  potential	  effects	  of	  reduced	  organ	  bath	  temperature	  on	  TRPV1	  function	  studies	  were	  undertaken	  in	  measure	  capsaicin	  responses	  urinary	  bladder	  from	  control	  and	  STZ-­‐treated	  rats.	  Carbachol	  responses	  were	  utilized	  to	  examine	  the	  effects	  of	  reduced	  organ	  bath	  temperatures	  on	  muscle	  contractility	  and	  the	  frequency	  and	  amplitude	  of	  spontaneous	  contractile	  activity	  was	  monitored.	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Methods	  	  Experiments	  were	  performed	  on	  3-­‐4	  weeks	  post	  control	  or	  STZ-­‐treated	  rat	  urinary	  bladder	  strips,	  set-­‐up	  as	  previously	  described.	  	  Organ	  bath	  temperatures	  were	  initially	  set	  to	  the	  lowest	  temperature	  of	  study	  (either	  32°C	  or	  34°C),	  carbachol	  concentration	  range	  applied	  to	  all	  tissues	  and	  capsaicin	  concentration	  ranges	  applied	  to	  one	  pair	  of	  tissues.	  	  After	  washout,	  organ	  bath	  temperatures	  were	  increased	  to	  34°C	  or	  37	  °C	  and	  resting	  tensions	  adjusted	  to	  1	  g.	  	  After	  30	  minutes	  equilibration	  time,	  a	  carbachol	  concentration	  range	  was	  applied	  to	  all	  tissues,	  followed	  by	  washout	  and	  equilibration.	  	  Finally	  a	  capsaicin	  concentration	  range	  was	  applied	  to	  the	  capsaicin-­‐untreated	  tissue	  pair.	  	  In	  the	  control	  tissues	  three	  organ	  bath	  temperatures	  were	  studied;	  32°C,	  34°C	  and	  37°C.	  	  In	  the	  STZ-­‐diabetic	  tissue,	  two	  organ	  bath	  temperatures	  were	  studied;	  32°C	  and	  37°C.	  Spontaneous	  activity	  measurements	  were	  taken,	  where	  frequency	  and	  amplitude	  of	  spontaneous	  contractile	  activity	  was	  measured	  at	  the	  different	  organ	  bath	  temperatures	  studied.	  Data	  analysis	  was	  performed	  as	  previously	  described.	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Results	  
	  
Carbachol	  responses	  at	  different	  organ	  bath	  temperatures	  in	  control	  rat	  
urinary	  bladder	  
	  First	  the	  effects	  of	  three	  different	  organ	  bath	  temperatures,	  37°C,	  34°C	  and	  32°C	  on	  responses	  to	  carbachol	  in	  urinary	  bladder	  tissue	  from	  control	  rats	  was	  examined.	  	  Increased	  responses	  to	  carbachol	  were	  seen	  at	  a	  reduced	  temperature	  of	  34°C.	  	  When	  the	  bath	  temperature	  was	  reduced	  further	  to	  32°C,	  there	  was	  a	  highly	  significant	  enhancement	  of	  the	  response	  to	  carbachol	  (Figure	  4.1).	  pEC50	  and	  Emax	  estimates	  were	  calculated	  (Table	  4.1).	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Capsaicin	  responses	  at	  different	  organ	  bath	  temperatures	  in	  control	  rat	  
urinary	  bladder	  
	  Next	  the	  responses	  to	  capsaicin	  were	  examined	  at	  the	  three	  different	  organ	  bath	  temperatures	  37°C,	  34°C	  and	  32°C,	  in	  urinary	  bladder	  tissue	  from	  naive	  rats.	  	  Here	  enhanced	  responses	  to	  capsaicin	  were	  only	  seen	  at	  the	  32°C	  organ	  bath	  temperature	  in	  comparison	  to	  responses	  at	  37°C.	  	  No	  enhancement	  of	  capsaicin	  responses	  was	  seen	  at	  the	  34°C	  organ	  bath	  temperature	  (Figure	  4.2).	  pEC50	  and	  Emax	  estimates	  were	  calculated	  (Table	  4.2).	  
	  Figure	  4.2	  Graph	  showing	  capsaicin	  responses	  of	  urinary	  bladder	  tissue	  from	  control	  rats	  at	  organ	  bath	  temperatures	  of	  	  37°C,	  34°C	  and	  32°C.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***p<0.001,	  comparing	  to	  37°C	  responses.	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The	  effect	  of	  organ	  bath	  temperature	  on	  responses	  to	  carbachol	  in	  urinary	  
bladder	  from	  STZ-­‐diabetic	  rats	  	  Next	  the	  effects	  of	  two	  organ	  bath	  temperatures	  37°C	  and	  32°C,	  were	  examined	  on	  carbachol	  responses	  in	  bladder	  from	  STZ-­‐diabetic	  rats.	  	  Here	  no	  enhancement	  of	  carbachol	  responses	  were	  seen	  with	  the	  reduced	  organ	  bath	  temperature	  of	  32°C	  (Figure	  4.3).	  pEC50	  and	  Emax	  estimates	  were	  calculated	  (Table	  4.1).	  	  
	  Figure	  4.3	  Graph	  showing	  carbachol	  responses	  of	  urinary	  bladder	  tissue	  from	  STZ-­‐treated	  rats	  at	  organ	  bath	  temperatures	  of	  	  37°C	  and	  32°C.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  	  No	  statistical	  significance	  was	  seen	  when	  tested	  by	  two-­‐way	  ANOVA.	  	  
The	  effect	  of	  organ	  bath	  temperature	  on	  responses	  to	  capsaicin	  urinary	  
bladder	  from	  STZ-­‐diabetic	  rats	  	  The	  responses	  to	  capsaicin	  in	  bladder	  from	  STZ-­‐diabetic	  rats	  were	  studied	  at	  two	  organ	  bath	  temperatures,	  37°C	  and	  32°C.	  	  Here	  a	  classically	  diminished	  response	  to	  capsaicin	  was	  observed	  at	  the	  standard	  organ	  bath	  temperature	  of	  37°C	  when	  comparing	  to	  control	  responses	  (Figure	  4.2,	  Figure	  4.4).	  	  Reduction	  of	  bath	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temperature	  to	  32°C	  had	  no	  enhancing	  effect	  on	  this	  diminished	  capsaicin	  response.	  pEC50	  and	  Emax	  estimates	  were	  calculated	  (Table	  4.2).	  	  	  
	  Figure	  4.4	  Graph	  showing	  capsaicin	  responses	  of	  urinary	  bladder	  tissue	  from	  STZ-­‐treated	  rats	  at	  organ	  bath	  temperatures	  of	  37°C	  and	  32°C.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  	  No	  statistical	  significance	  was	  seen	  when	  tested	  by	  two-­‐way	  ANOVA.	  	  Table	  4.1.	  Potency	  and	  efficacy	  estimates	  for	  urinary	  bladder	  responses	  to	  carbachol	  from	  control	  and	  STZ-­‐treated	  rats	  at	  different	  organ	  bath	  temperatures.	  	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	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  Table	  4.2.	  Potency	  and	  efficacy	  estimates	  for	  urinary	  bladder	  responses	  to	  capsaicin	  from	  control	  and	  STZ-­‐treated	  rats	  at	  different	  organ	  bath	  temperatures.	  	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips	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  Figure	  4.5	  Barcharts	  showing	  frequency	  (A)	  and	  amplitude	  (B)	  of	  the	  spontaneous	  contractile	  activity	  of	  urinary	  bladder	  tissue	  from	  control	  and	  STZ-­‐treated	  rats	  at	  organ	  bath	  temperatures	  of	  32°C,	  34	  °C	  and	  37°C.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  using	  one-­‐way	  ANOVA	  with	  post-­‐hoc	  Dunnett’s	  comparing	  to	  respective	  control,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***p<0.001,	  no	  significant	  difference	  was	  seen	  between	  37°C	  control	  and	  STZ	  for	  frequency	  or	  amplitude.	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Discussion	  	  
Reduction	  in	  organ	  bath	  temperatures	  caused	  marked	  enhancements	  in	  
carbachol	  responses	  in	  controls	  	  Carbachol	  responses	  were	  enhanced	  at	  the	  lower	  organ	  bath	  temperatures	  of	  34°C	  and	  32°C.	  	  Cooling	  is	  known	  to	  enhance	  the	  contractile	  ability	  of	  smooth	  muscle	  in	  numerous	  organs.	  	  In	  airway	  smooth	  muscle,	  cooling	  to	  20	  °C	  induces	  a	  supersensitivity	  to	  electrically	  evoked	  and	  acetylcholine	  evoked	  contractions	  (Ishii	  and	  Shimo,	  1985)	  and	  was	  seen	  to	  reduce	  resting	  membrane	  potential	  and	  thereby	  increase	  contractility	  (Souhrada	  and	  Souhrada,	  1981)	  .	  	  Ishii	  and	  Shimo	  postulated	  that	  the	  cause	  of	  this	  cooling	  induced	  supersensitivity	  was	  either	  an	  accelerated	  release	  of	  calcium	  from	  the	  intracellular	  stores,	  an	  inhibition	  of	  calcium	  extrusion	  from	  the	  cell	  or	  an	  inhibition	  of	  calcium	  reuptake	  by	  the	  intracellular	  stores.	  	  Studies	  on	  adrenergic	  agonist	  activity	  in	  mouse	  vas	  deferens	  also	  observed	  enhanced	  responses	  at	  the	  cooler	  temperature	  of	  26	  °C,	  and	  again	  altered	  cellular	  calcium	  handling	  was	  thought	  to	  be	  the	  mechanism	  of	  enhanced	  responses	  (Souilem	  et	  al.,	  1992).	  Another	  study	  by	  Souilem	  on	  mouse	  vas	  deferens	  put	  forward	  the	  idea	  that	  as	  well	  as	  increased	  intracellular	  release	  of	  calcium,	  an	  inhibition	  of	  the	  Na+/K+	  pump	  could	  be	  responsible	  for	  the	  hyperreactivity	  (Souilem	  et	  al.,	  1995).	  	  A	  study	  on	  guinea-­‐pig	  bladder	  revealed	  that	  lowering	  the	  temperature	  caused	  membrane	  depolarisation	  and	  again	  the	  cause	  for	  this	  was	  thought	  to	  be	  calcium	  related	  (Kurihara	  et	  al.,	  1974).	  So	  clearly	  evidence	  exists	  in	  the	  literature	  for	  cooling	  induced	  hyperreactivity	  due	  to	  altered	  calcium	  handling	  within	  the	  cell	  or	  membrane	  depolarisation.	  	  An	  additional	  mechanism	  that	  has	  been	  proposed	  is	  an	  increased	  phosphorylation	  of	  myosin	  light	  chain	  at	  lower	  temperatures	  (Sugaya	  and	  De	  Groat,	  2000).	  	  
Reduced	  organ	  bath	  temperature	  caused	  increased	  responsiveness	  to	  
capsaicin	  in	  controls	  	  The	  reduced	  organ	  bath	  temperature	  induced	  hyperreactivity	  was	  also	  observed	  in	  capsaicin	  responses	  in	  control	  animal	  tissue.	  In	  terms	  of	  the	  magnitude	  of	  
	   92	  
enhancement,	  similar	  fold	  increases	  in	  carbachol	  and	  capsaicin	  responses	  were	  seen:	  carbachol	  increased	  by	  approximately	  1.58	  and	  1.98-­‐fold,	  capsaicin	  responses	  were	  increased	  1.35	  and	  2.3	  fold	  at	  34°C	  and	  32	  °C	  organ	  bath	  temperatures	  respectively.	  	  It	  appears	  that	  the	  increases	  in	  capsaicin	  responses	  at	  lower	  temperatures	  are	  driven	  by	  a	  myogenic	  mechanism,	  rather	  than	  any	  direct	  effect	  on	  the	  TRPV1	  receptor	  itself.	  	  
No	  temperature	  induced	  hyperreactivity	  was	  observed	  for	  carbachol	  or	  
capsaicin	  in	  STZ-­‐treated	  rat	  tissue	  
	  Interestingly,	  no	  such	  temperature-­‐enhancement	  was	  seen	  in	  STZ-­‐diabetic	  tissue	  for	  either	  carbachol	  or	  capsaicin.	  	  These	  data	  imply	  that	  the	  mechanism	  driving	  low	  temperature	  enhancement	  of	  responses	  to	  carbachol	  and	  capsaicin	  is	  deficient	  in	  STZ-­‐diabetic	  tissue.	  Furthermore,	  the	  deficiency	  in	  this	  temperature	  sensitive	  mechanism	  may	  be	  the	  mechanism	  by	  which	  myogenic	  function	  is	  impaired	  in	  diabetes	  as	  evidenced	  by	  the	  reduced	  contractile	  responses	  to	  carbachol.	  	  This	  impairment	  likely	  plays	  a	  part	  in	  the	  diminished	  responses	  seen	  to	  capsaicin	  but	  because	  the	  decreases	  in	  capsaicin	  response	  are	  much	  larger	  than	  that	  seen	  in	  carbachol	  responses,	  it	  is	  unlikely	  that	  this	  myogenic	  impairment	  is	  the	  total	  cause	  of	  the	  diminished	  TRPV1	  response.	  The	  TRPV1	  channel	  desensitizes	  to	  repeated	  heat	  activation	  in	  much	  the	  same	  way	  that	  it	  desensitizes	  to	  acid	  and	  chemical	  agonists	  (Benham	  et	  al.,	  2003).	  So	  these	  studies	  do	  not	  preclude	  the	  notion	  that	  a	  change	  in	  the	  temperature	  threshold	  in	  the	  diabetic	  model	  had	  occurred	  and	  it	  was	  heat-­‐induced	  desensitisation	  of	  TRPV1	  responses	  that	  were	  causative	  to	  the	  diminished	  TRPV1	  responses	  seen	  in	  vitro.	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Organ	  bath	  temperature	  causes	  changes	  in	  spontaneous	  activity	  	  	  Reduction	  of	  the	  organ	  bath	  temperature	  caused	  a	  graded	  decrease	  in	  the	  frequency	  and	  a	  graded	  increase	  in	  the	  amplitude	  of	  spontaneous	  contractile	  activity	  of	  tissue	  from	  control	  and	  STZ-­‐treated	  rats.	  	  Such	  decreases/increases	  in	  response	  to	  temperature	  have	  been	  reported	  in	  adult	  rat	  bladder	  tissue	  (Sugaya	  and	  De	  Groat,	  2000)	  where	  they	  studied	  whole	  bladder	  in	  vitro	  and	  saw	  that	  the	  frequency	  of	  spontaneous	  contractions	  increased	  some	  1.5	  fold	  from	  28°C	  to	  37°C,	  and	  amplitudes	  were	  two-­‐fold	  larger	  at	  the	  lower	  temperature.	  	  	  However	  the	  result	  seen	  here	  for	  the	  STZ-­‐treated	  rat	  group	  was	  unexpected.	  There	  seems	  to	  be	  a	  disparity	  in	  the	  effects	  of	  temperature	  on	  spontaneous	  activity	  and	  muscarinic/TRPV1-­‐driven	  contractile	  response.	  Spontaneous	  activity	  and	  changes	  to	  it	  by	  temperature	  are	  similar	  in	  tissue	  from	  control	  and	  STZ-­‐treated	  rats,	  whereas	  changes	  to	  muscarinic/TRPV1	  responses	  appear	  deficient	  in	  STZ-­‐treated	  tissue.	  Sugaya	  summarized	  three	  possible	  mechanisms	  for	  the	  effects	  of	  temperature	  on	  spontaneous	  activity:	  through	  stretch	  activated	  channels,	  a	  depolarization	  of	  membrane	  potential,	  or	  desynchronization	  of	  muscle	  activity	  (Sugaya	  and	  De	  Groat,	  2000).	  	  The	  mechanism	  of	  desynchronization	  was	  explained	  by	  Sugaya	  as	  a	  ‘high	  level	  of	  spontaneous	  activity	  renders	  cells	  less	  susceptible	  to	  spread	  of	  electrical	  activity	  from	  adjacent	  cells,	  thereby	  preventing	  co-­‐ordinated	  contractions’.	  	  There	  may	  well	  be	  more	  than	  one	  mechanism	  underlying	  the	  changes	  seen	  with	  temperature	  and	  that	  in	  itself	  may	  provide	  an	  explanation	  for	  the	  disparity	  seen	  between	  changes	  to	  spontaneous	  and	  changes	  to	  carbachol/capsaicin	  evoked	  contractions.	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Chapter	  5	  	  
	  




	  Up	  to	  this	  point	  in	  my	  thesis	  I	  have	  examined	  the	  consequences	  of	  diabetes	  and	  the	  impact	  of	  organ	  bath	  temperature.	  	  The	  next	  phase	  of	  work	  was	  to	  define	  the	  role	  that	  a	  potential	  causative	  agent	  plays	  in	  the	  modulation	  of	  TRPV1	  function.	  	  This	  could	  gain	  a	  further	  understanding	  of	  the	  process	  of	  neuropathy,	  and	  might	  provide	  a	  potential	  therapeutic	  avenue	  to	  aid	  neuropathy	  prevention	  or	  regression.	  	  	  	  An	  ideal	  candidate	  causative	  agent	  would	  appear	  early	  in	  disease,	  persist	  even	  with	  good	  glucose	  control,	  be	  correlated	  to	  diabetic	  neuropathy,	  cause	  neuropathy	  in	  other	  disease	  states	  and	  be	  active	  at	  a	  mechanism	  of	  TRPV1	  down-­‐regulation.	  	  Down-­‐regulation	  of	  TRPV1	  function	  is	  known	  to	  occur	  through	  four	  main	  ways:	  firstly	  through	  direct	  desensitisation	  by	  TRPV1	  agonist	  exposure,	  secondly	  through	  cross-­‐desensitisation	  for	  example	  through	  TRPA1	  activation,	  thirdly	  through	  reduction	  in	  receptor	  number	  and	  finally	  through	  depletion	  or	  down-­‐regulation	  of	  effector	  pathway	  components.	  	  The	  candidate	  I	  chose	  to	  study	  is	  methylglyoxal,	  a	  highly	  reactive	  glucose	  metabolite	  recently	  identified	  as	  being	  a	  TRPA1	  agonist	  (Eberhardt	  et	  al.,	  2012).	  	  Methylglyoxal	  has	  been	  identified	  as	  a	  potential	  causative	  factor	  in	  many	  diabetic	  complications	  (Mclellan	  et	  al.,	  1994,	  Thornalley,	  1994).	  	  Recently	  high	  plasma	  levels	  have	  been	  correlated	  to	  the	  pain	  severity	  in	  diabetics	  suggestive	  of	  a	  direct	  correlative	  role	  of	  methylglyoxal	  to	  pain	  and	  perhaps	  to	  induction	  and	  maintenance	  of	  neuropathy	  (Eberhardt	  et	  al.,	  2012).	  	  This	  metabolite,	  I	  felt,	  warranted	  study	  in	  the	  context	  of	  how	  it	  would	  affect	  the	  TRPV1	  receptor,	  in	  controls	  and	  in	  diabetic	  animal	  tissue.	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Methylglyoxal	  	  Methylglyoxal	  is	  a	  glucose	  metabolite	  and	  is	  a	  neurotoxic	  reactive	  dicarbonyl	  compound	  (Fukunaga	  et	  al.,	  2004).	  	  High	  levels	  of	  methylglyoxal	  have	  been	  measured	  in	  diabetes	  and	  this	  metabolite	  has	  been	  identified	  as	  a	  potential	  culprit	  for	  many	  of	  the	  complications	  prevalent	  in	  diabetes,	  including	  neuropathy	  (Eberhardt	  et	  al.,	  2012).	  	  Reactive	  dicarbonyl	  compounds	  such	  as	  methylglyoxal	  are	  intermediates	  in	  the	  formation	  of	  advanced	  glycation	  endproducts	  (AGE),	  which	  are	  glycalated	  proteins,	  lipids	  and	  nucleic	  acids.	  	  The	  presence	  of	  AGE	  are	  considered	  detrimental	  in	  diabetes,	  Alzheimer’s	  disease,	  renal	  failure,	  aging	  and	  atherosclerosis	  (Ramasamy	  et	  al.,	  2005).	  	  In	  diabetes	  AGE	  induces	  alterations	  in	  cellular	  permeability	  and	  activates	  the	  receptor	  for	  AGE	  (RAGE)	  thus	  driving	  inflammation	  and	  tissue	  injury	  and	  thereby	  contributes	  to	  complications	  such	  as	  nephropathy	  (Ramasamy	  et	  al.,	  2005)	  
?Methylglyoxal	  levels	  are	  increased	  early	  in	  diabetes	  before	  complications	  develop	  and	  have	  been	  measured	  at	  842	  nmol/l	  in	  the	  plasma	  of	  young	  Type	  1	  diabetics,	  compared	  to	  the	  non-­‐diabetic	  levels	  of	  around	  439	  nmol/l	  (Han	  et	  al.,	  2007).	  	  However	  given	  that	  methylglyoxal	  is	  formed	  within	  the	  cell,	  the	  intracellular	  levels	  may	  be	  much	  higher	  than	  the	  measured	  extracellular	  plasma	  concentrations.	  	  Intracellular	  methylglyoxal	  levels	  are	  complicated	  to	  quantify	  as	  here	  it	  exists	  as	  free	  methylglyoxal	  and	  bound	  in	  adduct	  form	  (Lo	  et	  al.,	  1994).	  Intracellular	  levels	  may	  be	  as	  high	  as	  310	  μM	  (Chaplen	  et	  al.,	  1998),	  however	  in	  red	  blood	  cells	  levels	  have	  been	  measured	  at	  1.66	  and	  0.80	  nmol/ml	  packed	  red	  blood	  cells	  from	  diabetic	  and	  non-­‐diabetics	  respectively	  (Thornalley,	  1988).	  	  Methylglyoxal	  diffuses	  across	  the	  plasma	  membrane	  so	  an	  extracellular	  high	  concentration	  of	  methylglyoxal	  is	  likely	  reflective	  of	  increased	  intracellular	  levels.	  The	  levels	  of	  methylglyoxal	  in	  plasma	  have	  been	  correlated	  to	  pain	  in	  diabetic	  patients	  (Bierhaus	  et	  al.,	  2012).	  	  In	  this	  study,	  the	  plasma	  level	  of	  methylglyoxal	  in	  healthy	  controls	  was	  measured	  at	  200	  nM,	  this	  was	  shown	  to	  be	  increased	  in	  diabetics	  with	  no	  pain	  symptoms	  to	  500	  nM	  and	  was	  increased	  further	  to	  900	  nM	  in	  diabetics	  with	  pain	  (Bierhaus	  et	  al.,	  2012).	  	  Levels	  of	  methylglyoxal	  have	  been	  measured	  in	  urine	  of	  healthy	  volunteers	  at	  15	  μM	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(Espinosa-­‐Mansilla	  et	  al.,	  1998),	  suggesting	  that	  the	  bladder	  may	  be	  exposed	  to	  high	  levels	  of	  methylglyoxal.	  	  To	  cause	  an	  effect	  on	  TRPA1	  channels,	  the	  methylglyoxal	  levels	  need	  to	  increase	  intracellularly	  as	  the	  site	  of	  action	  is	  intracellular,	  and	  therefore	  reasonably	  high	  concentrations	  of	  methylglyoxal	  are	  needed	  for	  extracellular	  application.	  	  In	  vitro	  assays	  investigating	  the	  effects	  of	  methylglyoxal	  on	  pancreatic	  cells	  have	  shown	  stimulating	  effects	  of	  1mM	  methylglyoxal	  in	  the	  acute	  setting	  (Cook	  et	  al.,	  1998),	  with	  cytotoxicity	  by	  4-­‐6	  hours	  (Sheader	  et	  al.,	  2001).	  	  Studies	  with	  DRG	  showed	  that	  an	  acute	  extracellular	  application	  of	  3	  mM	  methylglyoxal	  rapidly	  increased	  intracellular	  levels	  of	  methylglyoxal	  from	  1.5	  μM	  to	  2.2	  μM	  (Eberhardt	  et	  al.,	  2012).	  	  Additionally	  this	  study	  by	  Eberhardt	  also	  demonstrated	  that	  human	  TRPA1	  was	  activated	  by	  the	  application	  of	  1,	  3	  and	  10	  mM	  methylglyoxal,	  applied	  extracellularly.	  These	  studies	  guided	  the	  use	  of	  mM	  concentrations	  of	  methylglyoxal.	  	  	  
Formation	  of	  methylglyoxal	  	  Methylglyoxal	  is	  formed	  inside	  cells	  from	  the	  triose	  phosphate	  intermediates	  of	  glycolysis,	  dihydroxyacetone	  phosphate	  and	  glyceraldehyde	  3-­‐phosphate,	  in	  a	  non-­‐enzymatic	  process	  known	  as	  the	  Maillard	  reaction.	  The	  Maillard	  reaction	  is	  a	  complex	  series	  of	  reactions	  of	  the	  carbonyl	  groups	  of	  reducing	  sugars	  with	  the	  primary	  amino	  groups	  of	  proteins.	  	  From	  these	  reactions,	  the	  corresponding	  Schiff	  bases	  are	  produced	  which	  then	  undergo	  Amadori	  rearrangements	  to	  yield	  protein-­‐derived	  aminomethyl-­‐	  ketones.	  	  Reactive	  oxygen	  species	  and	  reactive	  nitrogen	  species	  are	  then	  involved	  in	  glycoxidations	  of	  these	  Amadori	  compounds	  that	  are	  catalysed	  by	  transition-­‐metal-­‐ions,	  yielding	  1,2-­‐dicarbonyl	  compounds	  such	  as	  glyoxal	  and	  methylglyoxal.	  	  Autoxidation	  reactions	  of	  glucose,	  Schiff	  bases	  or	  the	  corresponding	  Amadori	  compounds	  also	  yield	  1,2-­‐dicarbonyl	  compounds.	  	  These	  dicarbonyl	  compounds	  are	  highly	  reactive	  with	  amino	  groups	  on	  proteins	  causing	  further	  glycoxidation,	  and	  resulting	  in	  protein	  cross-­‐linking	  and	  modification	  to	  produce	  AGEs.	  	  Typically	  the	  lysine	  and	  the	  arginine	  residues	  are	  affected.	  	  This	  is	  important	  as	  these	  residues	  are	  commonly	  located	  within	  the	  active	  sites	  on	  enzymes,	  and	  modification	  here	  can	  result	  in	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enzyme	  deactivation	  (Reddy	  and	  Beyaz,	  2006).	  	  The	  hyperglycemia	  and	  high	  levels	  of	  ketones	  present	  in	  uncontrolled	  diabetes	  thus	  leads	  to	  increased	  methylglyoxal	  production	  (Figure	  5.1).	  
	  	  Figure	  5.1	  Formation	  and	  detoxification	  of	  methylglyoxal.	  Taken	  from	  (Kiefer	  et	  al.,	  2013)	  
	  
Detoxification	  of	  methylglyoxal	  
	  The	  bodies	  main	  defence	  system	  against	  glycation	  is	  the	  glutathione-­‐dependent	  glyoxalase	  system	  consisting	  of	  glyoxalase	  1	  and	  glyoxalase	  II	  that	  act	  to	  detoxify	  methylglyoxal	  and	  other	  reactive	  α-­‐oxoaldehydes.	  	  In	  diabetes	  however,	  methylglyoxal	  levels	  remain	  high,	  even	  with	  good	  glucose	  control,	  due	  to	  an	  impairment	  in	  the	  glyoxalase	  system.	  This	  is	  because	  oxidative	  stress	  causes	  a	  depletion	  of	  glutathione	  and	  this	  suppresses	  the	  activity	  of	  the	  enzyme	  glyoxalases	  due	  to	  their	  glutathione	  dependence	  and	  can	  therefore	  lead	  to	  increased	  levels	  of	  methylglyoxal.	  	  In	  diabetes,	  there	  is	  evidence	  of	  increased	  oxidative	  stress	  and	  AGEs	  themselves	  may	  generate	  reactive	  oxygen	  species.	  	  	  RAGE	  activation	  by	  AGEs	  can	  additionally	  activate	  NADPH	  oxidase	  and	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mitochondrial	  pathways	  also	  resulting	  in	  oxidative	  stress.	  	  Additionally	  methylglyoxal	  can	  modify	  antioxidant	  proteins	  reducing	  their	  function,	  adding	  to	  the	  increased	  burden	  of	  oxidative	  stress.	  So	  without	  intervention	  to	  reduce	  the	  oxidative	  stress	  or	  to	  enhance	  the	  detoxification	  pathways,	  levels	  of	  methylglyoxal	  and	  oxidative	  stress	  remain	  high.	  	  Lower	  activity	  of	  glyoxalase	  1	  has	  been	  correlated	  with	  painful	  neuropathy	  in	  diabetes	  suggesting	  that	  the	  glyoxalase	  activity	  does	  modulate	  the	  diabetic	  neuropathy	  phenotype	  (Skapare	  et	  al.,	  2013)	  .	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Methylglyoxal	  may	  have	  a	  directly	  causative	  role	  in	  induction	  of	  Type	  2	  
diabetes	  	  Some	  studies	  have	  shown	  a	  causative	  effect	  of	  methylglyoxal	  in	  the	  development	  of	   insulin	   resistance,	   a	   hallmark	   of	   Type	   2	   diabetes.	   	   Methylglyoxal	   causes	   a	  modification	  of	  insulin	  through	  attachment	  to	  the	  arginine	  residue	  on	  the	  alpha-­‐chain	  of	  insulin.	  	  This	  methylglyoxal-­‐insulin	  adduct	  causes	  a	  decrease	  in	  insulin-­‐mediated	   uptake	   of	   glucose,	   reduces	   insulin	   secretion	   and	   reduces	   clearance.	  	  Methylglyoxal	  has	  been	  shown	   to	   impair	   the	   signalling	  of	   insulin	  and	   to	  play	  a	  role	   in	   obesity	   through	   stimulation	   of	   adipogenesis	   via	   upregulation	   of	   Akt	  signaling	  (Jia,	  2010)	  	  	  
TRPA1	  activation	  by	  methylglyoxal	  	  Methylglyoxal	  applied	  to	  the	  extracellular	  environment	  in	  vitro	  gains	  access	  to	  the	  cell	  and	  stimulates	  the	  TRPA1	  receptor	  thus	  causing	  the	  release	  of	  neuropeptides.	  	  Methylglyoxal	  is	  believed	  to	  interact	  with	  cysteine	  residues	  at	  the	  N-­‐terminus,	  a	  reversible	  reaction	  (Andersson	  et	  al.,	  2013)	  (Figure	  5.2)	  and	  covalently	  modify	  lysine	  residues	  	  (Eberhardt	  et	  al.,	  2012).	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Downregulation	  of	  TRPV1	  receptor	  function	  via	  cross-­‐desensitisation	  of	  
TRPA1	  
	  TRPV1	  and	  another	  sensory	  neuron	  receptor,	  TRPA1,	  are	  co-­‐located	  on	  the	  sensory	  neuron.	  	  This	  co-­‐localisation	  is	  so	  intricate	  that	  a	  dynamic	  cross-­‐sensitization	  and	  desensitisation	  can	  occur	  between	  these	  two	  receptors.	  The	  desensitisation	  process	  is	  likely	  to	  involve	  calcium	  signaling	  on	  shared	  intracellular	  components	  of	  the	  receptors.	  	  Agonist	  activation	  of	  one	  receptor	  leads	  to	  self-­‐desensitisation	  and	  possibly	  cross-­‐desensitisation.	  	  Similarly,	  sensitization	  processes	  on	  one	  receptor	  may	  lead	  to	  cross-­‐sensitisation.	  	  In	  addition	  to	  direct	  receptor	  cross-­‐	  sensitization/	  desensitisation,	  alterations	  in	  common	  effector	  mechanisms;	  sensory	  neuropeptide	  release,	  receptor	  activation	  and	  peptide	  deactivation	  processes,	  could	  also	  impact	  TRPV1	  and	  TRPA1	  functional	  activity.	  	  TRPV1	  and	  TRPA1	  share	  similar	  effector	  mechanisms	  at	  the	  local	  level,	  whereby	  agonist	  activation	  leads	  to	  release	  of	  sensory	  neuropeptides	  such	  as	  neurokinins	  and	  Substance	  P	  release	  which	  exert	  a	  functional	  effect	  via	  neurokinin	  receptors	  and	  Substance	  P	  receptors	  for	  example	  to	  cause	  muscle	  contraction	  in	  the	  bladder.	  	  Due	  to	  this	  neuropeptide	  release	  and	  activation	  of	  distinct	  peptidergic	  receptors,	  an	  additional	  explanation	  for	  modulation	  of	  function	  exists	  and	  should	  be	  considered.	  	  For	  example	  if	  the	  sensory	  neuropeptides	  were	  depleted,	  then	  the	  functional	  activity	  of	  TRPV1	  and	  TRPA1	  would	  be	  impaired.	  	  If	  the	  receptor	  number	  or	  pathway	  altered	  at	  the	  peptidergic	  level	  this	  too	  would	  impact	  on	  TRPV1/	  TRPA1	  function.	  	  Finally,	  an	  alteration	  in	  the	  peptidergic	  de-­‐activation	  process	  i.e.	  enzymatic	  breakdown	  of	  neuropeptides,	  would	  also	  impact	  on	  TRPV1/TRPA1	  function.	  
	  
TRPA1	  tool	  ligands	  	  A	  standard	  tool	  agonist	  for	  TRPA1,	  used	  extensively	  in	  the	  literature,	  is	  the	  mustard	  oil	  derived	  pungent	  compound	  allyl	  isothiocyanate	  (AITC).	  	  Other	  tool	  agonists	  include	  garlic-­‐derived	  compounds	  (Figure	  5.3)	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  Figure	  5.3	  Chemical	  structures	  of	  TRPA1	  agonist	  compounds	  allyl	  isothiocyanate	  (mustard	  oil),	  and	  the	  garlic	  derivatives,	  allicin,	  DADS,	  DAS,	  and	  dipropyl	  disulfide.	  Taken	  from	  (Bautista	  et	  al.,	  2005).	  	  A	  potent	  and	  selective	  TRPA1	  antagonist	  is	  HC-­‐030031	  (2-­‐(1,3-­‐Dimethyl-­‐2,6-­‐dioxo-­‐1,2,3,6-­‐tetrahydro-­‐7H-­‐purin-­‐7-­‐yl)-­‐N-­‐(4-­‐isopropylphenyl)acetamide)	  Figure	  5.4).	  	  This	  has	  been	  shown	  to	  antagonize	  AITC	  calcium	  influx	  with	  an	  IC50	  of	  6.2	  μM	  and	  does	  not	  block	  currents	  mediated	  by	  TRPV1,	  TRPV3,	  TRPV4,	  hERG	  or	  NaV1.2	  channels. It	  has	  also	  shown	  to	  be	  active	  in	  vivo,	  inhibiting	  AITC-­‐induced	  flinching	  (Mcnamara	  et	  al.,	  2007)	  and	  blocking	  AITC	  effects	  on	  COX2	  mRNA	  expression	  	  (Moilanen	  et	  al.,	  2012)	  	  
	  	  	  Figure	  5.4	  Chemical	  structure	  of	  HC-­‐030031	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  To	  define	  the	  role	  methylglyoxal	  plays	  in	  modulation	  of	  TRPV1	  function,	  the	  effects	  of	  this	  neuropathy-­‐causing	  agent	  were	  investigated	  in	  urinary	  bladder	  tissue	  from	  control	  animals	  and	  compared	  to	  responses	  seen	  in	  the	  STZ-­‐induced	  diabetic	  model.	  	  An	  acute	  exposure	  to	  methylglyoxal	  was	  examined	  on	  the	  subsequent	  responses	  to	  capsaicin,	  carbachol	  and	  to	  electrical	  field	  stimulation.	  	  The	  effects	  of	  a	  known	  TRPA1	  agonist	  AITC	  were	  studied	  to	  provide	  comparative	  responses	  and	  a	  TRPA1	  selective	  antagonist	  HC-­‐030031	  was	  used	  to	  explore	  the	  mode	  of	  action	  of	  methylglyoxal.	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Methods	  	  Experiments	  were	  performed	  on	  2	  weeks	  post	  control	  or	  STZ-­‐treated	  rat	  urinary	  bladder	  strips,	  set-­‐up	  as	  previously	  described.	  For	  electrical	  field	  stimulation	  studies	  bladder	  strips	  were	  suspended	  between	  electrodes.	  	  STZ-­‐treated	  animals	  were	  only	  used	  in	  these	  studies	  if	  blood	  glucose	  levels	  were	  >	  3	  fold	  higher	  than	  control	  levels.	  	  
Direct	  contractile	  effects	  of	  methylglyoxal	  	  and	  AITC	  and	  effects	  of	  acute	  
methylglyoxal	  exposure	  on	  subsequent	  capsaicin	  responses	  	  In	  2	  week	  post	  control	  and	  STZ-­‐treated	  urinary	  bladder	  tissue,	  single	  concentrations	  of	  methylglyoxal	  (0.1	  mM,	  0.3	  mM,	  1	  mM,	  3	  mM	  and	  10	  mM)	  or	  cumulative	  concentrations	  of	  AITC	  (1	  x	  10-­‐5M-­‐	  3	  x	  10-­‐3M)	  	  were	  applied	  to	  measure	  the	  direct	  effects	  of	  methylglyoxal	  and	  AITC	  as	  contractile	  agents.	  	  After	  a	  10	  minute	  incubation	  with	  no	  washout	  which	  allowed	  tensions	  to	  return	  to	  baseline	  levels,	  a	  concentration	  range	  of	  capsaicin	  was	  applied	  cumulatively	  (1	  x	  10-­‐9M-­‐	  3	  x	  10-­‐6M)	  to	  study	  the	  effects	  of	  methylglyoxal	  and	  AITC	  on	  TRPV1	  responses.	  	  Post	  washout	  and	  a	  40	  minute	  equilibration,	  3	  mM	  methylglyoxal	  was	  reapplied	  to	  examine	  whether	  repeated	  application	  would	  result	  in	  contraction.	  	  	  	  
Monitoring	  of	  carbachol	  responses	  following	  acute	  methylglyoxal	  exposure	  In	  2	  week	  post	  control	  and	  STZ-­‐treated	  urinary	  bladder	  tissue,	  a	  concentration	  range	  of	  carbachol	  (1	  x	  10-­‐8M-­‐	  3	  x	  10-­‐5M)	  was	  applied	  cumulatively	  following	  either	  vehicle	  control	  (water)	  or	  methylglyoxal	  acute	  exposure.	  	  	  
Effects	  of	  a	  TRPA1	  specific	  antagonist,	  HC-­‐030031	  	  	  First	  a	  concentration-­‐finding	  study	  was	  performed	  using	  2-­‐week	  post	  control	  urinary	  bladder	  tissue.	  A	  range	  of	  HC-­‐030031	  concentrations	  (10,	  30,100	  μM)	  or	  DMSO	  control	  were	  incubated	  for	  10	  minutes	  prior	  to	  application	  of	  0.1	  mM	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AITC.	  	  Following	  identification	  of	  the	  optimal	  concentration	  of	  30	  μM	  HC-­‐030031,	  this	  concentration	  was	  tested	  against	  3	  mM	  methylglyoxal	  to	  examine	  whether	  methylglyoxal	  was	  causing	  its	  effects	  through	  activation	  of	  the	  TRPA1	  receptor.	  	  
Effects	  of	  acute	  AITC	  and	  methylglyoxal	  +	  TRPA1	  antagonist	  HC-­‐030031	  on	  
subsequent	  capsaicin	  responses	  	  After	  exposure	  to	  vehicle	  controls	  ,0.1	  mM	  AITC	  or	  3	  mM	  methylglyoxal	  +	  30	  μM	  HC-­‐030031,	  with	  no	  washout,	  a	  concentration	  range	  of	  capsaicin	  was	  applied	  cumulatively	  (1	  x	  10-­‐9M-­‐	  3	  x	  10-­‐6M).	  	  
Effect	  of	  acute	  methylglyoxal	  application	  on	  repeated	  electrically-­‐evoked	  
contractions	  	  In	  2	  week	  post	  control	  and	  STZ-­‐treated	  urinary	  bladder	  tissue,	  the	  effects	  of	  a	  5	  minute	  preincubation	  with	  3	  mM	  methylglyoxal	  were	  examined	  on	  repeated	  electrically	  evoked	  contractions:	  submaximal	  voltage,	  40	  Hz,	  repeat	  pulses	  every	  minute,	  0.1	  ms	  pulse	  width,	  rate	  of	  50	  Hz,	  10	  sec	  duration.	  Next	  the	  effects	  of	  3	  mM	  methylglyoxal	  were	  examined	  during	  repeat	  electrically-­‐evoked	  contractions.	  	  Resuts	  were	  transformed	  to	  percent	  increases	  over	  the	  pre-­‐methylglyoxal	  contraction	  level.	  	  	  
Direct	  relaxant	  effects	  of	  methylglyoxal	  and	  AITC	  	  On	  the	  observation	  that	  a	  relaxation	  was	  seen	  on	  second	  application	  of	  methylglyoxal,	  an	  additional	  study	  of	  methylglyoxal’s	  effect	  on	  carbachol	  precontracted	  tissue	  was	  undertaken.	  	  Following	  maximal	  concentration	  addition	  of	  carbachol	  (3	  x	  10-­‐5M),	  tissues	  were	  allowed	  to	  reach	  the	  tonic	  phase	  of	  contraction	  then	  a	  cumulative	  concentration	  range	  of	  methylglyoxal	  	  or	  AITC	  (1x	  10-­‐5M-­‐	  1x	  10-­‐2M)	  	  was	  applied.	  	  	  To	  see	  if	  the	  methylglyoxal	  relaxant	  effects	  were	  TRPA1	  mediated,	  10	  and	  30	  μM	  HC-­‐030031	  were	  incubated	  for	  10	  minutes	  before	  methylglyoxal	  additions.	  




The	  direct	  contractile	  effects	  of	  methylglyoxal	  and	  AITC	  	  Previous	  in-­‐house	  data	  had	  demonstrated	  that	  application	  of	  AITC	  was	  able	  to	  cause	  a	  direct	  contractile	  response	  in	  urinary	  bladder	  (Katisart,	  2011).	  	  So	  the	  first	  studies	  were	  aimed	  at	  examining	  whether	  methylglyoxal	  would	  elicit	  similar	  effects	  and	  compare	  these	  to	  responses	  to	  AITC.	  
	  A	  concentration	  range	  of	  methylglyoxal	  or	  AITC	  was	  applied	  and	  contractile	  effects	  measured,	  a	  representative	  trace	  is	  shown	  (Figure	  5.5).	  	  Following	  washout,	  no	  contractile	  response	  to	  a	  second	  application	  of	  methylglyoxal	  was	  seen,	  but	  a	  small	  relaxant	  response	  from	  baseline	  tension	  was	  noted.	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The	  initial	  response	  to	  methylglyoxal	  was	  a	  transient	  phasic	  contraction	  and	  reduced	  responses	  were	  seen	  in	  the	  STZ-­‐treated	  animal	  group.	  AITC	  caused	  a	  more	  sustained	  contraction	  of	  similar	  maximal	  magnitude	  and	  was	  only	  tested	  in	  control	  tissues	  (Figure	  5.6).	  	  Potency	  and	  efficacy	  estimates	  were	  calculated	  (Table	  5.1).	  	  
	  Figure	  5.6	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  methylglyoxal	  or	  AITC	  in	  2-­‐weeks	  post	  control	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  2-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001,	  comparing	  responses	  to	  methylglyoxal	  in	  STZ	  to	  control.	  	  	  Table	  5.1	  Potency	  and	  efficacy	  estimates	  for	  methylglyoxal	  and	  AITC	  in	  tissue	  from	  2	  weeks	  post	  control	  or	  STZ-­‐treated	  rats.	  	  Data	  represent	  mean	  +	  s.e.m	  for	  >6	  urinary	  bladder	  strips.	  
	  Statistical	  analysis	  by	  Students	  t-­‐test	  comparing	  MG	  STZ	  to	  control	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001,	  comparing	  MG	  control	  to	  AITC	  control	  NS	  no	  significant	  difference.	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Effects	  of	  methylglyoxal	  and	  AITC	  on	  TRPV1	  responses	  
	  
The	  effects	  of	  acute	  methylglyoxal	  exposure	  on	  subsequent	  responses	  to	  
capsaicin	  Following	  a	  10	  minute	  incubation	  of	  a	  range	  of	  concentrations	  of	  methylglyoxal	  with	  no	  washout,	  the	  responses	  to	  a	  cumulative	  concentration	  range	  of	  capsacin	  in	  2	  weeks	  control	  and	  STZ-­‐treated	  rat	  tissue	  were	  examined.	  	  Capsaicin	  response	  in	  STZ-­‐treated	  rat	  tissue	  compared	  to	  control	  was	  clearly	  diminished	  as	  seen	  previously	  (Figure	  5.7).	  	  
	  Figure	  5.7	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  in	  2-­‐weeks	  post	  control	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  control.	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In	  urinary	  bladder	  from	  control	  animals	  the	  capsaicin	  reponses	  following	  1,	  3	  and	  10	  mM	  methylglyoxal	  were	  rightward	  shifted	  relating	  to	  a	  decreased	  potency.	  The	  urinary	  bladder	  from	  STZ-­‐treated	  animals	  also	  displayed	  a	  rightward	  shifted	  response	  following	  3	  and	  10	  mM	  methylglyoxal	  exposure	  (Figure	  5.8)	  (Table	  5.2)	  	  	  
	  Figure	  5.8	  Graphs	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  following	  acute	  exposure	  to	  a	  range	  of	  concentrations	  of	  methylglyoxal	  in	  2-­‐weeks	  post	  control	  (A)	  and	  STZ-­‐treated	  (B)	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	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Table	  5.2	  Potency	  and	  efficacy	  estimates	  for	  capsaicin	  +	  acute	  methylglyoxal	  in	  tissue	  from	  2	  weeks	  post	  control	  or	  STZ-­‐treated	  rats.	  	  Data	  represent	  mean	  +	  s.e.m	  for	  >6	  urinary	  bladder	  strips.	  
	  Statistical	  analysis	  by	  one-­‐way	  ANOVA	  comparing	  to	  control	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001,	  or	  by	  Students	  t-­‐test	  comparing	  STZ	  to	  control,	  $$$	  p<0.001.	  	  
	  
	  
The	  effects	  of	  acute	  AITC	  exposure	  on	  subsequent	  responses	  to	  capsaicin	  	  The	  effect	  of	  0.1	  mM	  AITC	  on	  subsequent	  response	  to	  a	  concentration	  range	  of	  capsaicin	  in	  control	  animal	  tissue	  was	  next	  examined	  where	  it	  was	  seen	  that	  AITC	  pre-­‐exposure	  caused	  a	  reduction	  in	  capsaicin	  efficacy	  	  (Figure	  5.9)	  (Table	  5.3)	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Figure	  5.9	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  following	  0.1	  mM	  AITC	  exposure	  in	  2-­‐weeks	  post	  control	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  control.	  	  Table	  5.3	  Potency	  and	  efficacy	  estimates	  for	  capsaicin	  responses	  +	  acute	  AITC.	  	  Data	  represent	  mean	  +	  s.e.m	  n	  >6	  urinary	  bladder	  strips.	  	  
	  Statistical	  analysis	  by	  Students	  t-­‐test	  comparing	  to	  control,	  NS	  no	  significant	  difference	  *p<0.05.	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Monitoring	  of	  carbachol	  responses	  following	  acute	  methylglyoxal	  exposure	  	  Following	  methylglyoxal	  and	  capsaicin	  exposure,	  responses	  to	  a	  cumulative	  concentration	  range	  of	  carbachol	  were	  examined.	  	  As	  seen	  previously,	  carbachol	  efficacy	  was	  reduced	  in	  the	  STZ-­‐treated	  animal	  group	  (Figure	  5.10)	  	  
	  Figure	  5.10	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  carbachol	  in	  2-­‐weeks	  post	  control	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001,	  comparing	  to	  control.	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Responses	  to	  carbachol	  in	  the	  control	  and	  STZ-­‐treated	  animal	  groups	  were	  unaltered	  by	  the	  3	  mM	  methylglyoxal	  exposure.	  	  However	  10	  mM	  methylglyoxal	  exposure	  caused	  a	  depressed	  maximum	  efficacy	  and	  a	  slight	  reduction	  in	  potency	  to	  carbachol	  in	  both	  control	  and	  STZ-­‐treated	  animal	  tissue	  (Figure	  5.11)	  (Table	  5.4)	  	  	  	  
	  Figure	  5.11	  Graphs	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  carbachol	  following	  methylglyoxal	  exposure	  in	  2-­‐weeks	  post	  control	  (A)	  and	  STZ-­‐treated	  	  (B)	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	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  Table	  5.4	  Potency	  and	  efficacy	  estimates	  for	  carbachol	  +	  acute	  methylglyoxal	  in	  tissue	  from	  2	  weeks	  post	  control	  or	  STZ-­‐treated	  rats.	  	  Data	  represent	  mean	  +	  s.e.m	  for	  >6	  urinary	  bladder	  strips.	  
	  Statistical	  analysis	  by	  one-­‐way	  ANOVA	  comparing	  to	  control	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001,	  or	  by	  Students	  t-­‐test	  comparing	  STZ	  to	  control,	  $$$	  p<0.001.	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Monitoring	  of	  carbachol	  responses	  following	  acute	  AITC	  exposure	  
	  Following	  exposure	  to	  0.1	  mM	  AITC,	  responses	  to	  carbachol	  in	  control	  animal	  tissue	  were	  leftward	  shifted	  with	  no	  effect	  on	  efficacy	  (Figure	  5.12)	  (Table	  5.5).	  	  
	  	  Figure	  5.12	  Graph	  showing	  contractile	  response	  to	  a	  concentration	  range	  of	  carbachol	  following	  0.1	  mM	  AITC	  exposure	  in	  2	  weeks	  post	  control	  rat	  tissue.	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  control.	  	  
	  	  Table	  5.5	  Potency	  and	  efficacy	  estimates	  for	  carbachol	  +	  acute	  AITC	  in	  tissue	  from	  2	  weeks	  post	  control	  rats.	  	  Data	  represent	  mean	  +	  s.e.m	  for	  >6	  urinary	  bladder	  strips.	  
	  Statistical	  analysis	  by	  Students	  t-­‐test	  comparing	  to	  vehicle,	  NS	  no	  significant	  difference,	  *	  p<0.05.	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The	  effects	  of	  a	  TRPA1	  antagonist	  HC-­‐030031	  	  Next	  the	  effects	  of	  a	  TRPA1	  selective	  antagonist	  HC-­‐030031	  were	  examined.	  	  First	  an	  optimal	  concentration-­‐finding	  study	  was	  completed	  by	  preincubating	  a	  concentration	  range	  of	  HC-­‐030031	  for	  10	  minutes	  prior	  to	  application	  of	  0.1	  mM	  TRPA1	  agonist	  AITC	  (Figure	  5.13).	  	  Application	  of	  0.1	  mM	  AITC	  gave	  a	  contraction	  of	  almost	  identical	  magnitude	  to	  that	  seen	  for	  3	  mM	  methylglyoxal,	  and	  although	  30	  μM	  HC-­‐030031	  did	  not	  completely	  inhibit	  AITC	  contraction,	  this	  was	  chosen	  as	  the	  optimal	  antagonist	  concentration	  as	  it	  showed	  no	  adverse	  effect	  versus	  carbachol	  responses,	  whereas	  the	  100	  μM	  concentration	  HC-­‐030031	  did	  cause	  a	  depression	  in	  carbachol	  responses.	  	  Then	  3	  mM	  methylglyoxal	  direct	  contractile	  effects	  were	  measured	  +	  preincubation	  of	  an	  optimum	  HC030031	  concentration	  of	  30	  μM	  or	  vehicle	  control	  (Figure	  5.13).	  	  30	  μM	  HC-­‐030031	  gave	  a	  near	  complete	  inhibition	  of	  3	  mM	  methyglyoxal	  direct	  contractile	  effects	  (Figure	  5.13).	  
	  Figure	  5.13	  Barcharts	  showing	  direct	  contractile	  effects	  of	  AITC	  +	  concentration	  range	  of	  TRPA1	  antagonist	  HC-­‐030031	  (A)	  and	  methylglyoxal	  +	  single	  concentration	  of	  HC-­‐030031	  (B)	  in	  urinary	  bladders	  from	  2	  week	  post	  control-­‐treated	  rats.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  by	  one-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  0.1	  mM	  AITC	  in	  A	  ,or	  by	  Students	  t-­‐test	  in	  B	  comparing	  to	  3	  mM	  methylglyoxal.	  	  
	   117	  
	  	  
The	  effects	  of	  acute	  AITC	  and	  methylglyoxal	  +	  TRPA1	  antagonist	  HC-­‐
030031	  on	  subsequent	  capsaicin	  responses	  	  Following	  exposure	  to	  0.1	  mM	  AITC	  +	  30	  μM	  HC-­‐030031	  or	  3	  mM	  methylglyoxal	  +	  30	  μM	  HC-­‐030031,	  with	  no	  washout,	  the	  effects	  of	  a	  concentration	  range	  of	  capsaicin	  were	  examined	  in	  2	  week	  post	  control-­‐treated	  rat	  tissue.	  	  Firstly	  it	  was	  seen	  that	  30	  μM	  HC-­‐030031	  alone	  had	  no	  effect	  on	  capsaicin	  responses.	  	  Secondly	  it	  was	  seen	  that	  0.1	  mM	  AITC	  in	  the	  presence	  of	  30	  μM	  HC-­‐030031	  continued	  to	  cause	  a	  mild	  depression	  of	  capsaicin	  efficacy	  but	  had	  increased	  capsaicin’s	  potency	  i.e.	  a	  leftward	  shift	  was	  seen	  (Figure	  5.14).	  	  3	  mM	  methylglyoxal	  caused	  a	  depressed	  capsaicin	  response	  and	  this	  was	  not	  altered	  by	  preincubation	  with	  30	  μM	  HC-­‐030031	  (Figure	  5.14)(Table	  5.6)	  
	  Figure	  5.14	  Graphs	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  following	  0.1	  mM	  AITC	  exposure	  +	  30	  μM	  HC-­‐030031	  (A)	  and	  following	  3	  mM	  methylglyoxal	  exposure	  +	  30	  μM	  HC-­‐030031	  (B)	  in	  2-­‐weeks	  post	  control	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001,	  comparing	  to	  control.	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Table	  5.6	  Potency	  and	  efficacy	  estimates	  for	  capsaicin	  responses	  +	  AITC	  and	  MG	  +	  HC-­‐030031.	  	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips	  	  
	  Statistical	  analysis	  by	  one-­‐way	  ANOVA	  comparing	  to	  vehicle	  NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001.	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Effect	  of	  acute	  methylglyoxal	  application	  on	  repeated	  electrically-­‐evoked	  
contraction	  	  The	  acute	  effects	  of	  methylglyoxal	  on	  repeated	  electrically-­‐evoked	  contraction	  were	  studied.	  	  A	  repeated	  twitch	  response	  was	  instigated	  using	  the	  submaximal	  voltage,	  40	  Hz,	  repeating	  pulses	  every	  minute.	  	  Here	  an	  initial	  fade	  in	  contractile	  response	  was	  noted	  which	  was	  followed	  by	  a	  reproducible	  contractile	  response.	  	  A	  single	  3	  mM	  concentration	  of	  methylglyoxal	  was	  applied	  to	  the	  tissue	  and	  incubated	  for	  5	  minutes	  then	  the	  repeated	  electrically-­‐evoked	  contractions	  were	  monitored.	  	  Here	  increased	  contractile	  responses	  were	  seen	  (Figure	  5.15)	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When	  transformed	  to	  percent	  increase,	  it	  could	  be	  clearly	  seen	  that	  the	  methylglyoxal-­‐induced	  increase	  was	  larger	  in	  the	  control	  group	  (Figure	  5.16)	  	  
	  Figure	  5.16	  Barcharts	  showing	  electrically-­‐evoked	  repeat	  responses	  in	  control	  and	  STZ-­‐treated	  urinary	  bladder	  strips	  before	  and	  after	  3	  mM	  methylglyoxal	  application	  (A)	  and	  percent	  increases	  induced	  by	  3	  mM	  methylglyoxal	  (B).	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  using	  Students	  t-­‐test,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001,	  comparing	  to	  respective	  control	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Direct	  relaxant	  effect	  of	  methylglyoxal	  on	  carbachol	  pre-­‐contracted	  urinary	  
bladder	  	  It	  was	  seen	  that	  a	  second	  application	  of	  methylglyoxal	  caused	  a	  relaxation	  from	  basal	  tension	  of	  the	  urinary	  bladder	  tissue.	  	  So	  this	  was	  studied	  in	  detail	  firstly	  looking	  at	  the	  effect	  of	  application	  of	  a	  concentration	  range	  of	  methylglyoxal	  on	  carbachol	  pre-­‐contracted	  tissue.	  	  Following	  the	  maximal	  concentration	  from	  the	  concentration	  range	  study	  of	  carbachol,	  tissue	  was	  left	  to	  reach	  tonic	  phase	  of	  contraction	  and	  then	  a	  concentration	  range	  of	  methylglyoxal	  was	  applied	  in	  a	  cumulative	  fashion.	  	  A	  representative	  trace	  of	  raw	  data	  is	  shown	  (Figure	  5.17)	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Responses	  were	  normalized	  to	  percent	  relaxation	  of	  carbachol	  contraction	  and	  it	  was	  seen	  that	  relaxant	  responses	  to	  methylglyoxal	  were	  concentration	  related	  and	  similar	  between	  control	  and	  STZ-­‐treated	  animals	  (Figure	  5.18).	  	  Following	  washout	  tissues	  remained	  viable	  (data	  not	  shown).	  	  
	  Figure	  5.18	  Graph	  showing	  relaxant	  response	  to	  a	  concentration	  range	  of	  methylglyoxal	  in	  carbachol	  precontracted	  2-­‐weeks	  post	  control	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  No	  statistically	  significant	  difference	  was	  seen	  between	  groups	  when	  tested	  by	  two-­‐way	  ANOVA.	  	  Next	  the	  effect	  of	  a	  TRPA1	  selective	  antagonist	  on	  this	  response	  was	  examined	  on	  this	  relaxant	  effect	  of	  methylglyoxal.	  	  10	  μM	  and	  30	  μM	  HC030031	  did	  not	  block	  the	  relaxation	  of	  carbachol	  response	  by	  methylglyoxal	  (Figure	  5.19)	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  Figure	  5.19	  Graph	  showing	  relaxant	  response	  to	  a	  concentration	  range	  of	  methylglyoxal	  +	  10	  μM	  and	  30	  μM	  HC030031	  in	  carbachol	  precontracted	  2-­‐weeks	  post	  control	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  No	  statistically	  significant	  difference	  was	  seen	  between	  groups	  when	  tested	  by	  two-­‐way	  ANOVA.	  	  The	  potential	  of	  relaxant	  responses	  to	  a	  known	  TRPA1	  agonist	  AITC	  was	  next	  examined,	  again	  using	  carbachol-­‐contracted	  tissue.	  	  Here	  it	  was	  observed	  that	  AITC	  produced	  a	  concentration	  related	  relaxant	  response	  similar	  to	  that	  seen	  with	  methylglyoxal	  (Figure	  5.20)	  
	   124	  
	  Figure	  5.20	  Graph	  showing	  relaxant	  response	  to	  a	  concentration	  range	  of	  AITC	  in	  carbachol	  precontracted	  2-­‐weeks	  post	  control	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  No	  statistically	  significant	  difference	  was	  seen	  between	  groups	  when	  tested	  by	  two-­‐way	  ANOVA.	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Discussion	  	  To	  define	  what	  role,	  if	  any,	  methylglyoxal	  plays	  in	  sensory	  neuropathy	  and	  the	  modulation	  of	  TRPV1	  function	  during	  diabetes,	  these	  studies	  were	  aimed	  at	  examining	  whether	  an	  acute	  exposure	  to	  methylglyoxal	  would	  affect	  TRPV1,	  muscarinic	  and	  electrically-­‐evoked	  responses.	  
	  
Methylglyoxal	  causes	  an	  immediate	  direct	  contractile	  effect	  similar	  in	  
magnitude	  to	  the	  TRPA1	  agonist	  AITC	  and	  blocked	  by	  a	  selective	  TRPA1	  
antagonist	  
	  The	  first	  finding	  was	  that	  methylglyoxal	  application	  causes	  an	  immediate	  transient	  contractile	  response	  that	  is	  concentration-­‐related.	  	  AITC	  was	  also	  seen	  to	  cause	  a	  contractile	  response	  but	  this	  was	  a	  more	  sustained	  response,	  and	  is	  believed	  to	  be	  via	  activation	  of	  TRPA1	  receptors.	  The	  magnitude	  of	  responses	  to	  methylglyoxal	  and	  AITC	  were	  very	  similar;	  the	  estimated	  Emax	  for	  methylglyoxal	  was	  33,	  for	  AITC	  32	  mgs	  tension	  per	  mg	  tissue	  weight.	  The	  use	  of	  a	  TRPA1	  selective	  antagonist	  HC-­‐030031	  at	  30	  μM,	  was	  able	  to	  nearly	  completely	  block	  the	  contractile	  response	  seen	  to	  AITC	  and	  to	  methylglyoxal	  suggesting	  that	  both	  compounds	  were	  eliciting	  their	  contractile	  activity	  in	  this	  tissue	  through	  activation	  of	  the	  TRPA1	  receptor.	  Methylglyoxal	  responses	  were	  seen	  to	  be	  markedly	  diminished	  in	  the	  tissue	  from	  STZ-­‐treated	  rats.	  	  This	  is	  suggestive	  of	  a	  down-­‐regulation	  of	  TRPA1	  function	  in	  diabetes.	  	  Data	  was	  not	  collected	  for	  AITC	  in	  STZ-­‐treated	  tissue,	  however	  previous	  in-­‐house	  studies	  have	  indicated	  that	  AITC	  responses	  are	  downregulated	  by	  the	  2-­‐week	  timepoint	  post	  STZ-­‐administration	  (Katisart,	  2011).	  	  
Acute	  methylglyoxal	  and	  AITC	  caused	  a	  diminished	  TRPV1	  response	  	  	  The	  next	  finding	  was	  that	  an	  acute	  pre-­‐exposure	  to	  methylglyoxal	  caused	  a	  reduced	  subsequent	  capsaicin	  response.	  The	  time	  between	  methylglyoxal	  exposure	  and	  capsaicin	  application	  was	  long	  enough	  to	  allow	  the	  tissue	  to	  return	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to	  baseline	  contractile	  state.	  	  Non-­‐linear	  regression	  analysis	  did	  provide	  estimates	  of	  efficacy	  where	  it	  appeared	  that	  this	  acute	  exposure	  did	  not	  affect	  the	  efficacy	  of	  capsaicin,	  but	  had	  caused	  a	  concentration-­‐related	  reduction	  in	  capsaicin	  potency	  in	  both	  control	  and	  in	  STZ-­‐treated	  animals.	  	  An	  extension	  of	  the	  concentration	  range	  of	  capsaicin	  would	  provide	  a	  more	  definitive	  answer	  as	  to	  whether	  efficacy	  had	  been	  reduced;	  the	  concentration	  range	  used	  here	  had	  been	  limited	  to	  reduce	  the	  ethanol	  load	  in	  the	  system.	  	  In	  the	  STZ-­‐treated	  tissue,	  capsaicin	  responses	  were	  reduced	  in	  terms	  of	  the	  efficacy	  of	  capsaicin,	  rather	  than	  potency,	  so	  although	  methylglyoxal	  did	  reduce	  capsaicin	  responses,	  it	  was	  in	  a	  different	  manner	  to	  that	  seen	  in	  diabetes.	  	  AITC	  exposure	  also	  caused	  a	  reduced	  subsequent	  response	  to	  capsaicin.	  	  At	  the	  single	  concentration	  tested	  of	  0.1	  mM,	  AITC	  caused	  a	  reduced	  efficacy	  response	  to	  capsaicin	  with	  the	  appearance	  of	  a	  shallow	  Hillslope	  (0.35+	  0.15)	  that	  may	  indicate	  a	  multiple	  affinity	  component	  response	  to	  capsaicin.	  	  	  	  
The	  TRPA1	  antagonist	  was	  unable	  to	  block	  methylglyoxal	  effect	  on	  TRPV1	  
responses	  and	  revealed	  a	  complexity	  in	  AITCs	  effect.	  	  HC-­‐030031	  was	  effective	  at	  blocking	  the	  direct	  contractile	  effect	  of	  methylglyoxal	  on	  the	  tissue	  but	  was	  unable	  to	  block	  the	  diminished	  responsiveness	  to	  capsaicin.	  	  This	  finding	  is	  suggestive	  of	  an	  alternate	  mode	  of	  methylglyoxal	  action	  in	  modulation	  of	  TRPV1	  function	  and	  warrants	  further	  study.	  	  The	  use	  of	  HC-­‐030031	  revealed	  some	  unexpected	  results	  with	  the	  AITC/capsaicin	  combination.	  	  Here	  it	  appeared	  that	  antagonism	  of	  TRPA1	  together	  with	  AITC	  exposure	  increased	  capsaicin	  potency.	  	  This	  suggests	  that	  the	  interactions	  between	  TRPA1	  and	  TRPV1	  are	  complex	  and	  multiple	  mechanisms	  are	  likely	  to	  be	  at	  play.	  A	  partial	  block	  of	  TRPA1	  activation	  or	  compartmental	  block	  of	  TRPA1	  may	  have	  revealed	  here	  a	  sensitizing	  role	  of	  TRPA1	  activation.	  	  An	  alternate	  explanation	  is	  that	  AITC	  is	  acting	  on	  additional	  receptors	  to	  TRPA1	  such	  as	  the	  P2X	  /P2Y	  purinergic	  receptors	  (Bartho	  et	  al.,	  2013).	  A	  sensitising	  action	  of	  purinergic	  receptors	  on	  TRPV1	  has	  been	  established	  in	  the	  literature	  (Wang	  et	  al.,	  2010).	  	  So	  the	  apparent	  sensitising	  activity	  of	  AITC	  on	  capsaicin	  response	  when	  in	  the	  presence	  of	  a	  TRPA1	  antagonist	  HC-­‐030031	  could	  be	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explained	  by	  a	  sensitising	  activity	  of	  AITC	  perhaps	  via	  purinoceptor	  activation,	  only	  revealed	  when	  the	  opposing	  desensitisation	  via	  TRPA1	  activation	  is	  blocked.	  	  This	  could	  be	  further	  explored	  through	  the	  use	  of	  purinoceptor	  antagonists.	  
	  
High	  methylglyoxal	  concentrations	  caused	  reduced	  carbachol	  responses	  	  Preexposure	  to	  methylglyoxal	  did	  appear	  to	  cause	  similar	  effects	  to	  carbachol	  responses	  as	  seen	  with	  STZ-­‐induced	  diabetes.	  The	  highest	  concentration	  of	  methylglyoxal,	  10	  mM,	  caused	  a	  reduced	  efficacy	  and	  potency	  response	  to	  carbachol.	  This	  however	  may	  be	  indicative	  of	  cellular	  toxicity	  at	  this	  high	  concentration.	  In	  some	  tissues	  an	  abolition	  of	  spontaneous	  contractile	  activity	  was	  noted	  which	  might	  indicate	  a	  detrimental	  effect	  of	  the	  high	  concentration	  of	  methylglyoxal.	  Carbachol	  responses	  following	  0.1	  mM	  AITC	  exposure	  however	  appeared	  to	  be	  leftward	  shifted	  i.e.	  increased	  in	  potency	  with	  no	  changes	  in	  efficacy.	  	  The	  inclusion	  of	  the	  antagonist	  HC-­‐030031	  alone	  had	  no	  effect	  on	  carbachol	  responses	  and	  the	  combination	  of	  HC-­‐030031	  +	  AITC	  gave	  similar	  increased	  potency	  carbachol	  responses	  as	  seen	  with	  AITC	  alone.	  	  
Methylglyoxal	  potentiated	  repeated	  electrically-­‐evoked	  contractions	  	  Study	  of	  repeated	  electrically	  evoked	  contraction	  with	  acute	  exposure	  to	  methylglyoxal	  revealed	  that	  methylglyoxal	  potentiated	  the	  electrically-­‐evoked	  responses.	  	  Methylglyoxal	  has	  been	  reported	  to	  be	  a	  direct	  GABAA	  agonist	  (Distler	  et	  al.,	  2012)	  and	  this	  might	  explain	  the	  potentiation	  seen	  here.	  This	  could	  be	  examined	  through	  the	  use	  of	  HC-­‐030031	  and	  GABA-­‐selective	  antagonists.	  	  Furthermore	  GABA	  receptors	  have	  been	  shown	  to	  modulate	  the	  efferent	  function	  of	  the	  TRPV1	  receptor	  (Santicioli	  et	  al.,	  1991)	  which	  may	  account	  for	  the	  diminished	  capsaicin	  responses	  seen	  following	  methylglyoxal	  exposure.	  	  Comparing	  the	  control	  tissue	  increases	  in	  electrically-­‐evoked	  contractions	  with	  STZ-­‐treated	  tissue	  increases,	  it	  was	  seen	  that	  methylglyoxal	  exerts	  a	  bigger	  effect	  in	  control	  tissue.	  	  The	  increase	  seen	  could	  be	  due	  to	  methylglyoxal	  causing	  an	  increased	  excitability	  of	  the	  membrane.	  The	  response	  to	  electrical	  stimuli	  was	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larger	  in	  STZ-­‐tissue,	  therefore	  one	  might	  assume	  that	  changes	  in	  excitability	  have	  already	  occurred	  in	  the	  diabetic	  model	  which	  would	  explain	  the	  smaller	  methylglyoxal	  induced-­‐increases	  seen	  in	  STZ-­‐tissue.	  	  
Repeated	  application	  of	  methylglyoxal	  and	  AITC	  caused	  a	  relaxant	  effect	  
not	  blocked	  by	  TRPA1	  antagonism	  	  It	  was	  noted	  that	  a	  repeat	  application	  to	  methylglyoxal	  did	  not	  cause	  a	  second	  contraction,	  but	  it	  did	  cause	  a	  small	  relaxation	  of	  basal	  tension.	  	  To	  further	  explore	  this,	  a	  study	  of	  methylglyoxal	  and	  AITC	  was	  performed	  on	  pre-­‐contracted	  tissue.	  So	  a	  concentration	  range	  of	  methylglyoxal	  and	  AITC	  were	  applied	  to	  carbachol	  pre-­‐contracted	  tissue	  and	  clear	  relaxant	  responses	  to	  both	  compounds	  were	  observed.	  	  No	  differences	  between	  control	  and	  STZ	  tissue	  were	  seen	  here	  and	  no	  block	  of	  the	  relaxant	  effect	  to	  methylglyoxal	  was	  seen	  using	  HC-­‐030031.	  This	  is	  suggestive	  of	  a	  common	  non-­‐TRPA1	  mediated	  effect	  of	  AITC	  and	  methylglyoxal.	  	  	  Acute	  methylglyoxal	  exposure	  has	  been	  shown	  to	  activate	  KATP	  channels	  directly	  (Yang	  et	  al.,	  2013)	  and	  KATP	  channel	  activation	  in	  detrusor	  smooth	  muscle	  has	  been	  reported	  to	  cause	  relaxation	  (Gopalakrishnan	  et	  al.,	  1999,	  Aishima	  et	  al.,	  2006).	  	  These	  channels	  are	  also	  important	  in	  maintaining	  resting	  membrane	  potentials	  so	  modification	  by	  methylglyoxal	  of	  the	  KATP	  channel	  subunits	  may	  also	  lead	  to	  changes	  in	  membrane	  excitability.	  	  	  
Methylglyoxal	  is	  causing	  multiple	  functional	  alterations	  which	  all	  may	  play	  
a	  role	  in	  neuropathy	  	  	  So	  clearly	  methylglyoxal	  is	  causing	  alterations	  in	  many	  of	  the	  functional	  parameters	  tested	  here	  in	  detrusor	  muscle	  that	  may	  underlie	  the	  progression	  of	  neuropathy.	  	  Methylglyoxal	  was	  seen	  to	  reduce	  TRPV1	  function,	  affect	  muscarinic	  function	  and	  facilitate	  electrically	  evoked	  contractions.	  	  Methylglyoxal	  appeared	  to	  be	  acting	  in	  part	  through	  activation	  of	  the	  TRPA1	  receptor	  but	  caused	  the	  diminished	  subsequent	  TRPV1	  function	  is	  through	  an	  unknown	  mechanism	  as	  the	  TRPA1	  selective	  antagonist	  was	  unable	  to	  block	  this	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effect.	  	  Methylglyoxal	  also	  caused	  facilitatory	  changes	  in	  other	  neuronal	  mechanisms	  seen	  through	  the	  changes	  in	  sensitivity	  to	  voltage	  by	  electrically-­‐evoked	  contractions.	  	  This	  facilitation	  may	  be	  through	  GABAA	  agonist	  activity,	  KATP	  activation	  or	  a	  combination	  of	  the	  two	  and	  warrants	  further	  study.	  Methylglyoxal	  additionally	  evoked	  a	  relaxation	  of	  precontracted	  detrusor	  muscle,	  which	  may	  be	  via	  KATP	  activation;	  this	  could	  be	  further	  studied	  using	  a	  blocker	  such	  as	  glibenclamide.	  This	  relaxant	  effect	  may	  be	  counterproductive	  versus	  detrusor	  contraction	  and	  therefore	  be	  important	  in	  causing	  the	  ineffective	  bladder	  emptying	  seen	  in	  diabetics.	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Chapter	  6	  	  
Defining	  the	  role	  that	  prolonged	  methylglyoxal	  exposure	  may	  
play	  in	  TRPV1	  modulation	  	  	  	  
Introduction	  
	  
	  In	  the	  acute	  setting,	  methylglyoxal	  exposure	  was	  seen	  firstly	  to	  induce	  a	  diminished	  subsequent	  TRPV1	  response	  and	  secondly	  to	  enhance	  repeated	  electrically-­‐evoked	  contractions.	  	  Looking	  at	  the	  exposure	  of	  methylglyoxal	  to	  sensory	  neurons	  in	  the	  context	  of	  diabetes	  clearly	  there	  is	  a	  more	  chronic	  exposure	  to	  this	  metabolite,	  and	  the	  effects	  of	  methylglyoxal	  may	  be	  different	  in	  a	  more	  chronic	  paradigm.	  The	  diminished	  TRPV1	  responses	  seen	  acutely	  may	  recover	  or	  exacerbate	  with	  an	  increased	  exposure	  time	  and	  the	  changes	  seen	  in	  electrically-­‐evoked	  contractions	  may	  also	  alter.	  	  	  A	  prolonged	  exposure	  setting	  also	  allows	  electrical	  field	  stimulation	  to	  be	  studied	  in	  more	  depth,	  which	  could	  provide	  further	  insight	  into	  how	  methylglyoxal	  is	  affecting	  neuronal	  excitability.	  	  However	  the	  organ	  bath	  methodology	  does	  have	  a	  constraint	  in	  how	  long	  tissue	  remains	  viable	  and	  reactive.	  	  So	  working	  within	  the	  constraints	  of	  the	  methodology,	  a	  more	  prolonged	  four-­‐hour	  exposure	  to	  methylglyoxal	  was	  performed	  to	  examine	  the	  effects	  of	  methylglyoxal	  on	  subsequent	  responses	  to	  capsaicin,	  carbachol	  and	  electrical	  field	  stimulation.	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Methods	  
	  
Effect	  of	  prolonged	  exposure	  to	  3	  mM	  methylglyoxal	  	  	  3	  mM	  methylglyoxal	  or	  vehicle	  control	  (water)	  was	  applied	  to	  equilibrated	  urinary	  bladder	  strips	  from	  2	  weeks	  post	  control	  and	  STZ-­‐treated	  animals	  and	  incubated	  for	  4	  hours.	  	  Following	  this	  time	  various	  studies	  were	  undertaken	  to	  examine	  the	  effects	  of	  a	  more	  chronic	  exposure	  to	  methylglyoxal.	  	  Capsaicin	  responses	  were	  studied	  using	  the	  standard	  format	  of	  application	  of	  a	  concentration	  range	  of	  capsaicin	  (1	  x	  10-­‐9M-­‐	  3	  x	  10-­‐6M).	  	  Carbachol	  responses	  were	  monitored	  using	  the	  standard	  concentration	  range	  ((1	  x	  10-­‐8M-­‐	  3	  x	  10-­‐5M)	  applied	  cumulatively.	  Finally	  electrical	  field	  stimulation	  was	  evaluated,	  firstly	  by	  applying	  a	  range	  of	  voltages	  (20-­‐90	  volts)	  using	  0.1	  ms	  pulse	  width,	  rate	  of	  50	  Hz,	  10	  sec	  duration.	  	  Secondly	  using	  submaximal	  voltage,	  a	  range	  of	  frequencies	  was	  next	  applied	  (0.25	  Hz-­‐	  40	  Hz).	  	  For	  the	  4	  Hz	  dataset,	  a	  more	  in-­‐depth	  analysis	  of	  the	  data	  was	  performed	  to	  evaluate	  the	  evolution	  of	  the	  electrically-­‐evoked	  contractile	  response	  over	  time	  of	  stimulation.	  	  Data	  points	  from	  every	  0.5	  sec	  from	  pre-­‐application	  of	  electrical	  stimulus	  for	  a	  total	  of	  30	  seconds	  were	  obtained	  from	  Labchart	  and	  stacked	  accordingly	  within	  excel	  to	  allow	  the	  generation	  of	  a	  data-­‐rich	  averaged	  contractile	  response	  plot.	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Results	  
	  
Prolonged	  incubation	  of	  methylglyoxal:	  effect	  on	  capsaicin	  response	  	  The	  first	  studies	  were	  to	  look	  at	  the	  effects	  of	  a	  more	  chronic	  4	  hour	  exposure	  to	  3	  mM	  methylglyoxal	  on	  subsequent	  response	  to	  capsaicin	  in	  urinary	  bladder	  from	  2	  weeks	  post	  control	  and	  STZ-­‐treated	  animals.	  	  Control	  time	  matched	  responses	  gave	  a	  less	  defined,	  more	  variable	  response	  to	  capsaicin	  than	  seen	  in	  acute	  studies	  (Figure	  6.1).	  	  STZ-­‐treated	  tissue	  capsaicin	  responses	  were	  significantly	  diminished	  when	  compared	  to	  control	  responses	  (Figure	  6.1)	  (Table	  6.1).	  
	  Figure	  6.1	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  following	  prolonged	  incubation	  (4	  hours)	  in	  2-­‐weeks	  post	  control	  	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  control.	  	  Exposure	  to	  3	  mM	  methylglyoxal	  over	  4	  hours	  caused	  a	  reduced	  capsaicin	  response	  in	  control	  animals	  and	  no	  significant	  change	  to	  the	  already	  diminished	  capsaicin	  response	  seen	  in	  STZ-­‐treated	  animal	  tissue	  (Figure	  6.2)	  (Table	  6.1)	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  Figure	  6.2	  Graphs	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  capsaicin	  following	  prolonged	  incubation	  (4	  hours)	  +	  3	  mM	  methylglyoxal	  in	  2-­‐weeks	  post	  control	  	  (A)	  and	  STZ-­‐treated	  (B)	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	  	  Table	  6.1	  Potency	  and	  efficacy	  estimates	  for	  capsaicin	  responses	  +	  MG	  	  in	  control	  and	  STZ-­‐treated	  urinary	  bladder	  tissue.	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips,	  additional	  constraint	  of	  Hillslope	  =	  1.0	  applied.	  	  
	  Statistical	  analysis	  by	  Students	  t-­‐test	  comparing	  to	  control	  ,NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001,	  comparing	  STZ	  to	  control	  $$	  p<0.01.	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Monitoring	  of	  carbachol	  responses	  following	  prolonged	  exposure	  to	  
methylglyoxal	  
	  Following	  the	  chronic	  exposure	  to	  methylglyoxal	  and	  examination	  of	  capsaicin	  responses,	  the	  responses	  to	  a	  concentration	  range	  of	  carbachol	  were	  examined.	  The	  carbachol	  responses	  appeared	  more	  robust	  than	  capsaicin	  responses	  in	  the	  prolonged	  exposure	  setting.	  	  The	  maximal	  responses	  of	  tissue	  from	  STZ-­‐treated	  rats	  to	  carbachol	  were	  significantly	  reduced	  in	  comparison	  to	  control	  responses	  (Figure	  6.3).	  Exposure	  to	  3	  mM	  methylglyoxal	  over	  4	  hours	  caused	  a	  slight	  but	  non-­‐statistically	  significant	  rightward	  shift	  in	  carbachol	  responses	  in	  control	  animal	  tissue	  (Figure	  6.4).	  	  In	  tissue	  from	  STZ-­‐treated	  animals,	  chronic	  3	  mM	  methylglyoxal	  exposure	  caused	  a	  significant	  enhancement	  in	  maximal	  efficacy	  of	  the	  carbachol	  response	  (Figure	  6.4)	  (Table	  6.2).	  	  
	  Figure	  6.3	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  carbachol	  following	  prolonged	  incubation	  (4	  hours)	  in	  2-­‐weeks	  post	  control	  and	  STZ-­‐treated	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001,	  comparing	  to	  control.	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  Figure	  6.4	  Graph	  showing	  contractile	  responses	  to	  a	  concentration	  range	  of	  carbachol	  following	  prolonged	  incubation	  (4	  hours)	  +	  3	  mM	  methylglyoxal	  in	  2-­‐weeks	  post	  control	  	  (A)	  and	  STZ-­‐treated	  (B)	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	  
	  Table	  6.2	  Potency	  and	  efficacy	  estimates	  for	  carbachol	  responses	  +	  MG	  in	  control	  and	  STZ-­‐treated	  urinary	  bladder	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  
	  Statistical	  analysis	  by	  Students	  t-­‐test	  comparing	  to	  control	  ,NS	  no	  significant	  difference,	  *	  p<0.05,	  **p<0.01,	  ***p<0.001,	  comparing	  STZ	  to	  control	  $$	  p<0.01.	  	   	  
!"#$% "&'(
)*+,-*. /012).0 $345676%388 5$93:%676843:$
96&;6;< $3:4676%3%4=> 5?935%6768@399=>
>AB /012).0 $3C@676%385 8@83%%678?3@8DD
96&;6;< $3C9676%3%@=> 55439%6768834:E
	   136	  
Electrical	  field	  stimulation	  following	  chronic	  exposure	  to	  methylglyoxal	  	  A	  study	  of	  electrical	  field	  stimulation	  on	  control	  and	  STZ-­‐treated	  animal	  tissue	  was	  undertaken	  to	  examine	  neurogenic	  effects	  of	  prolonged	  exposure	  to	  methylglyoxal.	  	  First	  responses	  to	  a	  voltage	  range	  at	  constant	  20	  Hz	  were	  examined.	  	  Here	  following	  a	  chronic	  incubation	  time	  of	  4	  hours,	  clear	  differences	  were	  seen	  between	  tissue	  from	  control	  and	  STZ-­‐treated	  animals	  where	  STZ-­‐treated	  tissue	  was	  seen	  to	  respond	  at	  lower	  voltages	  so	  the	  voltage	  response	  curve	  was	  leftward	  shifted	  and	  the	  maximal	  response	  was	  lower	  than	  that	  seen	  for	  control	  tissue.	  (Figure	  6.5).	  	  Exposure	  to	  3	  mM	  methylglyoxal	  caused	  similar	  changes	  in	  control	  and	  STZ-­‐treated	  animal	  tissue	  where	  in	  both	  groups	  the	  voltage	  response	  curves	  were	  leftward	  shifted	  (Figure	  6.6).	  	  	  
	  Figure	  6.5	  Graph	  showing	  contractile	  responses	  to	  electrical	  field	  stimulation	  over	  a	  range	  of	  voltages	  following	  prolonged	  incubation	  (4	  hours)	  in	  2-­‐weeks	  post	  control	  	  (A)	  and	  STZ-­‐treated	  (B)	  rat	  tissue.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	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ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  control.	  	  	  
	  	  Figure	  6.6	  Graphs	  showing	  contractile	  responses	  to	  electrical	  field	  stimulation	  over	  a	  range	  of	  voltages	  following	  prolonged	  incubation	  (4	  hours)	  +	  3	  mM	  methylglyoxal	  in	  tissue	  from	  2-­‐weeks	  post	  control	  	  (A)	  and	  STZ-­‐treated	  (B)	  rats.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	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Next	  a	  frequency	  response	  range	  was	  studied	  using	  maximally	  effective	  voltages.	  	  Here	  a	  comparison	  of	  tissue	  from	  control	  and	  STZ-­‐treated	  rats	  showed	  no	  difference	  in	  responses	  (Figure	  6.7).	  	  The	  prolonged	  incubation	  with	  3	  mM	  methylglyoxal	  caused	  an	  increase	  in	  electrically-­‐evoked	  contractile	  responses	  in	  tissue	  from	  both	  control	  and	  in	  STZ-­‐treated	  rats.	  	  Greater	  responses	  were	  only	  seen	  at	  the	  higher	  frequencies	  in	  tissue	  from	  control	  rats	  whereas	  in	  tissue	  from	  STZ-­‐treated	  rats	  the	  increased	  responses	  were	  seen	  over	  a	  wider	  range	  of	  frequencies	  (Figure	  6.8)	  	  	  
	  Figure	  6.7	  Graph	  showing	  contractile	  responses	  to	  electrical	  field	  stimulation	  over	  a	  range	  of	  frequencies	  following	  prolonged	  incubation	  (4	  hours)	  in	  tissue	  from	  2-­‐weeks	  post	  control	  	  (A)	  and	  STZ-­‐treated	  (B)	  rats.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  	  No	  statistically	  significant	  differences	  were	  seen	  by	  two-­‐way	  ANOVA.	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  Figure	  6.8	  Graphs	  showing	  contractile	  responses	  to	  electrical	  field	  stimulation	  over	  a	  range	  of	  frequencies	  following	  prolonged	  incubation	  (4	  hours)	  +	  3	  mM	  methylglyoxal	  in	  tissue	  from	  2-­‐weeks	  post	  control	  	  (A)	  and	  STZ-­‐treated	  (B)	  rats.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	  	  A	  more	  in-­‐depth	  analysis	  of	  the	  data	  was	  performed	  to	  evaluate	  the	  evolution	  of	  the	  electrically-­‐evoked	  contractile	  response	  over	  time	  of	  stimulation.	  	  Data	  points	  from	  every	  0.5	  sec	  from	  pre-­‐application	  of	  electrical	  stimulus	  for	  a	  total	  of	  30	  seconds	  were	  obtained	  from	  Labchart	  and	  stacked	  accordingly	  within	  excel	  to	  allow	  the	  generation	  of	  a	  data-­‐rich	  averaged	  contractile	  response	  plot.	  Here	  the	  4	  Hz	  data	  shows	  differences	  in	  contraction	  between	  tissue	  from	  control	  and	  STZ-­‐treated	  animal	  groups.	  Although	  the	  magnitude	  of	  response	  is	  the	  same,	  the	  shape	  of	  the	  contractile	  event	  differs	  subtlety:	  the	  STZ	  response	  is	  slower	  to	  reach	  maximum	  (Figure	  6.9).	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  Figure	  6.9	  Graph	  showing	  evolution	  of	  4	  Hz	  electrically-­‐evoked	  contractile	  response	  over	  time	  for	  tissue	  from	  control	  and	  STZ-­‐treated	  rats.	  	  Data	  represents	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  	  Comparison	  of	  tissue	  responses	  +	  chronic	  exposure	  to	  3	  mM	  methylglyoxal	  revealed	  that	  the	  methylglyoxal	  treated	  control	  tissue	  responded	  to	  the	  electrical	  stimulus	  to	  a	  similar	  maximum	  response	  but	  took	  a	  longer	  time	  to	  reach	  maximum	  contraction.	  Methylglyoxal	  treated	  STZ	  tissue	  also	  took	  a	  longer	  time	  to	  reach	  the	  maximum	  contraction	  however	  the	  maximum	  contraction	  reached	  was	  larger	  in	  magnitude	  than	  untreated	  STZ	  tissue	  (Figure	  6.10).	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  Figure	  6.10	  Graphs	  showing	  evolution	  of	  4	  Hz	  electrically-­‐evoked	  contractile	  response	  over	  time	  +	  chronic	  3	  mM	  methylglyoxal	  exposure	  for	  tissue	  from	  control	  (A)	  and	  STZ-­‐treated	  (B)	  rats.	  	  Data	  represents	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  	  	  These	  data	  were	  analysed	  to	  quantify	  the	  total	  contraction	  using	  area	  under	  the	  curve	  (AUC)	  and	  time	  to	  maximum	  contraction	  (Figure	  6.11).	  	  AUC	  values	  were	  not	  significantly	  different	  between	  groups,	  suggesting	  that	  the	  total	  resultant	  contractile	  activity	  was	  not	  altered	  by	  methylglyoxal	  or	  by	  STZ-­‐induced	  diabetes.	  	  The	  time	  taken	  to	  reach	  maxiumum	  contraction	  was	  seen	  to	  be	  increased	  in	  control-­‐methylglyoxal	  treated	  and	  in	  STZ-­‐induced	  diabetes,	  indicative	  of	  a	  kinetic	  deficit	  brought	  about	  by	  this	  metabolite	  and	  seen	  also	  in	  the	  disease.	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  Figure	  6.11	  Barcharts	  showing	  AUC	  data	  (A)	  and	  time	  to	  reach	  maximum	  contraction	  (B)	  for	  4Hz	  electrically-­‐evoked	  responses	  in	  control	  and	  STZ-­‐induced	  diabetic	  tissue	  +	  chronic	  3	  mM	  methylglyoxal.	  	  Data	  represents	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  one-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  ***represents	  p<0.001	  comparing	  to	  respective	  control.	  	  Examination	  of	  the	  raw	  data	  trace	  responses	  to	  the	  20	  Hz	  electrical	  stimulation,	  revealed	  a	  more	  similar	  shaped	  contractile	  response	  over	  time	  between	  the	  tissue	  from	  control	  and	  STZ-­‐treated	  animal	  groups.	  	  The	  effect	  of	  chronic	  methylglyoxal	  treatment	  was	  to	  increase	  the	  time	  taken	  to	  reach	  maximum	  response	  in	  both	  control	  and	  STZ-­‐treated	  animal	  tissue	  (Figure	  6.12)	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Discussion	  
	  
Methyglyoxal	  caused	  diminished	  capsaicin	  responses	  in	  tissue	  from	  control	  
but	  responses	  in	  general	  were	  reduced	  due	  to	  prolonged	  incubation	  time	  	  When	  a	  more	  prolonged	  exposure	  studies	  were	  performed,	  the	  first	  finding	  was	  that	  capsaicin	  responses	  in	  both	  control	  and	  STZ-­‐tissues	  were	  diminished,	  in	  the	  control	  non-­‐methylglyoxal	  exposed	  group.	  	  This	  is	  most	  likely	  due	  to	  deterioration	  in	  the	  sensory	  neuron	  population	  within	  the	  tissue	  over	  time.	  	  Responses	  to	  capsaicin	  were	  still	  present	  however	  and	  it	  could	  still	  be	  seen	  that	  STZ	  responses	  were	  diminished	  compared	  to	  control.	  	  3	  mM	  methylglyoxal	  caused	  a	  reduced	  efficacy	  response	  to	  capsaicin	  in	  control	  tissue,	  but	  responses	  in	  STZ-­‐tissue	  were	  already	  virtually	  nonexistent	  so	  no	  changes	  could	  be	  seen.	  	  	  	  
Methylglyoxal	  caused	  increased	  efficacy	  in	  STZ-­‐carbachol	  responses	  	  Monitoring	  of	  carbachol	  responses	  over	  this	  longer	  incubation	  period	  revealed	  that	  the	  carbachol	  response	  was	  more	  robust	  than	  the	  capsaicin	  response.	  In	  controls,	  methylglyoxal	  exposure	  caused	  a	  small	  non-­‐significant	  rightward	  shift	  in	  carbachol	  potency	  with	  no	  effect	  on	  efficacy.	  However	  in	  the	  STZ-­‐group,	  methylglyoxal	  caused	  a	  significant	  enhancement	  of	  carbachol	  response	  in	  terms	  of	  efficacy.	  	  Perhaps	  delivery	  of	  methylglyoxal	  to	  this	  tissue	  increased	  lactate	  levels	  through	  methylglyoxal	  breakdown,	  specifically	  the	  d-­‐Lactate	  isoform.	  	  Lactate	  levels	  have	  been	  shown	  be	  lower	  in	  STZ-­‐induced	  diabetic	  smooth	  muscle	  (Waring	  and	  Wendt,	  2000)	  and	  it	  is	  unknown	  whether	  a	  minor	  boost	  in	  or	  exposure	  to	  d-­‐	  lactate	  or	  another	  product	  of	  methylglyoxal	  breakdown	  could	  result	  in	  increased	  maximal	  contractile	  ability.	  A	  study	  of	  lactate	  effects	  in	  vascular	  smooth	  muscle	  has	  demonstrated	  increased	  KCL	  induced	  contractions	  in	  the	  presence	  of	  lactate	  containing	  buffer	  (Barron	  et	  al.,	  1997).	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Prolonged	  exposure	  to	  methylglyoxal	  increased	  the	  voltage	  sensitivity	  in	  
tissue	  from	  both	  control	  and	  STZ-­‐treated	  rats	  	  Finally	  an	  examination	  of	  electrical	  field	  stimulation	  was	  undertaken.	  	  Here	  it	  was	  seen	  that	  in	  the	  STZ-­‐group	  a	  reduced	  maximal	  response	  to	  a	  voltage	  range	  was	  seen,	  together	  with	  a	  leftward	  shift	  in	  the	  voltage-­‐response	  curve	  i.e.	  an	  increased	  sensitivity	  to	  lower	  voltages.	  	  	  This	  could	  be	  explained	  by	  an	  increased	  excitability	  of	  the	  cells	  caused	  by	  membrane	  changes	  in	  diabetes.	  Prolonged	  exposure	  to	  methylglyoxal	  increased	  voltage	  sensitivity	  in	  both	  control	  and	  STZ-­‐tissue	  suggestive	  of	  a	  methylglyoxal-­‐driven	  alteration	  in	  membrane	  excitability.	  Methylglyoxal	  has	  been	  reported	  to	  modify	  the	  NaV1.8	  receptor	  causing	  an	  increase	  in	  excitability	  and	  facilitated	  firing	  (Bierhaus	  et	  al.,	  2012)	  .	  	  As	  the	  STZ-­‐tissue	  still	  displayed	  increased	  voltage	  sensitivity	  following	  methylglyoxal,	  it	  appears	  at	  this	  early	  stage	  of	  diabetes	  that	  the	  voltage	  sensitivity	  increases	  seen	  due	  to	  the	  diabetic	  state	  are	  not	  maximal.	  	  	  	  
Methylglyoxal	  caused	  increased	  responses	  to	  a	  frequency	  range	  of	  
electrically-­‐evoked	  contractions	  	  No	  differences	  between	  control	  and	  STZ	  tissue	  were	  seen	  using	  maximal	  voltages	  and	  examining	  a	  range	  of	  frequencies.	  	  However	  following	  methylglyoxal	  exposure,	  increased	  responses	  to	  the	  higher	  frequencies	  were	  observed	  in	  the	  control	  group	  and	  to	  frequencies	  >	  1	  Hz	  in	  the	  STZ-­‐group.	  	  To	  try	  and	  understand	  where	  these	  differences	  were	  occurring	  a	  more	  in-­‐depth	  analysis	  of	  the	  data	  was	  performed.	  	  It	  appeared	  that	  the	  profile	  of	  contractile	  response	  over	  time	  at	  the	  4	  Hz	  level	  of	  stimulation	  was	  altered	  following	  methylglyoxal	  exposure.	  	  In	  the	  control	  methylglyoxal	  exposed	  tissue,	  the	  electrically-­‐evoked	  contraction	  was	  of	  the	  same	  magnitude	  as	  seen	  in	  tissue	  with	  no	  methylglyoxal	  exposure	  but	  took	  longer	  to	  reach	  the	  maximal	  contraction.	  	  This	  is	  suggestive	  of	  changes	  to	  the	  slower	  neurotransmitter	  release	  pathways	  such	  as	  the	  cholinergic	  system.	  In	  STZ	  tissue,	  methylglyoxal	  exposure	  again	  caused	  changes	  in	  the	  profile	  of	  contraction:	  here	  a	  higher	  maximal	  contraction	  was	  obtained	  and	  again	  the	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source	  of	  this	  change	  appeared	  to	  be	  at	  the	  slower	  neurotransmitter	  responses.	  	  At	  higher	  frequencies	  this	  change	  in	  contraction	  profile	  persisted.	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  Diabetes	  causes	  a	  rapid	  downregulation	  of	  TRPV1	  function	  in	  the	  bladder	  and	  the	  final	  series	  of	  studies	  were	  to	  explore	  the	  potential	  of	  reversing	  this	  diminished	  response.	  	  Previous	  in-­‐house	  data	  had	  shown	  this	  was	  possible	  with	  the	  use	  of	  bradykinin	  (Katisart,	  2011).	  So	  using	  this	  as	  a	  starting	  point	  I	  sought	  to	  repeat	  and	  extend	  these	  findings.	  In	  addition	  to	  this	  examination	  of	  bradykinin,	  I	  also	  chose	  to	  explore	  the	  potential	  of	  other	  known	  sensitisers	  of	  TRPV1;	  nerve	  growth	  factor	  (NGF)	  and	  insulin.	  
	  The	  TRPV1	  receptor	  can	  be	  modulated	  through	  dynamic	  sensitization	  and	  desensitisation	  processes	  which	  provide	  a	  rapid	  dial	  up	  or	  dial	  down	  control	  over	  its	  physiological	  function.	  	  There	  are	  two	  main	  ways	  in	  which	  TRPV1	  receptor	  function	  can	  be	  upregulated:	  firstly	  through	  increasing	  the	  sensitivity	  or	  functionality	  of	  the	  surface	  expressed	  receptors	  and	  secondly	  through	  an	  increase	  in	  surface	  (plasma	  membrane)	  expression	  of	  TRPV1	  channels.	  	  	  	  	  Phosphorylation	  of	  key	  sites	  on	  the	  TRPV1	  receptor	  may	  control	  both	  processes	  and	  site	  specific	  mutation	  studies	  where	  small	  portions	  of	  the	  receptor	  are	  modified	  have	  allowed	  identification	  of	  the	  parts	  of	  the	  receptor	  that	  are	  key	  to	  this	  	  (7.1)(Li	  et	  al.,	  Zhang	  et	  al.,	  2005a)	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Figure	  7.2.	  Schematic	  diagram	  of	  the	  signaling	  pathways	  important	  in	  sensitization	  of	  TRPV1	  by	  TrkA.	  The	  functionally	  most	  significant	  pathway	  is	  shown	  at	  the	  left	  (yellow,	  solid	  arrows).	  A	  smaller	  component	  of	  sensitization	  following	  exposure	  to	  NGF	  is	  mediated	  by	  phosphorylation	  of	  TRPV1	  at	  residues	  S502	  and	  S801,	  probably	  by	  the	  PLCγ/PKC	  pathway	  (green,	  dashed	  arrows).	  PKC	  is	  a	  crucial	  intermediate	  in	  sensitization	  of	  TRPV1	  by	  bradykinin	  (pathway	  shown	  at	  the	  lower	  right	  of	  the	  diagram).	  From	  Zhang	  et	  al	  2005	  
TRPV1	   receptor	   functionality	   can	   be	   altered	   by	   directly	   increasing	   the	   open	  channel	   probability	   as	   these	   ion	   channels	   exist	   in	   different	   states	   i.e.	   closed	  inactivated,	  closed	  and	  open.	  	  TRPV1	  receptor	  state	  may	  rely	  on	  the	  presence	  of	  intact	   membrane	   lipid	   rafts	   and	   has	   been	   found	   to	   be	   altered	   by	   the	  manipulation	   of	   the	   raft	   constituent	   components	   such	   as	   cholesterol,	   the	  phospholipid	  phosphatidylinositol-­‐4,5-­‐bisphosphate	  (PIP2)	  and	  ceramide	  (Liu	  et	  al,	  2006;	  Zhang	  et	  al,	  2004).	  	  NGF-­‐mediated	  sensitization	  of	  the	  excitability	  of	  rat	  sensory	   neurons	   is	   prevented	   by	   a	   blocking	   antibody	   to	   the	   p75	  neurotrophin	  receptor	  (Prescott	  et	  al.,	  2003).	  	  	  Phosphorylation	  of	  TRPV1	  by	  PIP2	  holds	  TRPV1	  under	   an	   inhibited	   state	   and	   sensitization	   of	   TRPV1	   can	   be	   gained	   by	   PIP2	  hydrolysis	   through	   receptor	   mediated	   activation	   of	   protein	   kinase	   C,	   A,	   or	  
!
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phospholipase	  A	  (Prescott	  et	  al.,	  2003).	   	  The	  receptors	  that	  can	  activate	  protein	  kinase	   C/A	   or	   phospholipase	   A	   include	   bradykinin,	   prostaglandin	   E2	   (PGE2),	  5HT	   and	   nerve	   growth	   factor	   (NGF).	   	   Furthermore,	   reinstatement	   of	   active	  TRPV1	   requires	   PIP2	   phosphorylation	   and	   maintenance	   of	   active	   TRPV1	   may	  depend	  on	   a	   continual	   basal	   phosphorylation	   by	   the	  PKC	   isoform,	   PKC-­‐epsilon	  (Srinivasan	   et	   al.,	   2008).	   	   	   Cyclin-­‐dependent	   kinase	   5	   (Cdk5)	   can	   also	   directly	  phosphorylate	   TRPV1	   and	   modulate	   its	   function:	   Cdk5	   inhibition	   has	   been	  shown	  to	  reduce	  TRPV1	  function	  (Pareek	  et	  al.,	  2007).	  	  Factors	   that	   induce	   translocation	  of	  TRPV1	  receptors	   to	   the	  plasma	  membrane	  include	  insulin,	  insulin	  growth	  factor	  and	  NGF.	  Deficiencies	  in	  or	  overexpression	  of	  these	  factors	  could	  either	  impair	  or	  sensitise	  TRPV1	  function	  (Van	  Buren	  et	  al,	  2005).	  Many	  of	  these	  enzymes,	  lipids,	  growth	  factors	  and	  mediators	  are	  altered	  during	  diabetes:	  
	  
Bradykinin	  	  Bradykinin	  is	  an	  endogenously	  produced	  pro-­‐inflammatory	  peptide,	  produced	  by	  plasma	  and	  tissue	  kallikrien-­‐kinin	  systems	  (Campbell,	  2001).	  	  Bradykinin	  acts	  through	  two	  G-­‐protein	  coupled	  receptors,	  bradykinin-­‐1	  (BK1)	  and	  bradykinin-­‐2	  (BK2),	  and	  is	  more	  selective	  for	  BK2	  receptors.	  	  There	  may	  be	  a	  third	  bradykinin	  receptor,	  bradykinin-­‐3,	  proposed	  on	  the	  basis	  of	  discrepant	  ligand	  affinity,	  but	  this	  has	  not	  yet	  been	  cloned	  (Hall,	  1997).	  	  	  The	  BK1	  receptor	  expression	  is	  generally	  low	  under	  normal	  physiological	  conditions,	  but	  is	  upregulated	  under	  stress	  conditions	  or	  after	  exposure	  to	  noxious	  stimuli	  such	  as	  the	  cytokines	  interleukin	  1-­‐	  β	  or	  tumor	  necrosis	  factor-­‐α	  (Marceau	  et	  al.,	  1998,	  Galizzi	  et	  al.,	  1994,	  Phagoo	  et	  al.,	  2000)	  and	  is	  upregulated	  in	  diabetes	  (Gabra	  and	  Sirois,	  2003).	  	  The	  BK2	  receptors	  have	  a	  constitutively	  higher	  level	  of	  expression	  in	  many	  tissues	  and	  can	  also	  be	  upregulated	  by	  cytokine	  exposure	  (Schmidlin	  et	  al.,	  1998,	  Haddad	  et	  al.,	  2000).	  	  	  Bradykinin	  is	  a	  potent	  mediator	  of	  inflammation	  and	  causes	  pain,	  vasodilation,	  increased	  vascular	  permeability,	  epithelial	  fluid	  secretion	  and	  smooth	  muscle	  contraction	  (Bellucci	  et	  al.,	  2007).	  Bradykinin	  also	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plays	  an	  important	  role	  in	  fluid	  regulation	  and	  electrolyte	  balance.	  	  In	  fibroblasts,	  bradykinin	  treatment	  causes	  rapid	  increases	  in	  ceramide	  and	  sphingosine	  levels,	  which	  are	  second	  messanger	  molecules	  able	  to	  mediate	  the	  action	  of	  extracellular	  signals	  such	  as	  cytokines	  and	  growth	  factors	  	  (Meacci	  et	  al.,	  1996).	  	  	  Both	  BK-­‐1	  and	  BK-­‐2	  have	  been	  shown	  to	  contract	  detrusor	  smooth	  muscle	  in	  a	  number	  of	  species	  (Maggi,	  1997)	  and	  the	  contraction	  is	  believed	  to	  be	  caused	  through	  prostaglandin	  formation	  (Nakahata	  et	  al.,	  1987)	  Selective	  agonists	  for	  BK1	  and	  BK2	  are	  [Lys-­‐des-­‐Arg9]-­‐bradykinin	  and	  [Phe8-­‐Y(CH-­‐NH)-­‐Arg9]-­‐bradykinin	  respectively.	  The	  latter	  peptide	  is	  resistant	  to	  carboxypeptidase	  cleavage	  and	  exhibits	  a	  5-­‐fold	  greater	  potency	  and	  a	  more	  prolonged	  duration	  of	  action	  than	  bradykinin	  in	  vivo	  	  (Drapeau	  et	  al.,	  1988).	  	  It	  is	  believed	  that	  pharmacological	  block	  of	  both	  receptors	  may	  be	  beneficial	  in	  hyperalgesia	  as	  bradykinin	  acts	  on	  either	  receptor	  to	  promote	  hyperalgesia	  (Levy	  and	  Zochodne,	  2000).	  	  In	  diabetic	  models,	  a	  BK-­‐1	  agonist	  has	  been	  seen	  to	  promote	  thermal	  hyperalgesia	  and	  BK-­‐1	  antagonists	  inhibit	  this	  (Gabra	  and	  Sirois,	  2003).	  	  	  Renal	  excretion	  of	  bradykinin	  has	  been	  seen	  to	  be	  increased	  by	  12	  weeks	  post	  STZ-­‐induced	  diabetes	  (Tschöpe	  et	  al.,	  1996).	  	  	  
	  
Nerve	  Growth	  factor	  (NGF)	  	  Tissues	  produce	  neurotrophic	  factors	  such	  as	  NGF	  and	  through	  retrograde	  transport	  along	  the	  axon	  to	  the	  dorsal	  root	  ganglion	  for	  example,	  maintain	  the	  structure	  and	  function	  of	  the	  neurons	  that	  innervate	  them	  (Sofroniew	  et	  al.,	  2001).	  	  NGF	  was	  originally	  found	  to	  be	  a	  survival	  factor	  during	  development	  for	  sensory	  and	  sympathetic	  neurons	  and	  plays	  a	  major	  a	  role	  in	  pain	  and	  hyperalgesia	  (Hefti	  et	  al.,	  2006).	  	  NGF	  exerts	  its	  actions	  through	  an	  interaction	  with	  the	  low-­‐affinity	  p75	  receptor	  and	  with	  Trk,	  a	  receptor	  tyrosine	  kinase	  encoded	  by	  the	  trk	  proto-­‐oncogene	  (Meakin	  and	  Shooter,	  1992).	  	  Disruption	  of	  the	  Trk/NGF	  receptor	  system	  in	  genetically	  engineered	  mice	  leads	  to	  severe	  sensory	  neuropathies,	  highlighting	  the	  role	  NGF	  plays	  in	  the	  development	  of	  an	  intact	  and	  functional	  sensory	  system	  (Smeyne	  et	  al.,	  1994)	  	  NGF	  has	  been	  seen	  to	  cause	  an	  increase	  in	  membrane	  expression	  of	  the	  TRPV1	  receptor	  in	  cell	  lines	  and	  primary	  neuronal	  preparations	  (Zhang	  et	  al.,	  2005b,	  Simonetti	  et	  al.,	  2006).	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  In	  diabetes	  it	  has	  been	  hypothesized	  that	  the	  disease	  impacts	  on	  NGF	  production	  and/or	  transport	  which	  in	  turn	  could	  deprive	  neurons	  of	  this	  neurotrophin	  and	  thereby	  be	  causative	  to	  diabetic	  neuropathy	  (Hellweg	  and	  Hartung,	  1990).	  However	  increases	  in	  bladder	  NGF	  followed	  by	  increases	  in	  DRG	  NGF	  levels	  have	  been	  observed	  acutely	  in	  the	  STZ-­‐diabetic	  rat	  model	  (Steinbacher	  and	  Nadelhaft,	  1998)	  .	  Other	  studies	  suggest	  a	  later	  decrease	  in	  bladder	  NGF,	  and	  this	  correlated	  with	  their	  measurement	  of	  cystopathy	  (Sasaki	  et	  al.,	  2002)	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Methods	  




Bradykinin	  	  For	  the	  investigation	  of	  bradykinin	  effects,	  firstly	  a	  cumulative	  concentration-­‐	  response	  range	  to	  bradykinin	  was	  examined	  in	  urinary	  bladder	  strips	  from	  control	  age-­‐matched	  animals	  and	  STZ-­‐induced	  diabetic	  animals.	  	  Following	  maximal	  contraction	  to	  bradykinin,	  tissues	  were	  left	  for	  10	  minutes	  (no	  washout),	  which	  allowed	  tensions	  to	  return	  to	  baseline,	  and	  then	  a	  cumulative	  capsaicin	  concentration	  range	  was	  applied.	  	  Carbachol	  response	  curves	  were	  also	  examined	  for	  any	  effects	  of	  pretreatment	  with	  bradykinin.	  	  Bradykinin	  effects	  were	  examined	  in	  the	  acute	  timecourse	  studies	  following	  STZ-­‐induction	  of	  diabetes	  to	  pinpoint	  when	  bradykinin	  effects	  were	  optimal.	  	  Then	  an	  exploration	  of	  the	  bradykinin	  receptor	  subtype	  was	  examined	  through	  the	  use	  of	  selective	  agonists	  for	  BK-­‐1	  receptor	  ([Lys-­‐des-­‐Arg9]-­‐BK)	  and	  BK-­‐2	  receptor	  ([Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK).	  	  Again	  cumulative	  concentration	  response	  curves	  were	  constructed	  for	  these	  agonists:	  following	  maximal	  contraction	  with	  no	  washout	  the	  tissues	  were	  left	  for	  10	  minutes	  after	  which	  time	  a	  capsaicin	  concentration	  range	  was	  applied.	  	  Further	  to	  these	  studies	  a	  combination	  study	  was	  performed	  using	  both	  selective	  agonists	  (1	  μM	  	  ([Lys-­‐des-­‐Arg9]-­‐BK	  +	  1	  μM	  	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK)	  .	  	  Finally	  a	  study	  where	  the	  effects	  of	  bradykinin	  were	  studied	  on	  capsaicin	  response	  +	  10	  μM	  indomethacin,	  an	  inhibitor	  of	  endogenous	  prostaglandin	  formation,	  was	  completed	  with	  the	  inclusion	  of	  an	  ETOH	  vehicle	  control.	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NGF	  	  The	  effects	  of	  20	  minute	  preincubation	  of	  100	  and	  300	  ng/ml	  of	  nerve	  growth	  factor	  with	  no	  wash	  out,	  were	  investigated	  on	  subsequent	  cumulative	  concentration	  range	  of	  capsaicin.	  	  	  
Insulin	  	  The	  effects	  of	  a	  20	  minute	  preincubation	  with	  1	  μM	  insulin,	  with	  no	  washout,	  was	  examined	  on	  a	  cumulatively	  applied	  concentration	  range	  of	  capsaicin	  responses.	  	  
Monitoring	  of	  effects	  on	  carbachol	  
	  A	  cumulative	  concentration	  range	  of	  carbachol	  was	  applied	  before	  and	  after	  the	  various	  treatments	  to	  monitor	  possible	  effects	  on	  muscarinic	  function.	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Results	  	  	  
The	  effects	  of	  bradykinin	  	  	  First	  the	  direct	  contractile	  reponses	  to	  a	  cumulative	  concentration	  range	  of	  bradykinin	  were	  examined	  in	  urinary	  bladder	  tissue	  from	  2	  days,	  2	  weeks	  and	  4	  weeks	  post	  control	  or	  STZ	  treatment.	  	  Bradykinin	  was	  seen	  to	  directly	  cause	  a	  concentration-­‐related	  contraction	  of	  urinary	  bladder	  strips,	  in	  control	  age-­‐matched	  and	  STZ-­‐induced	  diabetic	  animals,	  a	  representative	  trace	  from	  each	  is	  shown	  (Figure	  7.2)	  
	  	  	  Figure	  7.2	  Representative	  raw	  data	  traces	  of	  the	  effect	  of	  bradykinin	  on	  urinary	  bladder	  strips	  from	  an	  age-­‐matched	  control	  animal	  (A)	  and	  a	  STZ-­‐induced	  diabetic	  animal	  (B)	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The	  contractile	  responses	  to	  bradykinin	  remained	  consistent	  in	  control	  animal	  tissue	  at	  all	  timepoints	  studied.	  	  Bradykinin	  responses	  were	  enhanced	  in	  the	  2	  days	  post-­‐STZ	  group,	  with	  responses	  returning	  to	  control	  levels	  at	  2	  weeks	  and	  4-­‐weeks	  post	  STZ-­‐administration	  (Figure	  7.3)(Table	  7.1).	  
	  	  Figure	  7.3	  Graphs	  showing	  direct	  contractile	  effect	  of	  bradykinin	  in	  urinary	  bladder	  strips	  from	  control	  and	  STZ-­‐treated	  animals	  at	  2	  days	  (A)	  and	  2	  weeks	  (B)	  post-­‐treatment.	  	  Data	  represent	  mean	  +	  s.e.m.	  n>6	  urinary	  bladder	  strips.	  	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	  	  Table	  7.1	  Direct	  contractile	  effects	  of	  bradykinin:	  potency	  and	  efficacy	  in	  urinary	  bladder	  strips	  from	  control	  and	  STZ-­‐treated	  rats.	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	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  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  comparing	  to	  time-­‐matched	  control,	  NS	  non-­‐significant,	  *p<0.05,	  **p<0.01,	  ***p<0.001.	  	  
Effects	  of	  bradykinin	  on	  subsequent	  responses	  to	  capsaicin	  	  Following	  maximal	  bradykinin	  application	  and	  a	  10-­‐minute	  equilibration	  period	  with	  no	  wash-­‐out,	  responses	  to	  a	  cumulative	  concentration	  curve	  of	  capsaicin	  were	  examined	  at	  2	  days	  and	  2	  weeks	  post	  control	  or	  STZ-­‐administration.	  	  	  At	  the	  2	  days	  post	  treatment	  group,	  where	  no	  diminishment	  of	  capsaicin	  response	  was	  seen	  between	  control	  and	  STZ-­‐treated	  rats,	  no	  effect	  of	  exposure	  to	  1	  μM	  bradykinin	  for	  10	  minutes	  was	  seen	  (Figure	  7.4).	  
	  Figure	  7.4	  Graphs	  showing	  responses	  to	  capsaicin	  post-­‐bradykinin	  exposure	  in	  urinary	  bladder	  from	  2	  day	  post	  control	  (A)	  and	  STZ-­‐treated	  rats	  (B).	  	  	  Data	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represent	  mean	  +	  s.e.m.	  of	  >n	  of	  6	  urinary	  bladder	  strips.	  No	  statistical	  significance	  was	  seen	  by	  two-­‐way	  ANOVA.	  	  	  At	  the	  2	  weeks	  post	  treatment	  timepoint,	  where	  a	  clear	  diminished	  capsaicin	  response	  was	  seen,	  no	  effect	  of	  bradykinin	  pre-­‐exposure	  was	  noted	  in	  control	  animal	  tissue,	  but	  a	  significant	  enhancement	  of	  capsaicin	  responses	  back	  to	  control	  values	  in	  STZ-­‐treated	  animal	  tissue	  was	  observed	  (Figure	  7.5).	  
	  Figure	  7.5	  Graphs	  showing	  responses	  to	  capsaicin	  post-­‐bradykinin	  exposure	  in	  urinary	  bladder	  from	  2	  weeks	  post	  control	  (A)	  and	  STZ-­‐treated	  rats	  (B).	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  >n	  of	  6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  2-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	  	  	  
Direct	  contractile	  effects	  of	  bradykinin	  receptor	  subtype	  selective	  agonists	  	  Next	  the	  direct	  contractile	  effects	  of	  the	  BK-­‐1	  selective	  agonist,	  [Lys-­‐des-­‐Arg9]-­‐BK,	  and	  the	  BK-­‐2	  selective	  agonist,	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK	  were	  examined	  in	  urinary	  bladder	  strips	  from	  2	  weeks	  post	  control	  or	  STZ-­‐treated	  rats.	  	  The	  BK-­‐1	  selective	  agonist	  [Lys-­‐des-­‐Arg9]-­‐BK,	  caused	  a	  concentration-­‐related	  contraction	  of	  similar	  potency	  in	  control	  and	  in	  STZ-­‐treated	  rat	  tissue	  (Figure	  7.6).	  	  There	  was	  a	  significant	  difference	  in	  the	  magnitude	  of	  response,	  where	  the	  STZ-­‐treated	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animal	  tissue	  had	  a	  lower	  maximum	  response	  to	  this	  BK-­‐1	  selective	  agonist.	  	  The	  BK-­‐2	  selective	  agonist	  ,	  	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK	  also	  caused	  a	  concentration	  related	  contractile	  response,	  which	  in	  control	  animal	  tissue	  was	  of	  greater	  magnitude	  than	  seen	  for	  BK-­‐1	  selctive	  agonist.	  The	  BK-­‐2	  selective	  agonist	  gave	  a	  significantly	  different	  profile	  in	  STZ-­‐treated	  animal	  tissue	  where	  a	  much	  reduced	  response	  was	  seen	  (Figure	  7.6)	  (Table	  7.2).	  	  
	  Figure	  7.6	  Graphs	  showing	  responses	  to	  BK-­‐1	  selective	  agonist	  ,	  [Lys-­‐des-­‐Arg9]-­‐BK	  (A)	  and	  BK-­‐2	  selective	  agonist,	  	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK	  	  (B)	  in	  urinary	  bladder	  from	  2	  weeks	  post	  control	  and	  STZ-­‐treated	  rats.	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  >n	  of	  6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	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Table	  7.2:	  Potency	  and	  efficacy	  estimates	  for	  Bradykinin	  selective	  agonists	  on	  urinary	  bladder	  from	  2	  week	  post	  control	  or	  STZ	  administration.	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n>6	  urinary	  bladder	  strips.	  
	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  comparing	  to	  control,	  NS	  non-­‐significant,	  *p<0.05,	  **p<0.01,	  ***p<0.001.	  	  
The	  effects	  of	  bradykinin	  selective	  agonists	  on	  subsequent	  response	  to	  
capsaicin	  	  The	  effects	  of	  1	  μM	  BK-­‐1	  or	  1	  μM	  BK-­‐2	  selective	  agonists	  on	  the	  subsequent	  capsaicin	  responses	  were	  next	  examined.	  	  Neither	  agonist	  elicited	  the	  same	  effect	  as	  seen	  for	  bradykinin,	  i.e.	  no	  reversal	  of	  the	  diminished	  capsaicin	  response	  in	  STZ-­‐treated	  animal	  tissue	  was	  seen,	  although	  a	  small	  leftward	  shift	  in	  capsaicin	  potency	  was	  seen	  following	  BK-­‐1	  agonist	  preincubation	  (Figure	  7.7).	  	  	  
	  Figure	  7.7	  Graphs	  showing	  responses	  to	  capsaicin	  following	  pre-­‐exposure	  to	  BK-­‐1	  selective	  agonist,	  [Lys-­‐des-­‐Arg9]-­‐BK	  (A)	  and	  BK-­‐2	  selective	  agonist,	  	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK	  	  (B)	  in	  urinary	  bladder	  from	  2	  weeks	  post	  STZ-­‐treated	  rats.	  	  	  
!!!!!"#$%&#' !!!!!!!!()* !!!!!"#$%&#' !!!!!!!!!()*
+,-./01./2&345/67! !!89:4!;!:9<< !89=>!;!:9?<@( !!==9=A!;!89== !!!!!<B9>A!;!<9?:@(!"#$%&'()#&*+,&-./01&2344 !!89><!;!:9?> !89B=!;!:9<C@( !!>>98A!;!>988 !!!!!C<9C:!;!=9=BDDD
23#$E.% !!!!!!!!!!!!!!!!!!!!!!!FGHB:! !!!!!!!!!!!!!!!!!!!!GIJK
	   160	  
Data	  represent	  mean	  +	  s.e.m.	  of	  >n	  of	  6	  urinary	  bladder	  strips.	  No	  statistical	  significance	  was	  seen	  using	  two-­‐way	  ANOVA	  comparing	  to	  respective	  control.	  	  Next	  the	  effect	  of	  a	  combination	  of	  1	  μM	  BK-­‐1	  and	  1	  μM	  BK-­‐2	  selective	  agonist	  on	  subsequent	  response	  to	  capsaicin	  was	  examined.	  	  The	  combination	  BK-­‐1/	  BK-­‐2	  agonist	  elicited	  a	  direct	  contraction	  of	  similar	  magnitude	  in	  control	  and	  STZ-­‐treated	  animal	  tissue	  (Figure	  7.8)	  and	  also	  enhanced	  the	  subsequent	  response	  to	  capsaicin	  in	  STZ-­‐treated	  urinary	  bladder,	  to	  the	  level	  seen	  with	  bradykinin.	  	  In	  tissue	  from	  control-­‐treated	  animals	  a	  slight	  leftward	  shift	  in	  capsaicin	  potency	  was	  seen,	  but	  this	  was	  statistically	  non-­‐significant	  (Figure	  7.9).	  
	  Figure	  7.8	  Barchart	  showing	  direct	  contractile	  response	  to	  a	  combination	  of	  1	  μM	  BK-­‐1	  selective	  agonist	  ,	  [Lys-­‐des-­‐Arg9]-­‐BK	  and	  1	  μM	  BK-­‐2	  selective	  agonist,	  	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK	  	  in	  urinary	  bladder	  from	  2	  weeks	  post	  	  control	  and	  STZ-­‐treated	  rats.	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  >n	  of	  6	  urinary	  bladder	  strips.	  No	  statistical	  significance	  was	  seen	  using	  by	  Students	  t-­‐test.	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  Figure	  7.9	  Graphs	  showing	  responses	  to	  capsaicin	  following	  pre-­‐exposure	  to	  a	  combination	  of	  	  BK-­‐1	  selective	  agonist	  ,	  [Lys-­‐des-­‐Arg9]-­‐BK	  and	  BK-­‐2	  selective	  agonist,	  	  [Phe8-­‐y(Ch-­‐NH)-­‐Arg9]-­‐BK	  	  in	  urinary	  bladder	  from	  2	  weeks	  post	  	  control	  (A)	  and	  STZ-­‐treated	  (B)	  rats.	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  >n	  of	  6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control.	  	  
The	  effect	  of	  indomethacin	  on	  bradykinin	  responses	  	  Finally	  the	  effect	  of	  10	  μM	  indomethacin,	  a	  cyclooxygenase	  inhibitor,	  was	  examined	  on	  the	  responses	  to	  bradykinin	  in	  urinary	  bladder	  from	  STZ-­‐treated	  rats.	  	  Firstly	  direct	  contractile	  response	  to	  1μM	  bradykinin	  was	  examined	  in	  the	  presence	  and	  absence	  of	  indomethacin	  where	  it	  was	  seen	  that	  indomethacin	  significantly	  reduced	  but	  did	  not	  abolish	  the	  response	  (Figure	  4.10).	  	  Secondly	  the	  response	  to	  subsequent	  capsaicin	  application	  was	  examined	  where	  it	  was	  seen	  that	  in	  the	  presence	  of	  indomethacin,	  bradykinin	  pre-­‐exposure	  was	  not	  able	  to	  enhance	  the	  subsequent	  capsaicin	  response	  to	  the	  same	  degree	  as	  seen	  in	  the	  absence	  of	  indomethacin	  (Figure	  7.10).	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  Figure	  7.10	  Barchart	  and	  graph	  showing	  direct	  contractile	  response	  to	  1	  μM	  bradykinin	  +	  indomethacin	  (A)	  and	  subsequent	  capsaicin	  responses	  (B)	  in	  urinary	  bladder	  from	  2	  weeks	  post	  STZ-­‐treated	  	  rats.	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >	  6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  Students	  t-­‐test	  and	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  control.	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The	  effect	  of	  NGF	  on	  capsaicin	  responses	  	  Next	  the	  effect	  of	  preincubating	  NGF	  was	  examined	  on	  the	  subsequent	  response	  to	  capsaicin	  in	  urinary	  bladder	  from	  2	  weeks	  post	  control	  and	  STZ-­‐treated	  rats.	  NGF	  did	  not	  elicit	  a	  direct	  contractile	  or	  relaxant	  response	  on	  the	  urinary	  bladder	  strips,	  and	  did	  not	  enhance	  subsequent	  capsaicin	  responses	  in	  tissue	  from	  2	  weeks	  post	  control	  or	  STZ-­‐treated	  rats	  (Figure	  7.11).	  At	  the	  300	  ng/ml	  NGF	  concentration,	  there	  did	  appear	  to	  be	  a	  mild	  depression	  in	  the	  control	  tissue	  group,	  whereas	  no	  such	  effect	  was	  observed	  in	  the	  STZ-­‐treated	  group.	  
	  Figure	  7.11	  Graphs	  showing	  effects	  of	  NGF	  preincubation	  with	  no	  washout	  on	  subsequent	  capsaicin	  responses	  in	  urinary	  bladder	  from	  2	  weeks	  post	  	  control	  (A)	  and	  STZ-­‐treated	  	  (B)	  rats.	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >	  6	  urinary	  bladder	  strips.	  Statistical	  significance	  was	  tested	  by	  two-­‐way	  ANOVA	  with	  post-­‐hoc	  Bonferonni,	  *	  represents	  p<0.05,	  **	  p<0.01,	  ***	  p<0.001	  comparing	  to	  respective	  control	  	  
The	  effect	  of	  insulin	  on	  capsaicin	  and	  carbachol	  responses	  	  Finally	  the	  effect	  of	  1	  μM	  insulin,	  incubated	  for	  20	  minutes	  with	  no	  washout	  was	  studied	  firstly	  on	  capsaicin	  responses	  and	  secondly	  on	  carbachol	  responses	  of	  urinary	  bladder	  tissue	  from	  2	  week	  post	  control	  and	  STZ-­‐treated	  rats.	  The	  direct	  application	  of	  insulin	  caused	  a	  transient	  minor	  relaxation	  of	  the	  urinary	  bladder	  strips	  (control	  17.78+	  4.67,	  STZ	  23.00	  +	  6.35	  mgs	  relaxation	  per	  mg	  tissue	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weight)	  which	  returned	  to	  baseline	  before	  capsaicin	  application.	  Insulin	  preincubation	  had	  no	  effect	  on	  control	  or	  STZ-­‐treated	  animal	  tissue	  responses	  to	  capsaicin	  or	  carbachol	  (Figure	  7.12)	  	  
	  	  Figure	  7.12	  Graphs	  showing	  effects	  of	  insulin	  preincubation	  with	  no	  washout	  on	  subsequent	  capsaicin	  responses	  (A)	  and	  carbachol	  responses	  (B)	  in	  urinary	  bladder	  from	  2	  weeks	  post	  	  control	  and	  STZ-­‐treated	  	  rats.	  	  	  Data	  represent	  mean	  +	  s.e.m.	  of	  n	  >	  6	  urinary	  bladder	  strips.	  No	  statistical	  significance	  was	  found	  for	  insulin	  effects	  by	  two-­‐way	  ANOVA.	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Monitoring	  of	  carbachol	  responses	  throughout	  bradykinin	  and	  NGF	  studies	  	  The	  response	  to	  carbachol	  was	  seen	  to	  be	  of	  lower	  magnitude	  in	  the	  urinary	  bladders	  from	  2-­‐week	  post	  STZ-­‐treated	  in	  agreement	  with	  previous	  data	  (Table	  7.3).	  	  No	  significant	  alteration	  of	  carbachol	  responses	  were	  seen	  following	  bradykinin	  +	  indomethacin,	  indomethacin,	  BK-­‐1,	  BK-­‐2	  ,	  BK-­‐1	  +BK-­‐2	  combination	  or	  NGF	  preincubation.	  	  Table	  7.3	  Potency	  and	  efficacy	  estimates	  for	  carbachol	  responses	  in	  urinary	  bladders	  from	  2	  week	  control	  and	  STZ-­‐treated	  rats.	  Data	  represent	  mean	  +	  s.e.m	  n>6	  urinary	  bladder	  strips.	  	  
	  Statistical	  analysis	  by	  two-­‐way	  ANOVA	  comparing	  STZ	  to	  control,	  NS	  non-­‐significant,	  *p<0.05,	  **p<0.01,	  ***p<0.001.	  No	  significant	  difference	  was	  found	  with	  two-­‐way	  ANOVA	  comparing	  BK/NGF	  treatment	  with	  respective	  control.	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Discussion	  	  
Bradykinin	   preincubation	   was	   able	   to	   reverse	   the	   diminished	   TRPV1	  
response	  	  Bradykinin	   produced	   a	   consistent	   contractile	   response	   in	   control	   tissues	   over	  the	   time-­‐phase	   studied.	   In	   the	   STZ-­‐treated	   rat	   tissue,	   an	   enhanced	   efficacy	  response	  to	  bradykinin	  was	  seen	  at	  the	  2-­‐day	  post	  STZ-­‐treatment.	  	  This	  could	  be	  due	   to	  an	  acute	   inflammatory	  response	   following	   induction	  of	  diabetes	  by	  STZ,	  causing	   an	   upregulation	   of	   bradykinin	   receptor	   activation	   effector	   pathways	  such	  as	  prostaglandin	   release	   in	   the	  bladder.	   	  Due	   to	   its	   toxicity,	   STZ	  has	  been	  shown	   to	   cause	   an	   acute	   inflammatory	   response	   systemically	   with	   vascular	  leakage	  and	  proinflammatory	  gene	  upregulation	  (Kim	  et	  al.,	  2007)	  .	  Future	  work	  could	  be	  to	  dissect	  out	  which	  bradykinin	  receptor	  type	  was	  responsible	   for	  the	  enhanced	   bradykinin	   response	   with	   the	   use	   of	   selective	   agonist/antagonists.	  Following	  bradykinin	   application,	   an	   enhancement	   of	   the	   diminished	   capsaicin	  response	   in	  2	  weeks	  post	  STZ-­‐treated	  rat	  urinary	  bladder	  tissue	  was	  seen	  with	  no	  effect	  observed	  on	  control	  treated	  tissue.	  These	  data	  reproduced	  the	  findings	  of	   Katisart	   (Katisart,	   2011).	   	   The	   bradykinin-­‐capsaicin	   enhancement	   was	   not	  observed	  in	  2	  day	  post	  STZ-­‐treated	  tissue	  where	  the	  capsaicin	  response	  had	  not	  yet	  diminished.	  	  	  	  
Bradykinin	  reversal	  required	  dual	  BK-­‐1	  and	  BK-­‐2	  receptor	  activation	  	  Next	  BK-­‐1	  and	  BK-­‐2	  selective	  agonists	  were	  used	  to	  determine	  which	  bradykinin	  receptor	   subtype	   was	   responsible	   for	   the	   potentiating	   effect	   seen.	   	   When	  comparing	   BK-­‐1	   and	   BK-­‐2	   direct	   contractile	   effects	   in	   STZ-­‐diabetic	   to	   control	  tissue	   a	   slight	   reduction	   in	   BK-­‐1	   response	   and	   a	   significantly	   reduced	   BK-­‐2	  response	  was	  seen	  in	  the	  STZ-­‐diabetic	  tissue.	  	  Reduced	  BK-­‐1	  and	  BK-­‐2	  responses	  could	   imply	   a	   reduced	   receptor	   expression	   but	   published	   data	   demonstrates	  firstly	  a	  ubiquitously	  high	  expression	  of	  BK-­‐2	  receptors	  (Bellucci	  et	  al.,	  2007)	  and	  secondly	   an	   upregulation	   of	   BK-­‐1	   receptor	   expression	   in	   the	   STZ-­‐model	   of	  diabetes	   (Mage	   et	   al.,	   2002).	   The	   alteration	   in	   responses	   could	   be	   driven	   by	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changes	   in	   the	   effector	   mechanisms	   of	   BK-­‐1	   and	   BK-­‐2	   mediated	   contraction.	  	  Bladder	   bradykinin	   responses	   have	   been	   reported	   to	   increase	   over	   time	   post	  tissue	   setup,	   with	   larger	   increases	   in	   hypertropic	   tissue,	   and	   these	   have	   been	  attributed	   to	   increased	   prostaglandin	   production	   (Sjuve	   et	   al.,	   2000).	   This	  finding	  may	  offer	  some	  explanation	  as	  to	  the	  data	  seen	  here.	  	  The	  studies	  on	  BK-­‐1	  and	  BK-­‐2	  agonist	   responses	  were	  performed	  at	   a	   similar	  but	  not	   exact	   time	  of	  tissue	  incubation	  post	  setup	  (4-­‐5	  hours),	  and	  studies	  in	  control	  and	  STZ-­‐diabetic	  were	  not	  run	   in	  direct	  parallel	  as	  the	  main	  aim	  was	  to	  study	  responses	   in	  STZ-­‐diabetic	  tissue.	  However,	  the	  study	  of	  the	  effects	  of	  BK-­‐1	  and	  BK-­‐2	  combination	  was	  run	  in	  direct	  parallel	  in	  control	  and	  STZ-­‐diabetic	  animals.	  	  Here	  the	  resultant	  contractile	   responses	   were	   almost	   identical	   between	   control	   and	   STZ-­‐diabetic	  animals.	   	   An	   examination	   of	   BK-­‐1	   and	   BK-­‐2	   responses	   at	   varying	   times	   after	  setup	  would	  be	  a	  useful	  addition	  to	  this	  dataset	  and	  add	  confidence	  to	  the	  finding	  of	  depressed	  BK-­‐1	  and	  BK-­‐2	  activity	  seen	  in	  STZ-­‐tissue.	  Furthermore	  the	  rate	  of	  prostaglandin	  driven	   increases	   in	  bradykinin	  responses	  may	  very	  well	  differ	   in	  the	  STZ-­‐diabetic	  tissue	  and	  provide	  an	  explanation	  for	  the	  diminished	  BK-­‐1	  and	  BK-­‐2	  responses	  seen.	  	  Following	   BK-­‐1	   or	   BK-­‐2	   application,	   the	   capsaicin	   responses	  were	   not	   seen	   to	  mirror	   the	  potentiated	   response	   seen	   following	  bradykinin,	   i.e.	  no	  potentiation	  was	   seen.	   	  However,	   a	   combination	   of	   BK-­‐1	   and	  BK-­‐2	   agonist	   did	   produce	   the	  potentiated	  capsaicin	  response,	  indicating	  that	  the	  activation	  of	  both	  bradykinin	  receptor	  subtypes	  is	  essential.	  	  This	  could	  be	  further	  explored	  through	  the	  use	  of	  selective	   BK-­‐1	   and	   BK-­‐2	   antagonists	   which	   should	   both	   inhibit	   bradykinin	  activity	  on	  the	  TRPV1	  response.	  	  	  
Bradykinin	   reversal	   of	   TRPV1	   responses	  was	   blocked	   by	   cyclooxygenase	  
inhibition	  	  The	   mechanistic	   studies	   with	   indomethacin	   revealed	   that	   bradykinin	   direct	  contractile	  effect	  was	  reduced	  but	  not	  abolished	  in	  the	  presence	  of	  indomethacin	  in	  STZ-­‐diabetic	  tissue.	  	  This	  suggests	  that	  the	  mechanism	  of	  bradykinin	  induced	  bladder	  muscle	  contraction	  is	  partly	  through	  production	  of	  prostaglandins.	  Some	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literature	  evidence	  has	  suggested	   that	  bradykinin	  does	  elicit	   the	  contraction	  of	  bladder	  muscle	  through	  prostaglandin	  production	  in	  diabetic	  tissue	  and	  removal	  of	  the	  urothelium	  reduces	  the	  contractile	  effect	  of	  bradykinin	  (Pinna	  et	  al.,	  1994).	  The	  potentiating	  action	  of	  bradykinin	  on	  capsaicin	  response	  was	  seen	  to	  be	  much	  reduced	  in	  the	  presence	  of	  indomethacin.	  This	  finding	  implies	  that	  prostaglandin	  production	   is	   involved	   in	   the	   bradykinin-­‐induced	   TRPV1	   potentiation.	   	   The	  activation	   of	   protein	   kinase	   C	   by	   bradykinin	   leads	   to	   generation	   of	   PGE2	   from	  cyclooxygenase	   2	   (COX2),	   an	   inducible	   enzyme	  upregulated	   in	   inflamed	   tissue.	  	  The	   use	   of	   COX2	   specific	   inhibitors	   would	   further	   strengthen	   this	   finding.	  	  Additionally	   it	   would	   be	   useful	   to	   study	   the	   direct	   effects	   of	   PGE2	   and	  prostanoids	   receptor	   agonists/antagonists	   on	   TRPV1	   function,	   to	   gain	   an	  understanding	  of	  which	  prostanoid	  receptor	  is	  responsible.	  	  
Therapeutic	  manipulation	  of	  TRPV1	  dysfunction	  through	  ACE	  inhibition	  	  With	   the	   finding	   that	   bradykinin	   has	   the	   ability	   to	   modulate	   acute	   deficits	   in	  TRPV1	   function,	   some	   thought	   was	   given	   to	   how	   this	   information	   could	   be	  applied	  in	  the	  clinic.	  	  Therapeutically	  bradykinin	  levels	  can	  be	  enhanced	  through	  the	   use	   of	   angiotensin	   converting	   enzyme	   (ACE)	   inhibitors	   or	   vasopeptidase	  inhibitors	  which	  inhibit	  ACE	  and	  neutral	  endopeptidases.	  	  ACE	  not	  only	  converts	  angiotensin	  but	  also	  degrades	  bradykinin	  and	  so	  inhibiting	  this	  enzymes	  activity	  should	   prolong	   the	   biological	   life	   of	   bradykinin	   and	   increase	   its	   concentration.	  	  	  Some	   clinical	   evidence	  was	   found	  where	   a	   clinical	   trial	   of	   trandolopril,	   an	  ACE	  inhibitor	   was	   found	   to	   be	   of	   some	   use	   in	   diabetic	   neuropathy	   (Malik	   et	   al.,	  1998b)	  but	   side	  effects	  of	  ACE	   inhibitors	   include	  cough	  and	   ‘pins	  and	  needles’.	  	  These	  effects	  and	  side	  effects	  could	  be	  attributed	  to	  TRPV1	  modulation	  (Bessac	  and	   Jordt,	   2008).	   	   No	   studies	   on	   the	   possible	   utility	   of	   ACE	   inhibitors	   in	  treatment	  of	  diabetic	  cystopathy	  were	  found.	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Nerve	  growth	  factor	  was	  unable	  to	  reverse	  diminished	  TRPV1	  responses	  at	  
this	  acute	  stage	  	  The	   hypothesis	   that	   exogenous	   application	   of	   nerve	   growth	   factor	   would	  potentiate	   the	   TRPV1	   response	   either	   through	   increased	   expression	   of	   TRPV1	  receptor	   or	   by	   sensitizing	   TRPV1	   was	   next	   examined.	   	   Application	   of	  concentrations	  of	  NGF	  reported	  to	  elicit	  TRPV1-­‐sensitising	  effects	  (Zhang	  et	  al.,	  2005a)	   had	   no	   effect	   on	   capsaicin	   responses	   in	   either	   control	   or	   STZ-­‐diabetic	  tissue.	   	  This	  raised	  the	  question	  of	  whether	   increased	  TRPV1	  expression	  at	   the	  cell	   surface	   would	   result	   in	   an	   increased	   contractile	   response	   to	   capsaicin	  bearing	  in	  mind	  that	  capsaicin	  is	  cell	  penetrant.	  	  A	  study	  of	  the	  effects	  of	  NGF	  on	  a	  TRPV1	  agonist	  that	  is	  only	  able	  to	  activate	  exofacial	  TRPV1	  would	  answer	  this.	  In	  the	  absence	  of	  such	  a	  ligand,	  a	  more	  complex	  study	  could	  be	  performed	  which	  examines	  the	  antagonist	  potency	  of	  a	  cell	  impermeant	  TRPV1-­‐	  antagonist	  such	  as	  SB-­‐497794-­‐D.	   	   If	  NGF	   is	   able	   to	   increase	   cell	   surface	   expression	   of	   TRPV1,	   the	  antagonist	   potency	   versus	   capsaicin	   responses	   should	   be	   increased	   in	   the	  presence	  of	  NGF.	  	  The	  dataset	  produced	  so	  far	  implies	  that	  exogenously	  applied	  NGF	  is	  unable	  to	  sensitise	  TRPV1	  responses	  either	  in	  control	  or	  at	  the	  early	  stage	  of	  diabetes.	  	  A	  reduction	  in	  NGF	  levels	  in	  the	  diabetic	  bladder	  has	  been	  seen	  by	  8	  weeks	  (Li	  et	  al.)	  but	  NGF	  mRNA	  has	  been	  reported	  to	  be	  enhanced	  in	  the	  bladder	  at	  earlier	  timepoints	  (Koo	  et	  al.,	  1993)	  and	  therefore	  this	  ineffectiveness	  of	  NFG	  exogenously	   applied	   may	   simply	   be	   due	   to	   timing	   .	   	   NGF	   is	   produced	   and	  released	   by	   smooth	   muscle	   cells	   and	   urothelial	   cells	   of	   the	   bladder	   and	  transported	   to	   the	   DRG	   through	   retrograde	   axonal	   transport.	   	   If	   endogenous	  levels	   of	   NGF	   were	   already	   high	   or	   unchanged	   from	   control	   levels	   then	  exogenous	  application	  of	  NGF	  would	  be	  unlikely	   to	   sensitise	  TRPV1	  responses.	  	  With	  this	  in	  mind,	  the	  importance	  of	  NGF	  to	  TRPV1	  function	  may	  become	  more	  relevant	  to	  TRPV1	  dysfunction	  in	  this	  tissue	  at	  a	  later	  stage	  of	  diabetes	  than	  has	  been	  studied	  in	  this	  project,	  at	  a	  point	  when	  NGF	  levels	  are	  reduced.	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Insulin	  application	  was	  unable	  to	  sensitise	  TRPV1	  responses	  	  Lastly,	  an	  acute	  application	  of	  insulin	  was	  without	  effect	  on	  either	  capsaicin	  responses	  or	  carbachol	  responses.	  	  The	  hypothesis	  here	  was	  that	  deprivation	  of	  insulin	  may	  have	  caused	  a	  down	  regulation	  of	  TRPV1	  surface	  expression	  in	  the	  STZ-­‐diabetic	  tissue	  and	  by	  exposure	  to	  insulin	  a	  sensitization	  of	  TRPV1	  response	  may	  be	  afforded.	  	  This	  was	  not	  observable	  in	  these	  studies.	  	  No	  direct	  contractile	  effect	  of	  insulin	  was	  observed	  in	  urinary	  bladder	  from	  control	  or	  STZ-­‐treated	  rats,	  but	  a	  small	  relaxant	  effect	  was	  observed.	  	  There	  has	  been	  a	  report	  that	  insulin	  is	  able	  to	  directly	  activate	  the	  TRPV1	  receptor	  in	  a	  population	  of	  neuronal	  cells	  (Sathianathan	  et	  al.,	  2003).	  If	  insulin	  were	  to	  directly	  activate	  TRPV1	  in	  this	  system	  a	  direct	  contractile	  response	  and	  a	  subsequent	  reduced	  response	  to	  capsaicin	  would	  be	  observed;	  this	  was	  not	  the	  case	  in	  these	  studies.	  	  Responses	  to	  carbachol	  were	  monitored	  in	  this	  study,	  due	  to	  the	  fact	  that	  insulin	  will	  cause	  uptake	  of	  glucose	  into	  the	  smooth	  muscle	  and	  through	  this	  effect	  may	  alter	  muscle	  responsiveness	  to	  the	  muscarinic	  receptor	  activation.	  	  Again	  no	  significant	  changes	  were	  seen	  following	  insulin.	  	  	  	  	  The	  prominent	  findings	  here	  were	  that	  bradykinin	  was	  able	  to	  reverse	  the	  diminished	  TRPV1	  response,	  whereas	  NGF	  and	  insulin	  were	  without	  effect	  at	  this	  acute	  stage	  of	  diabetes.	  	  This	  implies	  that	  at	  this	  acute	  phase	  in	  this	  model	  system,	  TRPV1	  function	  retains	  some	  level	  of	  plasticity	  and	  suggests	  that	  early	  therapeutic	  intervention	  for	  e.g.	  by	  an	  ACE	  inhibitor	  may	  be	  beneficial	  in	  the	  treatment	  of	  diabetic	  cystopathy.	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Chapter	  8	  Overall	  discussion	  	  
Initial	  validation	  studies	  identified	  the	  urinary	  bladder	  as	  the	  most	  
appropriate	  model	  for	  study	  of	  TRPV1	  modulation	  in	  sensory	  neuropathy	  	  The	  first	  studies	  were	  aimed	  at	  finding	  the	  most	  suitable	  model	  to	  use	  for	  exploring	  how	  and	  why	  TRPV1	  function	  is	  being	  modulated	  during	  diabetic	  sensory	  neuropathy.	  	  Native	  tissue	  assays	  such	  as	  the	  urinary	  bladder	  in	  vitro	  model	  express	  numerous	  receptors	  endogenously	  and	  require	  minimal	  manipulation	  which	  avoids	  marked	  phenotypical	  changes	  that	  could	  potentially	  alter	  TRPV1	  responses.	  	  Ideally	  a	  sensory	  neuron	  preparation	  such	  as	  the	  DRG	  would	  have	  been	  studied	  in	  addition	  to	  the	  bladder.	  	  However	  acutely	  dissociated	  DRG	  preparations	  require	  manipulation	  to	  enzymatically	  dissociate	  the	  cells,	  inclusion	  of	  NGF	  to	  sustain	  neuronal	  viability	  and	  provision	  of	  extracellular	  matrix	  protein	  to	  cause	  cellular	  adherence	  to	  a	  coverslip.	  	  All	  of	  these	  steps	  could	  potentially	  alter	  TRPV1	  expression	  and	  functional	  state	  (Chen	  et	  al.,	  2011,	  Zhang	  et	  al.,	  2005a,	  Jeske	  et	  al.,	  2009a),	  which	  would	  be	  at	  odds	  with	  the	  experimental	  aims	  of	  examining	  how	  this	  receptor	  is	  modulated	  specifically	  in	  sensory	  neuropathy.	  	  To	  overcome	  these	  methodological	  issues,	  a	  functional	  assay	  such	  as	  intracellular	  calcium	  measurement	  could	  be	  studied	  in	  an	  intact	  DRG	  preparation.	  	  Pilot	  studies	  in	  intact	  DRG	  were	  attempted	  but	  insufficient	  FURA-­‐2AM	  loading	  and	  a	  subsequent	  low	  ratiometric	  signal	  hindered	  progress	  and	  therefore	  efforts	  were	  focused	  on	  the	  urinary	  bladder	  system.	  	  
Rapid	  onset	  of	  TRPV1	  dysfunction	  was	  seen	  following	  induction	  of	  diabetes	  	  Next	  the	  onset	  of	  TRPV1	  dysfunction	  was	  mapped	  in	  urinary	  bladder	  using	  the	  STZ-­‐induced	  diabetic	  rat	  model.	  	  Here	  diminished	  responses	  to	  capsaicin	  were	  seen	  robustly	  by	  2	  weeks,	  which	  persisted	  up	  to	  7-­‐10	  weeks	  following	  STZ-­‐treatment.	  There	  seems	  to	  be	  a	  slight	  discrepancy	  between	  these	  data	  and	  previous	  in-­‐house	  data	  in	  this	  respect(Katisart,	  2011),	  however	  the	  STZ-­‐model	  had	  been	  altered	  to	  reduce	  mortality	  and	  this	  may	  have	  impacted	  on	  the	  onset	  of	  TRPV1	  dysfunction.	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The	  source	  of	  TRPV1	  dysfunction	  is	  not	  entirely	  through	  myogenic	  decline	  	  To	  try	  and	  understand	  the	  source	  of	  TRPV1	  dysfunction	  which	  was	  one	  of	  reduced	  efficacy	  rather	  than	  altered	  potency,	  other	  functional	  measures	  were	  examined.	  	  Carbachol	  responses	  were	  measured	  to	  monitor	  myogenic	  changes	  and	  here	  a	  gradual	  progressive	  decline	  was	  seen.	  The	  profile	  of	  muscarinic	  decline	  did	  not	  match	  the	  acute	  decline	  that	  was	  seen	  in	  TRPV1	  function	  and	  because	  of	  this	  mismatch,	  the	  reduced	  muscle	  function	  could	  not	  fully	  explain	  the	  diminished	  TRPV1	  responsiveness.	  Additionally	  no	  difference	  was	  seen	  in	  the	  contractile	  kinetics	  of	  carbachol	  response,	  which	  provided	  additional	  evidence	  that	  muscle	  contractility	  was	  largely	  unaltered	  at	  this	  acute	  stage.	  No	  differences	  were	  seen	  in	  frequency	  of	  spontaneous	  activity	  but	  a	  slight	  significant	  decrease	  in	  amplitude	  was	  seen	  in	  the	  urinary	  bladder	  from	  STZ-­‐treated	  rats,	  which	  could	  be	  attributed	  to	  the	  minor	  myogenic	  decline.	  	  	  An	  increase	  in	  the	  mechanisms	  that	  terminate	  the	  action	  of	  the	  neuropeptides	  released	  through	  TRPV1	  activation	  could	  explain	  a	  diminished	  TRPV1	  function.	  However,	  no	  differences	  were	  noted	  in	  the	  rate	  of	  recovery	  of	  tissue	  following	  capsaicin	  exposure,	  suggestive	  of	  no	  change	  to	  the	  degradative	  pathways	  that	  terminate	  the	  contractile	  response	  to	  the	  neuropeptides.	  	  In	  terms	  of	  neuropeptide	  content	  of	  the	  tissue,	  although	  no	  measure	  was	  made	  of	  these	  in	  this	  thesis,	  there	  is	  evidence	  in	  the	  literature	  that	  neuropeptides	  such	  as	  Substance	  P	  are	  unaltered	  in	  the	  bladder	  at	  up	  to	  9	  weeks	  following	  diabetic	  induction	  (Steers	  et	  al.,	  1994).	  	  Therefore	  it	  appears	  that	  the	  dysfunction	  seen	  in	  the	  TRPV1	  receptor	  is	  due	  to	  an	  alteration	  in	  its	  function.	  	  
Diabetes	  is	  causing	  changes	  in	  neuroexitability	  that	  extend	  beyond	  TRPV1	  
function	  	  Neurally	  mediated	  contractile	  activity	  was	  examined	  through	  the	  use	  of	  electrical	  field	  stimulation	  and	  these	  studies	  revealed	  an	  increased	  voltage	  sensitivity	  in	  diabetic	  tissue.	  	  This	  alteration	  in	  neurogenically	  mediated	  contraction	  is	  in	  agreement	  with	  the	  literature	  and	  has	  been	  attributed	  to	  changes	  in	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neuroexitability	  (Tammela	  et	  al.,	  1994).	  	  Such	  changes	  highlight	  the	  fact	  that	  changes	  are	  occurring	  in	  the	  neuronal	  population	  and	  are	  not	  just	  limited	  to	  TRPV1	  function.	  	  	  
Reduced	  organ	  bath	  temperature	  changes	  in	  muscarinic/	  TRPV1	  function	  
were	  deficient	  in	  diabetic	  tissue	  	  TRPV1	  is	  a	  temperature	  sensitive	  ion	  channel	  and	  the	  effects	  of	  organ	  bath	  temperature	  on	  TRPV1	  and	  muscarinic	  function	  were	  studied.	  	  Reduced	  organ	  bath	  temperature	  caused	  increased	  responses	  to	  carbachol	  and	  capsaicin	  in	  control	  tissue	  and	  increased	  amplitude	  but	  decreased	  frequency	  of	  spontaneous	  activity.	  	  In	  tissue	  from	  STZ-­‐diabetic	  rats,	  the	  decreased	  organ	  bath	  temperature	  had	  no	  effect	  on	  either	  carbachol	  or	  capsaicin	  responses	  but	  did	  cause	  a	  reduction	  in	  frequency	  and	  an	  increase	  in	  amplitude	  of	  spontaneous	  activity.	  	  These	  temperature	  data	  suggest	  that	  the	  mechanism	  that	  drives	  changes	  in	  muscarinic/	  TRPV1	  responses	  is	  deficient	  in	  diabetes	  whereas	  the	  mechanism	  that	  drives	  changes	  in	  spontaneous	  activity	  is	  not.	  	  	  	  
Methylglyoxal	  could	  be	  causative	  to	  the	  TRPV1	  dysfunction	  but	  its	  actions	  
extend	  beyond	  TRPA1	  activation	  	  Next	  to	  gain	  an	  understanding	  of	  what	  could	  be	  causing	  the	  TRPV1	  dysfunction	  and	  other	  neuronal	  changes	  in	  diabetes,	  the	  acute	  exposure	  to	  a	  potential	  neuropathy	  causative	  agent,	  methylglyoxal	  was	  studied.	  	  To	  examine	  whether	  methylglyoxal	  effect	  was	  via	  TRPA1	  activation,	  TRPA1	  ligands	  were	  used.	  	  	  
Methylglyoxal	  did	  cause	  TRPA1	  activation	  but	  effects	  on	  TRPV1	  function	  
were	  not	  blocked	  by	  TRPA1	  antagonism	  
	  Methylglyoxal	  caused	  a	  direct	  contractile	  response	  in	  control	  tissue	  of	  a	  similar	  magnitude	  to	  that	  seen	  with	  AITC,	  suggestive	  of	  TRPA1	  activation.	  	  A	  diminished	  response	  was	  seen	  to	  methylglyoxal	  in	  STZ-­‐diabetic	  tissue	  which	  implies	  that	  a	  reduced	  TRPA1	  activity	  accompanies	  the	  diminished	  TRPV1	  function	  in	  diabetes.	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Following	  acute	  methylglyoxal	  and	  AITC	  exposure,	  diminished	  capsaicin	  responses	  were	  seen,	  suggestive	  of	  a	  cross-­‐desensitisation	  of	  TRPV1.	  	  A	  TRPA1	  selective	  antagonist	  was	  seen	  to	  block	  both	  methylglyoxal	  and	  AITCs	  direct	  contractile	  effect	  in	  urinary	  bladder	  of	  controls.	  	  However	  the	  TRPA1	  antagonist	  did	  not	  block	  the	  effect	  of	  methylglyoxal	  on	  subsequent	  capsaicin	  responses,	  which	  implies	  an	  alternative	  mechanism	  by	  which	  methylglyoxal	  is	  reducing	  TRPV1	  response.	  	  Furthermore	  TRPA1	  antagonism	  revealed	  a	  sensitising	  action	  of	  AITC	  on	  capsaicin	  responses	  suggestive	  of	  a	  complexity	  between	  desensitisation/sensitisation	  mechanisms	  between	  TRPA1	  and	  TRPV1.	  	  The	  highest	  concentration	  of	  methylglyoxal	  10	  mM	  was	  seen	  to	  cause	  a	  reduced	  subsequent	  carbachol	  response,	  which	  may	  be	  due	  to	  cellular	  toxicity.	  	  
Methylglyoxal	  demonstrated	  additional	  activity	  	  Acute	  methylglyoxal	  exposure	  caused	  increased	  responses	  to	  repeated	  electrically-­‐evoked	  contractions.	  Increased	  repeated	  electrically	  evoked	  responses	  were	  seen	  in	  the	  presence	  of	  acute	  methylglyoxal	  and	  may	  be	  via	  methylglyoxal	  effect	  as	  a	  GABA	  A	  agonist	  (Distler	  et	  al.,	  2012)	  as	  GABA	  A	  agonists	  are	  known	  to	  potentiate	  neurotransmitter	  release	  (Santicioli	  et	  al.,	  1991)	  	  Second	  application	  of	  methylglyoxal	  was	  seen	  to	  cause	  a	  relaxation	  from	  basal	  tension	  and	  further	  study	  of	  this	  revealed	  that	  both	  methylglyoxal	  and	  AITC	  caused	  relaxation	  of	  carbachol	  precontracted	  tissue.	  	  No	  differences	  in	  this	  response	  were	  seen	  between	  control	  and	  STZ-­‐tissue	  and	  this	  response	  was	  not	  blocked	  by	  TRPA1	  antagonism.	  Although	  the	  mechanism	  for	  this	  activity	  was	  not	  defined	  here,	  this	  action	  of	  methylglyoxal	  may	  have	  a	  bearing	  on	  bladder	  function	  in	  diabetes.	  	  
Prolonged	  methylglyoxal	  exposure	  revealed	  effects	  on	  neuroexcitability	  
	  To	  mimic	  the	  exposure	  to	  methylglyoxal	  as	  would	  be	  seen	  in	  diabetes,	  a	  more	  prolonged	  exposure	  was	  studied.	  Here	  methylglyoxal	  exposure	  continued	  to	  diminish	  the	  subsequent	  response	  to	  capsaicin	  in	  control	  tissue.	  	  However	  the	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prolonged	  exposure	  protocol	  had	  detrimental	  effects	  in	  itself	  on	  measurement	  of	  TRPV1	  function,	  and	  capsaicin	  responses	  in	  STZ-­‐treated	  rat	  tissue	  were	  virtually	  non-­‐existent.	  This	  highlights	  the	  fragility	  of	  neuronal	  preparations	  in	  vitro.	  Responses	  to	  carbachol	  were	  seen	  to	  be	  more	  robust	  and	  here	  prolonged	  exposure	  to	  methylglyoxal	  caused	  an	  enhancement	  in	  carbachol	  efficacy	  in	  STZ-­‐treated	  tissue:	  the	  reasons	  for	  this	  are	  not	  understood.	  	  Pronounced	  leftward	  shifts	  in	  voltage	  sensitivity	  were	  seen	  for	  electrical	  field	  stimulation,	  and	  these	  were	  apparent	  in	  both	  control	  and	  STZ-­‐treated	  groups.	  	  Increases	  were	  seen	  in	  frequency	  responses	  for	  a	  wide	  range	  of	  frequencies	  for	  STZ	  and	  a	  smaller	  range	  for	  control.	  This	  increased	  sensitivity	  was	  similar	  to	  that	  seen	  in	  STZ-­‐induced	  diabetes	  and	  may	  suggest	  that	  the	  diabetic-­‐induced	  changes	  to	  membrane	  excitability	  are	  directly	  due	  to	  methylglyoxal.	  	  	  A	  more	  detailed	  examination	  of	  the	  contractile	  profile	  data	  for	  these	  responses	  revealed	  that	  methylglyoxal	  exposure	  altered	  the	  ‘slow	  neurotransmitter’	  responses	  and	  therefore	  may	  be	  affecting	  cholinergic	  responses.	  	  This	  could	  be	  studied	  in	  more	  depth	  to	  gain	  an	  understanding	  of	  how	  methylglyoxal	  is	  causing	  changes	  in	  membrane	  excitability.	  	  
	  
Diminished	  TRPV1	  responses	  were	  reversed	  by	  bradykinin,	  so	  retained	  a	  
level	  of	  plasticity	  
	  The	  final	  part	  of	  this	  thesis	  was	  to	  examine	  the	  potential	  of	  rescuing	  the	  diminished	  TRPV1	  response	  through	  the	  use	  of	  three	  known	  sensitising	  agents,	  bradykinin,	  NGF	  and	  insulin.	  	  Bradykinin	  was	  the	  only	  agent	  seen	  to	  reverse	  the	  TRPV1	  diminished	  response	  back	  up	  to	  control	  equivalent	  levels.	  	  Through	  the	  use	  of	  bradykinin	  selective	  agonists	  individually	  and	  in	  combination	  it	  was	  seen	  that	  the	  dual	  activation	  of	  BK-­‐1	  and	  BK-­‐2	  receptor	  was	  necessary	  to	  reverse	  TRPV1	  response.	  	  The	  use	  of	  indomethacin	  revealed	  that	  the	  likely	  mechanism	  of	  action	  of	  bradykinin	  was	  through	  prostaglandin	  production	  as	  indomethacin	  blocked	  diminished	  TRPV1	  reversal.	  	  This	  finding	  affirms	  previous	  data	  generated	  in-­‐house	  (Katisart,	  2011),	  and	  offers	  a	  mechanism	  of	  action	  of	  bradykinin	  effect	  on	  the	  diminished	  TRPV1	  responses	  of	  prostaglandin	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generation.	  	  Prostaglandins	  are	  known	  to	  sensitise	  TRPV1	  responses	  through	  activation	  of	  protein	  kinase	  A/C	  	  (Moriyama	  et	  al.,	  2005,	  Gu	  et	  al.,	  2003),	  which	  is	  thought	  to	  release	  TRPV1	  from	  the	  inhibitory	  control	  of	  PIP2	  .	  	  In	  the	  urinary	  bladder	  a	  reversal	  of	  diminished	  TRPV1	  function	  would	  likely	  be	  beneficial	  in	  treatment	  of	  diabetic	  cystopathy.	  	  Increased	  sensation	  would	  aid	  urinary	  voiding	  but	  a	  fine	  balance	  probably	  exists	  regaining	  normal	  function	  and	  inducing	  pain.	  Diabetics	  are	  prone	  to	  the	  development	  of	  bladder	  pain/	  cystitis	  following	  infection	  (Nicolle,	  2005)	  and	  are	  more	  prone	  to	  infections	  due	  to	  the	  increased	  glucose	  levels	  in	  their	  urine	  (Rayfield	  et	  al.,	  1982,	  Stapleton,	  2002).	  	  	  
	  
Considering	  the	  information	  provided	  by	  this	  thesis	  a	  number	  of	  potential	  




	  An	  agent	  that	  reduces	  the	  effects	  of	  methylglyoxal	  either	  by	  enhancing	  its	  degradation,	  reducing	  its	  production	  or	  blocking	  its	  effect	  would	  be	  beneficial	  in	  the	  treatment	  of	  sensory	  neuropathy.	  	  Metformin,	  an	  antidiabetic	  agent	  has	  been	  shown	  to	  bind	  to	  methylglyoxal	  and	  potentially	  block	  methylglyoxal	  effects	  (Ruggiero-­‐Lopez	  et	  al.,	  1999),	  metformin	  has	  also	  been	  shown	  to	  reduce	  systemic	  levels	  of	  methylglyoxal	  (Beisswenger	  et	  al.,	  1999).	  Gliclazide	  has	  been	  shown	  to	  act	  as	  an	  antiglycation	  agent	  and	  reduces	  AGE	  formation	  by	  methylglyoxal	  (Li	  et	  al.,	  2008).	  	  However	  equimolar	  concentrations	  are	  required	  which	  requires	  large	  doses	  of	  these	  compounds	  to	  be	  administered.	  	  Additionally	  neither	  of	  these	  compounds	  are	  effective	  at	  resolution	  of	  diabetic	  complications	  such	  as	  neuropathy	  and	  this	  may	  be	  due	  to	  efficacy	  and	  site	  of	  action.	  In	  terms	  of	  the	  ideal	  compound,	  one	  designed	  specifically	  to	  interfere	  with	  the	  binding	  of	  methylglyoxal	  to	  the	  cysteine	  residues	  may	  be	  the	  most	  effective	  at	  blocking	  the	  action	  of	  methylglyoxal	  effect	  on	  neuropathy.	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Enhancement	  of	  endogenous	  bradykinin	  levels	  through	  the	  use	  of	  ACE	  
inhibition	  	  Angiotensin	  converting	  enzyme	  (ACE)	  inhibitors	  act	  to	  limit	  the	  conversion	  of	  angiotensin	  II	  to	  angiotensin	  I	  and	  are	  used	  as	  antihypertensives.	  	  In	  addition	  to	  its	  action	  on	  angiotensin,	  ACE	  also	  facilitates	  the	  breakdown	  of	  endogenous	  bradykinin	  (Fox	  et	  al.,	  1996)	  and	  therefore	  the	  early	  use	  of	  an	  ACE	  inhibitor	  may	  be	  beneficial	  in	  treatment	  of	  diabetic	  cystopathy,	  through	  enhancement	  of	  endogenous	  bradykinin	  levels.	  	  	  As	  these	  compounds	  are	  in	  extensive	  clinical	  use	  there	  is	  some	  evidence	  that	  ACE	  inhibitors	  are	  of	  benefit	  in	  diabetic	  neuropathy	  (Coppey	  et	  al.,	  2006,	  Reja	  et	  al.,	  1995)	  but	  some	  studies	  have	  shown	  no	  benefit	  (Malik	  et	  al.,	  1998a)	  and	  none	  to	  my	  knowledge	  have	  been	  designed	  to	  specially	  examine	  the	  effectiveness	  of	  ACE	  inhibition	  on	  bladder	  cystopathy.	  	  
TRPV1	  antagonism	  	  Finally	  the	  early	  use	  of	  a	  TRPV1	  antagonist	  may	  be	  beneficial	  in	  sensory	  neuropathy.	  	  Not	  only	  should	  the	  TRPV1	  antagonist	  reduce	  the	  pain	  that	  is	  often	  experienced	  in	  neuropathy	  but	  may	  also	  reduce	  the	  detrimental	  modulation	  of	  TRPV1	  by	  interfering	  with	  phosphorylation	  of	  this	  receptor.	  Clinical	  use	  of	  TRPV1	  antagonists	  have	  been	  halted	  by	  the	  hyperthermic	  response	  to	  antagonists	  (Gavva	  et	  al.,	  2008).	  	  It	  is	  believed	  that	  a	  tonic	  activation	  of	  the	  TRPV1	  receptor	  is	  present	  and	  when	  a	  TRPV1	  antagonist	  is	  administered,	  the	  consequence	  of	  this	  is	  to	  cause	  hyperthermia	  (Gavva	  et	  al.,	  2007).	  However	  given	  the	  early	  peripheral	  downregulation	  of	  TRPV1	  function	  seen	  in	  the	  rat	  diabetic	  model,	  it	  is	  unknown	  how	  a	  diabetic	  would	  respond	  to	  TRPV1	  antagonism.	  The	  diabetic	  population	  may	  be	  resistant	  to	  such	  hyperthermic	  effects	  and	  examination	  of	  a	  TRPV1	  antagonist	  on	  body	  temperature	  in	  control	  and	  diabetic	  rats	  coupled	  with	  effects	  on	  pain	  neuropathic	  readouts	  would	  be	  a	  very	  interesting	  study.	  	  If	  TRPV1	  antagonists	  caused	  hyperthermia	  in	  the	  diabetic	  rat,	  it	  would	  suggest	  that	  peripheral	  TRPV1	  function	  has	  not	  been	  diminished	  to	  the	  same	  extent	  as	  seen	  in	  the	  urinary	  bladder,	  as	  the	  mechanism	  of	  hyperthermia	  is	  thought	  to	  be	  via	  a	  peripheral	  vascular	  thermoregulatory	  response.	  If	  TRPV1	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antagonism	  did	  not	  cause	  hyperthermia	  in	  diabetic	  rats,	  but	  were	  active	  against	  neuropathic	  pain,	  it	  potentially	  opens	  up	  a	  human	  population	  in	  which	  TRPV1	  antagonists	  could	  be	  used	  therapeutically.	  	  	  	  
Summary	  statement	  	  In	  the	  acute	  stage	  of	  diabetes,	  TRPV1	  function	  in	  the	  urinary	  bladder	  is	  downregulated.	  	  The	  downregulation	  at	  this	  stage	  may	  be	  caused	  by	  exposure	  to	  methylglyoxal	  although	  methylglyoxal	  acts	  via	  multiple	  mechanisms	  and	  TRPA1	  blockade	  did	  not	  prevent	  TRPV1	  downregulation.	  	  Bradykinin	  receptor	  activation,	  likely	  through	  prostaglandin	  production,	  was	  able	  to	  reverse	  the	  acute	  stage	  STZ-­‐induced	  TRPV1	  downregulation	  whereas	  other	  sensitising	  agents	  NGF	  or	  insulin	  were	  not	  able	  to	  reverse	  diminished	  TRPV1	  function.	  These	  studies	  have	  identified	  that	  the	  TRPV1	  dysfunction	  that	  presents	  acutely	  in	  diabetic	  sensory	  neuropathy	  retains	  a	  level	  of	  plasticity	  that	  could	  be	  therapeutically	  manipulated	  and	  thereby	  be	  of	  benefit	  in	  treatment	  of	  diabetic	  neuropathy.	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